PMID-sentid Pub_year Sent_text comp_official_name comp_offset protein_name organism prot_offset 34000957-0 2021 Influence of UGT2B7 and UGT1A6 polymorphisms on plasma concentration to dose ratio of valproic acid in Chinese epileptic children. Valproic Acid 86-99 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 13-19 34000957-2 2021 Significantly lower lnCDRVPA was also observed in pediatric patients with UGT1A6 rs2070959 (A > G) GG genotype compared to those AA genotype (beta = -0.270, p = 0.021).This research indicated that UGT2B7 rs7668258 (C > T) and UGT1A6 rs2070959 (A > G) polymorphisms may be correlated to the normalized plasma concentrations of VPA in Chinese epileptic children. lncdrvpa 20-28 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 197-203 34000957-2 2021 Significantly lower lnCDRVPA was also observed in pediatric patients with UGT1A6 rs2070959 (A > G) GG genotype compared to those AA genotype (beta = -0.270, p = 0.021).This research indicated that UGT2B7 rs7668258 (C > T) and UGT1A6 rs2070959 (A > G) polymorphisms may be correlated to the normalized plasma concentrations of VPA in Chinese epileptic children. Valproic Acid 25-28 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 197-203 33857625-21 2021 Monte Carlo simulation based on optimal PopPK model revealed that the LTG dosage administered to carriers of the UGT2B7 rs4356975 CT or TT genotype required a 33% to 50% increase to reach the pre-pregnancy target concentration, and carriers of the ABCB1 rs1128503 GG genotype required a 33% to 66% lower dose of LTG than carriers of the ABCB1 rs1128503 AA or AG genotype. Lamotrigine 70-73 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 113-119 33610566-8 2021 Moreover, isobavachalcone demonstrated broad-spectrum inhibitory effects against CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, UGT1A1, UGT1A9, UGT2B7 with IC50 values of 1.08-9.78 muM. isobavachalcone 10-25 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 138-144 33671323-5 2021 The carbamazepine model applies metabolism by CYP3A4 and CYP2C8 to produce carbamazepine-10,11-epoxide, metabolism by CYP2B6 and UDP-glucuronosyltransferase (UGT) 2B7 and glomerular filtration. Carbamazepine 4-17 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 129-166 33847389-3 2021 Pharmacokinetically, morphine is primarily metabolized in the liver via glucuronidation by the enzyme uridine diphosphate glucuronosyltransferase family 2-member B7 (UGT2B7) and encounters the transporter proteins organic cation transporter isoform 1 (OCT1) and p-glycoprotein (ABCB1) as it is being distributed throughout the body. Morphine 21-29 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 102-164 33847389-3 2021 Pharmacokinetically, morphine is primarily metabolized in the liver via glucuronidation by the enzyme uridine diphosphate glucuronosyltransferase family 2-member B7 (UGT2B7) and encounters the transporter proteins organic cation transporter isoform 1 (OCT1) and p-glycoprotein (ABCB1) as it is being distributed throughout the body. Morphine 21-29 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 166-172 33446524-4 2021 UDP-glucuronosyltransferase (UGT) 1A10 and UGT2B7 were found to increase candesartan N2-glucuronide and candesartan acyl-beta-D-glucuronide formation in a candesartan concentration-dependent manner. candesartan 73-84 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 43-49 33446524-4 2021 UDP-glucuronosyltransferase (UGT) 1A10 and UGT2B7 were found to increase candesartan N2-glucuronide and candesartan acyl-beta-D-glucuronide formation in a candesartan concentration-dependent manner. n2-glucuronide 85-99 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 43-49 33446524-4 2021 UDP-glucuronosyltransferase (UGT) 1A10 and UGT2B7 were found to increase candesartan N2-glucuronide and candesartan acyl-beta-D-glucuronide formation in a candesartan concentration-dependent manner. candesartan acyl-beta-d-glucuronide 104-139 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 43-49 33446524-4 2021 UDP-glucuronosyltransferase (UGT) 1A10 and UGT2B7 were found to increase candesartan N2-glucuronide and candesartan acyl-beta-D-glucuronide formation in a candesartan concentration-dependent manner. candesartan 104-115 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 43-49 33870481-0 2021 1H, 13C and 15N chemical shift assignments of the C-terminal domain of human UDP-Glucuronosyltransferase 2B7 (UGT2B7-C). Hydrogen 0-2 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 77-108 33870481-0 2021 1H, 13C and 15N chemical shift assignments of the C-terminal domain of human UDP-Glucuronosyltransferase 2B7 (UGT2B7-C). Hydrogen 0-2 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 110-118 33870481-0 2021 1H, 13C and 15N chemical shift assignments of the C-terminal domain of human UDP-Glucuronosyltransferase 2B7 (UGT2B7-C). Carbon-13 4-7 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 77-108 33870481-0 2021 1H, 13C and 15N chemical shift assignments of the C-terminal domain of human UDP-Glucuronosyltransferase 2B7 (UGT2B7-C). Carbon-13 4-7 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 110-118 33870481-0 2021 1H, 13C and 15N chemical shift assignments of the C-terminal domain of human UDP-Glucuronosyltransferase 2B7 (UGT2B7-C). 15n 12-15 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 77-108 33870481-0 2021 1H, 13C and 15N chemical shift assignments of the C-terminal domain of human UDP-Glucuronosyltransferase 2B7 (UGT2B7-C). 15n 12-15 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 110-118 33870481-4 2021 To better understand this mode of resistance, we studied the UGT2B7 enzyme associated with glucuronidation of cancer drugs such as Tamoxifen and Sorafenib. Tamoxifen 131-140 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 61-67 33870481-4 2021 To better understand this mode of resistance, we studied the UGT2B7 enzyme associated with glucuronidation of cancer drugs such as Tamoxifen and Sorafenib. Sorafenib 145-154 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 61-67 33870481-5 2021 We report 1H, 13C and 15N backbone (> 90%) and side-chain assignments (~ 78% completeness according to CYANA) for the C-terminal domain of UGT2B7 (UGT2B7-C). Hydrogen 10-12 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 139-145 33870481-5 2021 We report 1H, 13C and 15N backbone (> 90%) and side-chain assignments (~ 78% completeness according to CYANA) for the C-terminal domain of UGT2B7 (UGT2B7-C). Hydrogen 10-12 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 147-155 33870481-5 2021 We report 1H, 13C and 15N backbone (> 90%) and side-chain assignments (~ 78% completeness according to CYANA) for the C-terminal domain of UGT2B7 (UGT2B7-C). Carbon-13 14-17 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 139-145 33870481-5 2021 We report 1H, 13C and 15N backbone (> 90%) and side-chain assignments (~ 78% completeness according to CYANA) for the C-terminal domain of UGT2B7 (UGT2B7-C). 15n 22-25 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 139-145 33870481-5 2021 We report 1H, 13C and 15N backbone (> 90%) and side-chain assignments (~ 78% completeness according to CYANA) for the C-terminal domain of UGT2B7 (UGT2B7-C). 15n 22-25 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 147-155 33995076-8 2021 In contrast, PRH did not alter UGT2B7 mRNA levels or protein concentrations in SCHH, and formation of the UGT2B7-derived labetalol glucuronide metabolite was decreased following PRH exposure. Labetalol 121-130 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 106-112 33995076-8 2021 In contrast, PRH did not alter UGT2B7 mRNA levels or protein concentrations in SCHH, and formation of the UGT2B7-derived labetalol glucuronide metabolite was decreased following PRH exposure. Glucuronides 131-142 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 106-112 33832852-1 2021 BACKGROUND: Epirubicin is metabolized by uridine glucuronosyltransferase 2B7 (UGT2B7). Epirubicin 12-22 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 78-84 33309889-4 2021 The performance of the microreactor is characterized using glucuronidation of 8-hydroxyquinoline (via multiple UGTs) and zidovudine (via UGT2B7) as the model reactions. Zidovudine 121-131 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 137-143 33387482-10 2021 Interestingly, treatment with entacapone, which is used for the treatment of Parkinson"s disease and is an inhibitor of FTO, decreased HNF4alpha and UGT2B7 expression. entacapone 30-40 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 149-155 33400134-0 2021 UGT1A6 and UGT2B7 Gene Polymorphism and its Effect in Pediatric Epileptic Patients on Sodium Valproate Monotherapy. Valproic Acid 86-102 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 11-17 33535454-3 2021 Eudesmin, fargesin, epimagnolin A, magnolin, and yangambin inhibited UGT1A1 and UGT1A3 activities, but showed negligible inhibition of UGT1A4, UGT16, UGT1A9, and UGT2B7 activities at 200 muM in pooled human liver microsomes. epiyangambin 49-58 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 162-168 32873964-5 2021 These include protein-altering variants in steroid hormone production genes (POR, UGT2B7). Steroids 43-50 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 82-88 33387482-0 2021 The N6-methyladenosine modification posttranscriptionally regulates hepatic UGT2B7 expression. N-methyladenosine 4-22 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 76-82 33387482-3 2021 Treatment of HepaRG cells with 3-deazaadenosine, an inhibitor of RNA methylation, significantly increased UGT1A1, UGT1A3, UGT1A4, UGT1A9, UGT2B7, UGT2B10, and UGT2B15 mRNA levels (1.3- to 2.6-fold). 3-deazaadenosine 31-47 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 138-144 32483200-4 2020 Patients with the UGT2B7-161T allele were treated with 21.22% higher LTG daily dose than those with CC genotype. Lamotrigine 69-72 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 18-24 33008919-0 2020 Arginine-259 of UDP-glycosyltransferase 2B7 (UGT2B7) confers UDP-sugar selectivity. Uridine Diphosphate Sugars 61-70 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 16-43 33008919-0 2020 Arginine-259 of UDP-glycosyltransferase 2B7 (UGT2B7) confers UDP-sugar selectivity. Uridine Diphosphate Sugars 61-70 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 45-51 33020067-5 2020 Inhibition of HLM CLint with 10 microM digoxin or tranilast (UGT1A9) and 3 microM 16beta-phenyllongifolol (UGT2B7/UGT2B4) resulted in fraction metabolism (fm) estimates of 0.81 and 0.19 for UGT1A9 and UGT2B7/UGT2B4, respectively. 16beta-phenyllongifolol 82-105 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 107-113 33008919-2 2020 Although UDP-glucuronic acid (UDP-GlcUA) is most commonly employed as the cofactor by UGT1 and UGT2 family enzymes, UGT2B7 and several other enzymes can utilise both UDP-GlcUA and UDP-glucose (UDP-Glc), leading to the formation of glucuronide and glucoside conjugates. Uridine Diphosphate Glucuronic Acid 9-28 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 116-122 33008919-2 2020 Although UDP-glucuronic acid (UDP-GlcUA) is most commonly employed as the cofactor by UGT1 and UGT2 family enzymes, UGT2B7 and several other enzymes can utilise both UDP-GlcUA and UDP-glucose (UDP-Glc), leading to the formation of glucuronide and glucoside conjugates. Uridine Diphosphate Glucuronic Acid 30-39 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 116-122 33008919-2 2020 Although UDP-glucuronic acid (UDP-GlcUA) is most commonly employed as the cofactor by UGT1 and UGT2 family enzymes, UGT2B7 and several other enzymes can utilise both UDP-GlcUA and UDP-glucose (UDP-Glc), leading to the formation of glucuronide and glucoside conjugates. Uridine Diphosphate Glucuronic Acid 166-175 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 116-122 33008919-2 2020 Although UDP-glucuronic acid (UDP-GlcUA) is most commonly employed as the cofactor by UGT1 and UGT2 family enzymes, UGT2B7 and several other enzymes can utilise both UDP-GlcUA and UDP-glucose (UDP-Glc), leading to the formation of glucuronide and glucoside conjugates. Glucose 184-191 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 116-122 33008919-2 2020 Although UDP-glucuronic acid (UDP-GlcUA) is most commonly employed as the cofactor by UGT1 and UGT2 family enzymes, UGT2B7 and several other enzymes can utilise both UDP-GlcUA and UDP-glucose (UDP-Glc), leading to the formation of glucuronide and glucoside conjugates. Uridine Diphosphate Glucose 30-37 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 116-122 33008919-2 2020 Although UDP-glucuronic acid (UDP-GlcUA) is most commonly employed as the cofactor by UGT1 and UGT2 family enzymes, UGT2B7 and several other enzymes can utilise both UDP-GlcUA and UDP-glucose (UDP-Glc), leading to the formation of glucuronide and glucoside conjugates. Glucuronides 231-242 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 116-122 33008919-2 2020 Although UDP-glucuronic acid (UDP-GlcUA) is most commonly employed as the cofactor by UGT1 and UGT2 family enzymes, UGT2B7 and several other enzymes can utilise both UDP-GlcUA and UDP-glucose (UDP-Glc), leading to the formation of glucuronide and glucoside conjugates. Glucosides 247-256 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 116-122 33008919-3 2020 An investigation of UGT2B7 catalysed morphine glycosidation indicated that glucuronidation is the principal route of metabolism because the binding affinity of UDP-GlcUA is higher than that of UDP-Glc. Morphine 37-45 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 20-26 33008919-3 2020 An investigation of UGT2B7 catalysed morphine glycosidation indicated that glucuronidation is the principal route of metabolism because the binding affinity of UDP-GlcUA is higher than that of UDP-Glc. Uridine Diphosphate Glucuronic Acid 160-169 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 20-26 33008919-3 2020 An investigation of UGT2B7 catalysed morphine glycosidation indicated that glucuronidation is the principal route of metabolism because the binding affinity of UDP-GlcUA is higher than that of UDP-Glc. Uridine Diphosphate Glucose 160-167 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 20-26 33008919-4 2020 Currently, it is unclear which residues in the UGT2B7 cofactor binding domain are responsible for the preferential binding of UDP-GlcUA. Uridine Diphosphate Glucuronic Acid 126-135 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-53 32483200-7 2020 Despite the numerous drug-metabolizing enzymes and transporter genetic variants analyzed, our results revealed that co-treatment with VPA was the most significant factor influencing LTG plasma concentration, followed by UGT1A4*1b, and that patients carrying UGT2B7 c.-161T required higher LTG daily doses. Valproic Acid 134-137 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 258-264 32483200-7 2020 Despite the numerous drug-metabolizing enzymes and transporter genetic variants analyzed, our results revealed that co-treatment with VPA was the most significant factor influencing LTG plasma concentration, followed by UGT1A4*1b, and that patients carrying UGT2B7 c.-161T required higher LTG daily doses. Lamotrigine 289-292 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 258-264 32520597-8 2020 With the exception of Rivastigmine (UGT2B7, BCHE-K), the other AChEIs are primarily metabolized via CYP2D6, CYP3A4, and UGT enzymes, with involvement of ABC transporters and cholinergic genes (CHAT, ACHE, BCHE, SLC5A7, SLC18A3, CHRNA7) in most ethnic groups. Rivastigmine 22-34 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 36-42 32763815-14 2020 Isozymes of CYP1A2, CYP2C9, UGT1A1, UGT1A6, UGT1A9, UGT2B7 and UGT2B15 were involved in phase I and phase II metabolism of osalmid. osalmide 123-130 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 52-58 32107351-1 2020 BACKGROUND: The aim of the study was to investigate how age and genetic polymorphisms of UGT1A6 and UGT2B7 contribute to the concentrations of valproic acid (VPA) and its hepatotoxic metabolites in Chinese pediatric patients with epilepsy. Valproic Acid 143-156 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 100-106 32107351-1 2020 BACKGROUND: The aim of the study was to investigate how age and genetic polymorphisms of UGT1A6 and UGT2B7 contribute to the concentrations of valproic acid (VPA) and its hepatotoxic metabolites in Chinese pediatric patients with epilepsy. Valproic Acid 158-161 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 100-106 32107351-4 2020 RESULTS: Significant association was observed between the UGT2B7 802C>T genotype and dose-adjusted concentrations of VPA, 4-ene-VPA, and 2,4-diene-VPA. Valproic Acid 117-120 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 58-64 32107351-4 2020 RESULTS: Significant association was observed between the UGT2B7 802C>T genotype and dose-adjusted concentrations of VPA, 4-ene-VPA, and 2,4-diene-VPA. 4-ene 122-127 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 58-64 32107351-4 2020 RESULTS: Significant association was observed between the UGT2B7 802C>T genotype and dose-adjusted concentrations of VPA, 4-ene-VPA, and 2,4-diene-VPA. Valproic Acid 128-131 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 58-64 32107351-4 2020 RESULTS: Significant association was observed between the UGT2B7 802C>T genotype and dose-adjusted concentrations of VPA, 4-ene-VPA, and 2,4-diene-VPA. 2,5-DIMETHYL-2,4-HEXADIENE 137-146 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 58-64 32107351-4 2020 RESULTS: Significant association was observed between the UGT2B7 802C>T genotype and dose-adjusted concentrations of VPA, 4-ene-VPA, and 2,4-diene-VPA. Valproic Acid 128-131 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 58-64 32176075-8 2020 The homozygous polymorphism (TT) of UGT2B7 showed higher bisphenol A and PAEs concentrations in serum. bisphenol A 57-68 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 36-42 32538071-0 2020 Metabolism and toxicity of emodin: Genome-wide association studies reveal hepatocyte nuclear factor 4alpha regulates UGT2B7 and emodin glucuronidation. Emodin 27-33 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 117-123 32538071-2 2020 Our previous studies demonstrated that genetic polymorphisms of UDP-Glucuronosyltransferase 2B7 (UGT2B7) had an effect on the glucuronidation and detoxification of emodin. Emodin 164-170 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 64-95 32401749-0 2020 Influences of UGT2B7 rs7439366 and rs12233719 Polymorphisms on Fentanyl Sensitivity in Chinese Gynecologic Patients. Fentanyl 63-71 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 14-20 32401749-1 2020 BACKGROUND This study discussed potential influences of UDP glucuronosyltransferase family 2 member B7 (UGT2B7) rs7439366 and rs12233719 polymorphisms on fentanyl sensitivity among Chinese gynecologic patients. Fentanyl 154-162 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 56-102 32401749-1 2020 BACKGROUND This study discussed potential influences of UDP glucuronosyltransferase family 2 member B7 (UGT2B7) rs7439366 and rs12233719 polymorphisms on fentanyl sensitivity among Chinese gynecologic patients. Fentanyl 154-162 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 104-110 31233374-10 2020 Glucuronidation of glycyrol was primarily mediated by UGT1A1, UGT1A3, UGT1A9, and UGT2B7. glycyrol 19-27 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 82-88 31233374-12 2020 In conclusion, glycyrol undergoes the efficient metabolic hydroxylation and glucuronidation reactions in human liver microsomes, which are predominantly catalyzed by CYP1A2, UGT1A1/3/9, and UGT2B7. glycyrol 15-23 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 190-196 32187543-3 2020 Our platform identifies vitamin A palmitate and abietic acid as inhibitors of P-gp and UGT2B7, respectively; in silico, in vitro, ex vivo, and in vivo validations support these interactions. retinol palmitate 24-43 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 87-93 32187543-3 2020 Our platform identifies vitamin A palmitate and abietic acid as inhibitors of P-gp and UGT2B7, respectively; in silico, in vitro, ex vivo, and in vivo validations support these interactions. abietic acid 48-60 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 87-93 32176075-8 2020 The homozygous polymorphism (TT) of UGT2B7 showed higher bisphenol A and PAEs concentrations in serum. phenyl-2-aminoethyl sulfide 73-77 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 36-42 31815452-5 2020 It was determined that UGT2B7 converts bromfenac to BI, and that while CYP2C8, CYP2C9 and CYP2C19 catalyze the hydroxylation of bromfenac, only CYP2C9 forms thioether adducts when incubated with NAC or GSH as trapping agents. bromfenac 52-54 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 23-29 32185219-0 2020 Association of SCN1A, SCN2A, and UGT2B7 Polymorphisms with Responsiveness to Valproic Acid in the Treatment of Epilepsy. Valproic Acid 77-90 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 33-39 31812603-4 2020 Our data indicated that PT exhibited potent inhibition against HLM, UGT1A6, UGT1A9, UGT2B7, and UGT2B15, moderate inhibition against UGT1A1, UGT1A3, UGT1A8, and UGT2B4, negligible inhibition against UGT1A4, UGT1A7, UGT1A10, and UGT2B17. pterostilbene 24-26 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 84-90 31999978-6 2020 Glucuronidation of 20-HETE by UGT2B7 and UGT1A9 recombinant enzymes was significantly inhibited by indomethacin, mefanemic acid, diclofenac, ibuprofen, naproxen, and celecoxib (P < 0.001). 20-hydroxy-5,8,11,14-eicosatetraenoic acid 19-26 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 30-36 31999978-6 2020 Glucuronidation of 20-HETE by UGT2B7 and UGT1A9 recombinant enzymes was significantly inhibited by indomethacin, mefanemic acid, diclofenac, ibuprofen, naproxen, and celecoxib (P < 0.001). Indomethacin 99-111 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 30-36 31999978-6 2020 Glucuronidation of 20-HETE by UGT2B7 and UGT1A9 recombinant enzymes was significantly inhibited by indomethacin, mefanemic acid, diclofenac, ibuprofen, naproxen, and celecoxib (P < 0.001). mefanemic acid 113-127 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 30-36 31999978-6 2020 Glucuronidation of 20-HETE by UGT2B7 and UGT1A9 recombinant enzymes was significantly inhibited by indomethacin, mefanemic acid, diclofenac, ibuprofen, naproxen, and celecoxib (P < 0.001). Diclofenac 129-139 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 30-36 31999978-6 2020 Glucuronidation of 20-HETE by UGT2B7 and UGT1A9 recombinant enzymes was significantly inhibited by indomethacin, mefanemic acid, diclofenac, ibuprofen, naproxen, and celecoxib (P < 0.001). Ibuprofen 141-150 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 30-36 31999978-6 2020 Glucuronidation of 20-HETE by UGT2B7 and UGT1A9 recombinant enzymes was significantly inhibited by indomethacin, mefanemic acid, diclofenac, ibuprofen, naproxen, and celecoxib (P < 0.001). Naproxen 152-160 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 30-36 31999978-6 2020 Glucuronidation of 20-HETE by UGT2B7 and UGT1A9 recombinant enzymes was significantly inhibited by indomethacin, mefanemic acid, diclofenac, ibuprofen, naproxen, and celecoxib (P < 0.001). Celecoxib 166-175 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 30-36 31999978-8 2020 Diclofenac further decreased 20-HETE glucuronidation in HLMs carrying UGT2B7*2 alleles compared with the wild-type HLMs. Diclofenac 0-10 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 70-76 31979355-3 2020 Empagliflozin is metabolized and inactivated by UGT1A9 and by other related isoforms UGT2B7, UGT1A3, and UGT1A8. empagliflozin 0-13 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 85-91 31815452-5 2020 It was determined that UGT2B7 converts bromfenac to BI, and that while CYP2C8, CYP2C9 and CYP2C19 catalyze the hydroxylation of bromfenac, only CYP2C9 forms thioether adducts when incubated with NAC or GSH as trapping agents. bromfenac 39-48 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 23-29 31815452-5 2020 It was determined that UGT2B7 converts bromfenac to BI, and that while CYP2C8, CYP2C9 and CYP2C19 catalyze the hydroxylation of bromfenac, only CYP2C9 forms thioether adducts when incubated with NAC or GSH as trapping agents. bromfenac 128-137 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 23-29 31421085-6 2019 KEY FINDINGS: At 100 muM, licoricidin strongly inhibited CYP2C9, CYP2C19, CYP3A4, UGT1A3, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT2B4, UGT2B7, UGT2B15, and UGT2B17. licoricidin 26-37 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 130-136 31472352-7 2020 The inhibition kinetics determination showed that the inhibition kinetic parameter Ki value was calculated to be 2.85, 3.99 and 31.00 muM for the inhibition of UGT1A3, UGT1A7, and UGT2B7 by representative BPs, 2,4,6-TBP. bps 205-208 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 180-186 31648049-10 2020 UGT2B7, UGT1A3, and UGT1A9 were primarily responsible for nalbuphine glucuronidation; only UGT2B7 produced nalbuphine-6-glucuronide. Nalbuphine 58-68 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 31648049-10 2020 UGT2B7, UGT1A3, and UGT1A9 were primarily responsible for nalbuphine glucuronidation; only UGT2B7 produced nalbuphine-6-glucuronide. Nalbuphine 107-131 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 91-97 31474408-0 2020 Association of UGT2B7 and CaMK4 with response of valproic acid in Chinese children with epilepsy. Valproic Acid 49-62 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 15-21 31474408-10 2020 CONCLUSION: Two SNPs (UGT2B7 and CaMK4) were associated with VPA response, which may explain the pharmacological mechanism of VPA resistance to some extent. Valproic Acid 61-64 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 22-28 31474408-10 2020 CONCLUSION: Two SNPs (UGT2B7 and CaMK4) were associated with VPA response, which may explain the pharmacological mechanism of VPA resistance to some extent. Valproic Acid 126-129 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 22-28 31554697-0 2019 Potential Regulation of UGT2B10 and UGT2B7 by miR-485-5p in Human Liver. mir-485-5p 46-56 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 36-42 31554697-9 2019 UGT2B10 and UGT2B7 activities were probed using nicotine and 3"-azido-3"-deoxythymidine, respectively, and significant decreases in glucuronidation activity were observed for both substrates in HuH-7 and Hep3B cells upon overexpression of miR-485-5p mimic. Nicotine 48-56 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 12-18 31554697-9 2019 UGT2B10 and UGT2B7 activities were probed using nicotine and 3"-azido-3"-deoxythymidine, respectively, and significant decreases in glucuronidation activity were observed for both substrates in HuH-7 and Hep3B cells upon overexpression of miR-485-5p mimic. Zidovudine 61-87 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 12-18 31515991-3 2019 Auriculasin inhibited UGT1A6, UGT1A8, UGT1A10, UGT2B7, CYP2C9, and CYP3A4 strongly at a concentration of 100 muM. auriculasin 0-11 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-53 31128210-6 2019 The further enzyme kinetic studies demonstrated that shikonin was not only a competitive inhibitor of human UGT1A1, UGT1A9, and UGT2B7, but also presented competitive inhibition on rat UGT1A1 and AZTG reactions. shikonin 53-61 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 128-134 31607718-0 2019 Roles of UGT2B7 C802T gene polymorphism on the efficacy of morphine treatment on cancer pain among the Chinese han population. Morphine 59-67 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 9-15 31607718-2 2019 Since UGT2B7 plays an important role in the metabolism of morphine, UGT2B7 gene mutation may influence the efficacy of morphine in patients with cancer being treated by this medication. Morphine 58-66 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 6-12 31607718-2 2019 Since UGT2B7 plays an important role in the metabolism of morphine, UGT2B7 gene mutation may influence the efficacy of morphine in patients with cancer being treated by this medication. Morphine 119-127 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 6-12 31607718-2 2019 Since UGT2B7 plays an important role in the metabolism of morphine, UGT2B7 gene mutation may influence the efficacy of morphine in patients with cancer being treated by this medication. Morphine 119-127 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 68-74 31607718-3 2019 Aims: The aim of this study is to investigate the relationship between the polymorphisms of UGT2B7 and the efficacy of morphine treatment on cancer pain among the Chinese Han population. Morphine 119-127 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 92-98 31607718-11 2019 Conclusion: The polymorphism of UGT2B7 C802T, but not UGT2B7 G221T, has been associated with the efficacy of morphine treatment on cancer pain among Chinese Han population. Morphine 109-117 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 32-38 30301385-6 2019 Co-administration of probenecid (an UGT2B7 inhibitor) or fluconazole (an UGT2B7 and CYP3A4 inhibitor) was predicted to increase area under the curve for mirabegron to 115% or 174%, respectively. Probenecid 21-31 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 36-42 31433338-10 2019 For non-CYP drug-metabolizing enzymes, UGT1A9 is inhibited by CBD and CBN, whereas UGT2B7 is inhibited by CBD but activated by CBN. Cannabidiol 106-109 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 83-89 30739312-0 2019 Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study. taxane 49-55 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 34-40 30739312-6 2019 NR1I3 was correlated to paclitaxel-TrPN and UGT2B7 to docetaxel-TrPN. Docetaxel 54-63 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 44-50 30739312-6 2019 NR1I3 was correlated to paclitaxel-TrPN and UGT2B7 to docetaxel-TrPN. trpn 64-68 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 44-50 30301385-6 2019 Co-administration of probenecid (an UGT2B7 inhibitor) or fluconazole (an UGT2B7 and CYP3A4 inhibitor) was predicted to increase area under the curve for mirabegron to 115% or 174%, respectively. Fluconazole 57-68 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 73-79 30944207-5 2019 We found that although the dilysine motif functioned as the ER retention signal in a chimera that replaced the cytoplasmic domain of CD4 with that of UGT2B7, UGT2B7 truncated mutants lacking this motif extensively colocalized with CNX, indicating dilysine motif-independent ER retention of UGT2B7. lysyllysine 27-35 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 150-156 30824817-6 2019 These data identify UGT2B7 as a potentially significant explanatory marker for T:M1 variability in a population of tramadol-exposed individuals of Finnish ancestry. Tramadol 115-123 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 20-26 30044687-7 2019 UGT1A1, UGT1A3, UGT1A7, UGT1A8, UGT1A9, UGT1A10 and UGT2B7 participated in the formation of 4-O-glucuronide, with UGT1A9 exhibiting the highest catalytic activity in this biotransformation. 4-o-glucuronide 92-107 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 52-58 30944207-5 2019 We found that although the dilysine motif functioned as the ER retention signal in a chimera that replaced the cytoplasmic domain of CD4 with that of UGT2B7, UGT2B7 truncated mutants lacking this motif extensively colocalized with CNX, indicating dilysine motif-independent ER retention of UGT2B7. lysyllysine 27-35 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 158-164 30944207-5 2019 We found that although the dilysine motif functioned as the ER retention signal in a chimera that replaced the cytoplasmic domain of CD4 with that of UGT2B7, UGT2B7 truncated mutants lacking this motif extensively colocalized with CNX, indicating dilysine motif-independent ER retention of UGT2B7. lysyllysine 27-35 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 158-164 30466000-2 2019 The involvement of selected enzymes (CYP1A2, CYP2C19, CYP2E1, CYP3 A4, UGT1A1, UGT1A6, and UGT2B7) in the metabolism of RA and the inhibitory effect of RA on the enzyme activity were comprehensively evaluated using human recombinant isozyme system. rosmarinic acid 120-122 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 91-97 30823561-5 2019 The metabolism of 25B-NBF was catalyzed by CYP1A1, CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2J2, CYP3A4, and UGT2B7 enzymes. SSW3KY7SWW 18-25 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 112-118 30168665-2 2019 Thus, the objective of this meta-analysis was to analyse the influence of UGT1A4 and UGT2B7 genetic polymorphisms on lamotrigine concentration. Lamotrigine 117-128 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 85-91 30168665-3 2019 Through searching, screening, selection, data extraction and quantitative analyses, the influence of UGT1A4 and UGT2B7 genetic polymorphisms on lamotrigine concentration-to-dose ratio (CDR) was assessed by meta-analysis of nine studies. Lamotrigine 144-155 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 112-118 30168665-3 2019 Through searching, screening, selection, data extraction and quantitative analyses, the influence of UGT1A4 and UGT2B7 genetic polymorphisms on lamotrigine concentration-to-dose ratio (CDR) was assessed by meta-analysis of nine studies. cdr 185-188 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 112-118 30168665-5 2019 Only the UGT2B7 -161C>T homozygous variant had significantly higher CDR values than the wild-type (WT) and heterozygous variant (SDM = 0.634, 95% CI = 0.056-1.222). cdr 71-74 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 9-15 30168665-6 2019 In conclusion, CDR of lamotrigine was significantly higher for the UGT2B7 -161C>T homozygous variant than for the WT and heterozygous variant. cdr 15-18 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 67-73 30168665-6 2019 In conclusion, CDR of lamotrigine was significantly higher for the UGT2B7 -161C>T homozygous variant than for the WT and heterozygous variant. Lamotrigine 22-33 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 67-73 30672747-9 2019 Body weight, age, hepatic and renal functions, and the UGT2B7 rs62298861 polymorphism are relevant predictors of midazolam pharmacokinetic variables. Midazolam 113-122 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 55-61 30300922-2 2019 The pharmacogenetic (PG) effect of variants at the loci of organic cation transporter 1 (OCT1) and UDP-glucuronosyltransferase 2B7 (UGT2B7) on age-dependent morphine clearance were evaluated in a cohort of critically ill neonatal patients using an opportunistic sampling design. Morphine 157-165 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 99-130 30300922-2 2019 The pharmacogenetic (PG) effect of variants at the loci of organic cation transporter 1 (OCT1) and UDP-glucuronosyltransferase 2B7 (UGT2B7) on age-dependent morphine clearance were evaluated in a cohort of critically ill neonatal patients using an opportunistic sampling design. Morphine 157-165 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 132-138 30466000-7 2019 By constructing Line weaver-Burk plots, the type of inhibition exhibited by RA on CYP and UGT activities was determined as follows: CYP2C19, mixed inhibition; CYP2E1, UGT1A1, UGT1A6, and UGT2B7, competitive inhibition. rosmarinic acid 76-78 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 187-193 30709768-5 2019 Relationships between child behavior (Internalizing, Externalizing on the Child Behavior Checklist), morphine exposure, neonatal clinical variables, and morphine biotransformation gene variants in ABCB1, UGT1A9, UGT 2B7*2, ABCC2, ABCC3, SLCO1B1, CYP3A4, COMT were examined. Morphine 153-161 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 212-219 30489548-0 2019 Relationship Between UGT1A4 and UGT2B7 Polymorphisms and the Steady-State Plasma Concentrations of Lamotrigine in Patients With Treatment-Resistant Depressive Disorder Receiving Lamotrigine as Augmentation Therapy. Lamotrigine 99-110 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 32-38 30409834-6 2019 In a panel of 13 recombinantly expressed UGTs, UGT1A9 and UGT2B7 were the major isoforms responsible for IPO glucuronidation. 4-ipomeanol 105-108 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 58-64 30409834-9 2019 We conclude that IPO glucuronidation in human kidney is mediated by UGT1A9 and UGT2B7. 4-ipomeanol 17-20 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 79-85 30489548-0 2019 Relationship Between UGT1A4 and UGT2B7 Polymorphisms and the Steady-State Plasma Concentrations of Lamotrigine in Patients With Treatment-Resistant Depressive Disorder Receiving Lamotrigine as Augmentation Therapy. Lamotrigine 178-189 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 32-38 30489548-2 2019 Lamotrigine is mainly metabolized by UGT1A4 and UGT2B7, and polymorphisms of said UGTs that affect enzyme activities have been reported. Lamotrigine 0-11 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 48-54 30421550-6 2019 MECHANISM: Morphine is metabolized by UDP-glucuronosyltransferase (UGT)-2B7 and UGT1A1 to form its major metabolites morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). Morphine 11-19 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 38-75 30421550-6 2019 MECHANISM: Morphine is metabolized by UDP-glucuronosyltransferase (UGT)-2B7 and UGT1A1 to form its major metabolites morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). morphine-3-glucuronide 117-139 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 38-75 30421550-6 2019 MECHANISM: Morphine is metabolized by UDP-glucuronosyltransferase (UGT)-2B7 and UGT1A1 to form its major metabolites morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). morphine-6-glucuronide 150-172 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 38-75 30442353-0 2018 Polymorphisms in IMPDH2, UGT2B7, and CES2 genes influence the risk of graft rejection in kidney transplant recipients taking mycophenolate mofetil. Mycophenolic Acid 125-146 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 25-31 30554488-1 2019 PURPOSE: The present study aimed to investigate correlations between uridine glucuronosyltransferase 2B7 (UGT2B7) -161 single nucleotide polymorphism C to T (C>T) and the occurrence of cardiotoxicity in Chinese breast cancer (BC) patients undergoing epirubicin/cyclophosphamide-docetaxel (EC-D) adjuvant chemotherapy. Docetaxel 281-290 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 69-104 30554488-1 2019 PURPOSE: The present study aimed to investigate correlations between uridine glucuronosyltransferase 2B7 (UGT2B7) -161 single nucleotide polymorphism C to T (C>T) and the occurrence of cardiotoxicity in Chinese breast cancer (BC) patients undergoing epirubicin/cyclophosphamide-docetaxel (EC-D) adjuvant chemotherapy. Docetaxel 281-290 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 106-112 30554488-8 2019 Multivariate logistic regression revealed that UGT2B7 -161 T allele could independently predict a low occurrence of cardiotoxicity in BC patients undergoing EC-D adjuvant chemotherapy (p=0.004). ec-d 157-161 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-53 29397056-6 2018 Bioinformatics analysis was used to predict sequence and structural features of H. parallela UGT proteins, and revealed important domains and residues involved in sugar donor binding and catalysis by comparison with human UGT2B7. Sugars 163-168 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 222-228 30554488-0 2019 Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy. Epirubicin 92-102 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 15-21 30554488-0 2019 Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy. Cyclophosphamide 103-119 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 15-21 30554488-0 2019 Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy. Docetaxel 120-129 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 15-21 30554488-1 2019 PURPOSE: The present study aimed to investigate correlations between uridine glucuronosyltransferase 2B7 (UGT2B7) -161 single nucleotide polymorphism C to T (C>T) and the occurrence of cardiotoxicity in Chinese breast cancer (BC) patients undergoing epirubicin/cyclophosphamide-docetaxel (EC-D) adjuvant chemotherapy. Epirubicin 253-263 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 69-104 30554488-1 2019 PURPOSE: The present study aimed to investigate correlations between uridine glucuronosyltransferase 2B7 (UGT2B7) -161 single nucleotide polymorphism C to T (C>T) and the occurrence of cardiotoxicity in Chinese breast cancer (BC) patients undergoing epirubicin/cyclophosphamide-docetaxel (EC-D) adjuvant chemotherapy. Epirubicin 253-263 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 106-112 30554488-1 2019 PURPOSE: The present study aimed to investigate correlations between uridine glucuronosyltransferase 2B7 (UGT2B7) -161 single nucleotide polymorphism C to T (C>T) and the occurrence of cardiotoxicity in Chinese breast cancer (BC) patients undergoing epirubicin/cyclophosphamide-docetaxel (EC-D) adjuvant chemotherapy. Cyclophosphamide 264-280 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 69-104 30554488-1 2019 PURPOSE: The present study aimed to investigate correlations between uridine glucuronosyltransferase 2B7 (UGT2B7) -161 single nucleotide polymorphism C to T (C>T) and the occurrence of cardiotoxicity in Chinese breast cancer (BC) patients undergoing epirubicin/cyclophosphamide-docetaxel (EC-D) adjuvant chemotherapy. Cyclophosphamide 264-280 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 106-112 29723751-8 2018 Pentachlorophenol (PCP) was chosen as the representative CPs to determine the IC50 value towards UGT1A6, UGT1A9 and UGT2B7. Pentachlorophenol 0-17 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 116-122 30248416-6 2018 Similarly, in vitro experiments proved that probenecid reduced the cell viability of emodin-treated HepG2 cells through inhibiting UGT1A9, UGT2B7 and MRP2. Probenecid 44-54 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 139-145 30345879-0 2018 Impact of UGT2B7 and ABCC2 genetic polymorphisms on mycophenolic acid metabolism in Chinese renal transplant recipients. Mycophenolic Acid 52-69 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 10-16 30347696-4 2018 Zidovudine (ZDV) was used as the probe substrate to determine UGT2B7 activity. Zidovudine 0-10 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 62-68 30347696-4 2018 Zidovudine (ZDV) was used as the probe substrate to determine UGT2B7 activity. Zidovudine 12-15 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 62-68 30036684-4 2018 Herein, we designed and optimized a validated cocktail method for the simultaneous evaluation of drug-mediated inhibition of the main five UGT isoforms using respective specific probe substrates (estradiol for UGT1A1, chenodeoxycholic acid for UGT1A3, serotonin for UGT1A6, propofol for UGT1A9/PROG and zidovudine for UGT2B7/AZTG) in human and rat liver microsomes by liquid chromatography-tandem mass spectrometry (LCMS/MS). Estradiol 196-205 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 318-324 30107347-0 2018 Drug-drug interaction potential of antitumor acridine agent C-1748: The substrate of UDP-glucuronosyltransferases 2B7, 2B17 and the inhibitor of 1A9 and 2B7. Acridines 45-53 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 85-123 29723751-8 2018 Pentachlorophenol (PCP) was chosen as the representative CPs to determine the IC50 value towards UGT1A6, UGT1A9 and UGT2B7. Pentachlorophenol 19-22 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 116-122 29723751-8 2018 Pentachlorophenol (PCP) was chosen as the representative CPs to determine the IC50 value towards UGT1A6, UGT1A9 and UGT2B7. Chlorophenols 57-60 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 116-122 29723751-10 2018 PCP was demonstrated to show competitive inhibition towards UGT1A6, UGT1A9 and UGT2B7, and the inhibition kinetic parameters (Ki) was calculated to be 0.18 muM, 0.01 muM and 5.37 muM for the inhibition of PCP towards UGT1A6, UGT1A9 and UGT2B7. Pentachlorophenol 0-3 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 79-85 30170758-2 2018 The primary enzyme involved in the metabolism of ertugliflozin is uridine diphosphate-glucuronosyltransferase (UGT) 1A9, with minor contributions from UGT2B7 and cytochrome P450 (CYP) isoenzymes 3A4, 3A5, and 2C8. ertugliflozin 49-62 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 151-157 29723751-10 2018 PCP was demonstrated to show competitive inhibition towards UGT1A6, UGT1A9 and UGT2B7, and the inhibition kinetic parameters (Ki) was calculated to be 0.18 muM, 0.01 muM and 5.37 muM for the inhibition of PCP towards UGT1A6, UGT1A9 and UGT2B7. Pentachlorophenol 0-3 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 236-242 30170758-3 2018 Rifampin induces UGT1A9, UGT2B7, CYP3A4, and CYP3A5. Rifampin 0-8 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 25-31 29723751-10 2018 PCP was demonstrated to show competitive inhibition towards UGT1A6, UGT1A9 and UGT2B7, and the inhibition kinetic parameters (Ki) was calculated to be 0.18 muM, 0.01 muM and 5.37 muM for the inhibition of PCP towards UGT1A6, UGT1A9 and UGT2B7. Pentachlorophenol 205-208 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 79-85 30072626-7 2018 Moreover, we identified that UGT2B7 is the major UGT isoform catalyzing the glucuronidation of loxoprofen and its alcoholic metabolites. loxoprofen 95-105 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 29-35 32002956-0 2018 Drug-drug interaction potential of antitumor acridine agent C-1748: The substrate of UDP-glucuronosyltransferases 2B7, 2B17 and the inhibitor of 1A9 and 2B7. Acridines 45-53 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 85-123 32002956-0 2018 Drug-drug interaction potential of antitumor acridine agent C-1748: The substrate of UDP-glucuronosyltransferases 2B7, 2B17 and the inhibitor of 1A9 and 2B7. 9-(2'-hydroxyethylamino)-4-methyl-1-nitroacridine 60-66 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 85-123 29666902-0 2018 Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model. Valproic Acid 41-54 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 31-37 32186076-6 2018 YMJHT inhibited CYP2E1 activity, with a negligible inhibition on the activities of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, UGT1A1, UGT1A4 and UGT2B7. ymjht 0-5 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 151-157 29695616-7 2018 Integration of UGT2B7 abundance in cirrhotic livers into the liver cirrhosis (Child Pugh C) model of Simcyp improved the prediction of zidovudine and morphine PK in subjects with Child Pugh C liver cirrhosis. Zidovudine 135-145 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 15-21 29920988-0 2018 PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small Infants. Morphine 14-22 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 79-85 29920988-6 2018 This study suggests that morphine exhibits age-dependent extraction, likely due to the developmental increase in OCT1 and UGT2B7 protein expression/activity and hepatic blood-flow. Morphine 25-33 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 122-128 29502154-0 2018 The impact of UGT2B7 C802T and CYP3A4*1G polymorphisms on pain relief in cancer patients receiving oxycontin. Oxycodone 99-108 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 14-20 29502154-8 2018 CONCLUSION: The palliative effect of oxycontin is better in patients with UGT2B7 802CC than in those with 802TT. Oxycodone 37-46 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 74-80 29695616-7 2018 Integration of UGT2B7 abundance in cirrhotic livers into the liver cirrhosis (Child Pugh C) model of Simcyp improved the prediction of zidovudine and morphine PK in subjects with Child Pugh C liver cirrhosis. Morphine 150-158 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 15-21 30045320-0 2018 Effects of CYP3A5 and UGT2B7 variants on steady-state carbamazepine concentrations in Chinese epileptic patients. Carbamazepine 54-67 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 22-28 30045320-8 2018 UGT2B7*2 patients exhibited lower dose-normalized CBZ concentrations and larger CBZ dose requirements than UGT2B7*1/*1 patients (P = .0139, P = .032, respectively). Carbamazepine 50-53 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 30045320-8 2018 UGT2B7*2 patients exhibited lower dose-normalized CBZ concentrations and larger CBZ dose requirements than UGT2B7*1/*1 patients (P = .0139, P = .032, respectively). Carbamazepine 80-83 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 30045320-10 2018 Moreover, a significant difference in body weight-normalized CBZ dose between UGT2B7 GC and TT haplotype patients was observed (P = .0154). Carbamazepine 61-64 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 78-84 30045320-11 2018 In conclusion, our study found that the UGT2B7*2 variant, but not the CYP3A5*3 or UGT2B7*3 variant, could affect steady-state CBZ concentrations in epileptic patients. Carbamazepine 126-129 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 40-46 29164523-7 2018 This result was supported by the correlation between M11 formation activity and UGT2B7 marker enzyme activity (3-glucuronidation of morphine, r 2 = 0.330, p = 0.020) in individual HLMs; inhibition by mefenamic acid in pooled HLMs (IC50 = 22.8 muM); and relatively similar K m values between pooled HLMs and rhUGT2B7 (1260 vs. 486 muM). Morphine 132-140 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 80-86 29172026-8 2018 Morphine is mainly excreted as phase II metabolites: about 70% of the parent compound is found to be biotransformed by UGT2B7 to morphine-3-glucuronide (6065%) and morphine-6-glucuronide (5-10%). Morphine 0-8 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 119-125 29172026-8 2018 Morphine is mainly excreted as phase II metabolites: about 70% of the parent compound is found to be biotransformed by UGT2B7 to morphine-3-glucuronide (6065%) and morphine-6-glucuronide (5-10%). morphine-3-glucuronide 129-151 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 119-125 29172026-9 2018 A reduction of the enzymatic activity of the UGT2B7 was recorded in the presence of 9 of the 14 drugs under investigation (ketoconazole, miconazole, itraconazole, diclofenac, ibuprofen, clonazepam, lorazepam, lormetazepam, and triazolam), with a consequent significant reduction of the levels of the glucuronide metabolites. Ketoconazole 123-135 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 45-51 29172026-9 2018 A reduction of the enzymatic activity of the UGT2B7 was recorded in the presence of 9 of the 14 drugs under investigation (ketoconazole, miconazole, itraconazole, diclofenac, ibuprofen, clonazepam, lorazepam, lormetazepam, and triazolam), with a consequent significant reduction of the levels of the glucuronide metabolites. Miconazole 137-147 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 45-51 29172026-9 2018 A reduction of the enzymatic activity of the UGT2B7 was recorded in the presence of 9 of the 14 drugs under investigation (ketoconazole, miconazole, itraconazole, diclofenac, ibuprofen, clonazepam, lorazepam, lormetazepam, and triazolam), with a consequent significant reduction of the levels of the glucuronide metabolites. Itraconazole 149-161 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 45-51 29172026-9 2018 A reduction of the enzymatic activity of the UGT2B7 was recorded in the presence of 9 of the 14 drugs under investigation (ketoconazole, miconazole, itraconazole, diclofenac, ibuprofen, clonazepam, lorazepam, lormetazepam, and triazolam), with a consequent significant reduction of the levels of the glucuronide metabolites. Diclofenac 163-173 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 45-51 29172026-9 2018 A reduction of the enzymatic activity of the UGT2B7 was recorded in the presence of 9 of the 14 drugs under investigation (ketoconazole, miconazole, itraconazole, diclofenac, ibuprofen, clonazepam, lorazepam, lormetazepam, and triazolam), with a consequent significant reduction of the levels of the glucuronide metabolites. Ibuprofen 175-184 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 45-51 29172026-9 2018 A reduction of the enzymatic activity of the UGT2B7 was recorded in the presence of 9 of the 14 drugs under investigation (ketoconazole, miconazole, itraconazole, diclofenac, ibuprofen, clonazepam, lorazepam, lormetazepam, and triazolam), with a consequent significant reduction of the levels of the glucuronide metabolites. Clonazepam 186-196 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 45-51 29172026-9 2018 A reduction of the enzymatic activity of the UGT2B7 was recorded in the presence of 9 of the 14 drugs under investigation (ketoconazole, miconazole, itraconazole, diclofenac, ibuprofen, clonazepam, lorazepam, lormetazepam, and triazolam), with a consequent significant reduction of the levels of the glucuronide metabolites. Lorazepam 198-207 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 45-51 29172026-9 2018 A reduction of the enzymatic activity of the UGT2B7 was recorded in the presence of 9 of the 14 drugs under investigation (ketoconazole, miconazole, itraconazole, diclofenac, ibuprofen, clonazepam, lorazepam, lormetazepam, and triazolam), with a consequent significant reduction of the levels of the glucuronide metabolites. Glucuronides 300-311 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 45-51 29172026-9 2018 A reduction of the enzymatic activity of the UGT2B7 was recorded in the presence of 9 of the 14 drugs under investigation (ketoconazole, miconazole, itraconazole, diclofenac, ibuprofen, clonazepam, lorazepam, lormetazepam, and triazolam), with a consequent significant reduction of the levels of the glucuronide metabolites. lormetazepam 209-221 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 45-51 29172026-9 2018 A reduction of the enzymatic activity of the UGT2B7 was recorded in the presence of 9 of the 14 drugs under investigation (ketoconazole, miconazole, itraconazole, diclofenac, ibuprofen, clonazepam, lorazepam, lormetazepam, and triazolam), with a consequent significant reduction of the levels of the glucuronide metabolites. Triazolam 227-236 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 45-51 29587224-7 2018 As for the regioselectivity, except for UGT1A8 and UGT2B7, most UGT isoforms exhibit preference for the position of 3-OH on icaritin structure. icaritin 124-132 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 51-57 29272031-7 2018 The GCGG haplotype of UGT2B7 was also associated with breast cancer (OR = 1.22, 95% CI = 1.04-1.45; P = .027). gcgg 4-8 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 22-28 29679912-0 2018 Effects of UGT2B7, SCN1A and CYP3A4 on the therapeutic response of sodium valproate treatment in children with generalized seizures. Valproic Acid 67-83 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 11-17 28903608-0 2018 Influence of substrates on the in vitro kinetics of steviol glucuronidation and interaction between steviol glycosides metabolites and UGT2B7. stevioside 100-118 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 135-141 28903608-3 2018 The present study investigated kinetics of steviol glucuronidation in human liver microsome and a recombinant human UDP-glucuronosyltransferases isomer, UGT2B7, along with molecular docking to analyse interaction between UGT2B7 and steviol or glucose. steviol 43-50 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 153-159 28903608-3 2018 The present study investigated kinetics of steviol glucuronidation in human liver microsome and a recombinant human UDP-glucuronosyltransferases isomer, UGT2B7, along with molecular docking to analyse interaction between UGT2B7 and steviol or glucose. steviol 43-50 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 221-227 29679912-7 2018 CONCLUSION: In children with generalized seizures on VPA therapy, polymorphisms of UGT2B7, CYP3A4, and SCN1A genes were associated with seizure reduction. Valproic Acid 53-56 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 83-89 28398354-3 2018 Recently, trans-acting opiate metabolism and analgesic response enzymes (UGT2B7, ABCB1, OPRM1 and COMT) have been incorporated into pharmacogenetic studies to generate more comprehensive metabolic profiles of patients. Opiate Alkaloids 23-29 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 73-79 28548030-5 2018 The results showed that 100 muM of everolimus exerted more than 80% inhibition toward UGT1A1, UGT-1A3 and UGT-2B7. Everolimus 35-45 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 106-113 28548030-6 2018 UGT1A3 and UGT2B7 were selected to elucidate the inhibition mechanism, and in silico docking showed that hydrogen bonds and hydrophobic interactions mainly contributed to the strong binding of everolimus toward the activity cavity of UGT1A3 and UGT2B7. Hydrogen 105-113 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 245-251 28548030-6 2018 UGT1A3 and UGT2B7 were selected to elucidate the inhibition mechanism, and in silico docking showed that hydrogen bonds and hydrophobic interactions mainly contributed to the strong binding of everolimus toward the activity cavity of UGT1A3 and UGT2B7. Everolimus 193-203 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 11-17 28548030-6 2018 UGT1A3 and UGT2B7 were selected to elucidate the inhibition mechanism, and in silico docking showed that hydrogen bonds and hydrophobic interactions mainly contributed to the strong binding of everolimus toward the activity cavity of UGT1A3 and UGT2B7. Everolimus 193-203 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 245-251 28548030-8 2018 The inhibition kinetic parameters (Ki) were calculated to be 2.3, 0.07 and 4.4 muM for the inhibition of everolimus toward UGT1A1, UGT-1A3 and UGT-2B7, respectively. Everolimus 105-115 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 143-150 29328989-4 2018 100 muM phthalate monoesters exhibited negligible inhibition towards the activity of UGT1A1, UGT1A3, UGT1A6, UGT1A8, UGT1A10, UGT2B4, UGT2B7, UGT2B15 and UGT2B17. phthalic acid 8-17 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 134-140 29243113-0 2018 Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis. Valproic Acid 54-67 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 10-16 29243113-8 2018 We found that the UGT2B7 G211T polymorphism was associated with adjusted plasma VPA concentration (GG versus TT: P = 0.01, I 2 = 97%; GG versus GT: P < 0.00001, I 2 = 0%). Valproic Acid 80-83 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 18-24 29562678-6 2018 Five UGTs (UGT1A3, UGT2B4, UGT2B7, UGT1A9 and UGT1A8) were identified that produced abundant Ib monoglucuronide, especially UGT1A3. ib monoglucuronide 93-111 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 27-33 29138287-8 2018 The UGT2B17 inhibitor imatinib and the UGT2B7 and UGT1A9 inhibitor mefenamic acid inhibited clopidogrel carboxylic acid glucuronidation in HIMs and HLMs, respectively. clopidogrel carboxylic acid 92-119 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 39-45 29240983-6 2018 The formation of CAG was significantly inhibited by azidothymidine and gemfibrozil (well-characterized UGT2B7 substrates) in a concentration-dependent manner, or by fluconazole (a typical UGT2B7-selective inhibitor) in a time-dependent manner, for both HLMs and rUGT2B7, respectively. Gemfibrozil 71-82 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 103-109 29240983-6 2018 The formation of CAG was significantly inhibited by azidothymidine and gemfibrozil (well-characterized UGT2B7 substrates) in a concentration-dependent manner, or by fluconazole (a typical UGT2B7-selective inhibitor) in a time-dependent manner, for both HLMs and rUGT2B7, respectively. Gemfibrozil 71-82 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 188-194 29240983-6 2018 The formation of CAG was significantly inhibited by azidothymidine and gemfibrozil (well-characterized UGT2B7 substrates) in a concentration-dependent manner, or by fluconazole (a typical UGT2B7-selective inhibitor) in a time-dependent manner, for both HLMs and rUGT2B7, respectively. Fluconazole 165-176 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 188-194 29240983-7 2018 In addition, CCA inhibited azidothymidine glucuronidation (catalyzed almost exclusively by UGT2B7) by HLMs and rUGT2B7 in a concentration-dependent manner, indicating that CCA is a substrate of UGT2B7. clopidogrel carboxylic acid 13-16 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 91-97 29240983-7 2018 In addition, CCA inhibited azidothymidine glucuronidation (catalyzed almost exclusively by UGT2B7) by HLMs and rUGT2B7 in a concentration-dependent manner, indicating that CCA is a substrate of UGT2B7. clopidogrel carboxylic acid 13-16 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 112-118 29240983-7 2018 In addition, CCA inhibited azidothymidine glucuronidation (catalyzed almost exclusively by UGT2B7) by HLMs and rUGT2B7 in a concentration-dependent manner, indicating that CCA is a substrate of UGT2B7. Zidovudine 27-41 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 91-97 29240983-7 2018 In addition, CCA inhibited azidothymidine glucuronidation (catalyzed almost exclusively by UGT2B7) by HLMs and rUGT2B7 in a concentration-dependent manner, indicating that CCA is a substrate of UGT2B7. Zidovudine 27-41 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 112-118 29240983-7 2018 In addition, CCA inhibited azidothymidine glucuronidation (catalyzed almost exclusively by UGT2B7) by HLMs and rUGT2B7 in a concentration-dependent manner, indicating that CCA is a substrate of UGT2B7. clopidogrel carboxylic acid 172-175 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 91-97 29240983-7 2018 In addition, CCA inhibited azidothymidine glucuronidation (catalyzed almost exclusively by UGT2B7) by HLMs and rUGT2B7 in a concentration-dependent manner, indicating that CCA is a substrate of UGT2B7. clopidogrel carboxylic acid 172-175 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 112-118 29240983-8 2018 These results reveal that UGT2B7 is the major enzyme catalyzing clopidogrel glucuronidation in the human liver, and that there is the potential for drug-drug interactions between clopidogrel and the other substrate drugs of UGT2B7. Clopidogrel 64-75 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 26-32 29240983-8 2018 These results reveal that UGT2B7 is the major enzyme catalyzing clopidogrel glucuronidation in the human liver, and that there is the potential for drug-drug interactions between clopidogrel and the other substrate drugs of UGT2B7. Clopidogrel 64-75 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 224-230 29240983-8 2018 These results reveal that UGT2B7 is the major enzyme catalyzing clopidogrel glucuronidation in the human liver, and that there is the potential for drug-drug interactions between clopidogrel and the other substrate drugs of UGT2B7. Clopidogrel 179-190 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 26-32 29240983-8 2018 These results reveal that UGT2B7 is the major enzyme catalyzing clopidogrel glucuronidation in the human liver, and that there is the potential for drug-drug interactions between clopidogrel and the other substrate drugs of UGT2B7. Clopidogrel 179-190 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 224-230 29138287-0 2018 Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions . clopidogrel carboxylic acid 0-27 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 66-72 29138287-5 2018 UGT2B7 and UGT2B17 exhibited the greatest level of clopidogrel carboxylic acid glucuronidation activities, with a CLint,u of 2.42 and 2.82 microl min-1 mg-1, respectively. clopidogrel carboxylic acid 51-78 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 29138287-8 2018 The UGT2B17 inhibitor imatinib and the UGT2B7 and UGT1A9 inhibitor mefenamic acid inhibited clopidogrel carboxylic acid glucuronidation in HIMs and HLMs, respectively. Mefenamic Acid 67-81 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 39-45 29285606-9 2018 Regarding phase II metabolism, UGT2B7, 1A8 and 1A3 showed highest activity in glucuronidation of tamoxifen bisphenol and metabolite E. Anti-estrogenic metabolites (Z)-4-hydroxytamoxifen, (Z)-endoxifen and (Z)-norendoxifen inhibited the activity of CYP2C enzymes while tamoxifen bisphenol consistently induced CYPs similar to rifampicin and phenobarbital. 1,1-bis(4-hydroxyphenyl)-2-phenylbut-1-ene 97-116 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 31-37 29285606-9 2018 Regarding phase II metabolism, UGT2B7, 1A8 and 1A3 showed highest activity in glucuronidation of tamoxifen bisphenol and metabolite E. Anti-estrogenic metabolites (Z)-4-hydroxytamoxifen, (Z)-endoxifen and (Z)-norendoxifen inhibited the activity of CYP2C enzymes while tamoxifen bisphenol consistently induced CYPs similar to rifampicin and phenobarbital. hydroxytamoxifen 163-185 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 31-37 29285606-9 2018 Regarding phase II metabolism, UGT2B7, 1A8 and 1A3 showed highest activity in glucuronidation of tamoxifen bisphenol and metabolite E. Anti-estrogenic metabolites (Z)-4-hydroxytamoxifen, (Z)-endoxifen and (Z)-norendoxifen inhibited the activity of CYP2C enzymes while tamoxifen bisphenol consistently induced CYPs similar to rifampicin and phenobarbital. 4-hydroxy-N-desmethyltamoxifen 187-200 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 31-37 29285606-9 2018 Regarding phase II metabolism, UGT2B7, 1A8 and 1A3 showed highest activity in glucuronidation of tamoxifen bisphenol and metabolite E. Anti-estrogenic metabolites (Z)-4-hydroxytamoxifen, (Z)-endoxifen and (Z)-norendoxifen inhibited the activity of CYP2C enzymes while tamoxifen bisphenol consistently induced CYPs similar to rifampicin and phenobarbital. (z)-norendoxifen 205-221 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 31-37 29285606-9 2018 Regarding phase II metabolism, UGT2B7, 1A8 and 1A3 showed highest activity in glucuronidation of tamoxifen bisphenol and metabolite E. Anti-estrogenic metabolites (Z)-4-hydroxytamoxifen, (Z)-endoxifen and (Z)-norendoxifen inhibited the activity of CYP2C enzymes while tamoxifen bisphenol consistently induced CYPs similar to rifampicin and phenobarbital. 1,1-bis(4-hydroxyphenyl)-2-phenylbut-1-ene 268-287 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 31-37 29285606-9 2018 Regarding phase II metabolism, UGT2B7, 1A8 and 1A3 showed highest activity in glucuronidation of tamoxifen bisphenol and metabolite E. Anti-estrogenic metabolites (Z)-4-hydroxytamoxifen, (Z)-endoxifen and (Z)-norendoxifen inhibited the activity of CYP2C enzymes while tamoxifen bisphenol consistently induced CYPs similar to rifampicin and phenobarbital. Rifampin 325-335 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 31-37 29285606-9 2018 Regarding phase II metabolism, UGT2B7, 1A8 and 1A3 showed highest activity in glucuronidation of tamoxifen bisphenol and metabolite E. Anti-estrogenic metabolites (Z)-4-hydroxytamoxifen, (Z)-endoxifen and (Z)-norendoxifen inhibited the activity of CYP2C enzymes while tamoxifen bisphenol consistently induced CYPs similar to rifampicin and phenobarbital. Phenobarbital 340-353 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 31-37 29363349-2 2018 Fentanyl (metabolized by Cytochrome P450 3A4) and morphine (glucuronidated by UDP-glucuronosyltransferase-2B7) served as model drugs to provide insight in maturation patterns of these enzymes and provide understanding of the impact of non-maturational factors to optimize dosing in infants. Morphine 50-58 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 78-109 29190510-2 2018 Downstream metabolic enzymes encoded by UGT2B7, ABCB1, OPRM1, and COMT also have been implicated in variable individual response to drugs due to their activity at different stages of the tramadol ADME (absorption, distribution, metabolism, and excretion) process. Tramadol 187-195 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 40-46 29203276-0 2018 Effect of UGT2B7*2 and CYP2C8*4 polymorphisms on diclofenac metabolism. Diclofenac 49-59 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 10-16 29203276-5 2018 Previous association studies showed that possession of the UGT2B7*2 and CYP2C8*4 alleles is more common in cases of diclofenac-induced DILI. Diclofenac 116-126 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 59-65 29203276-6 2018 In the present study, the metabolism of diclofenac by UGT2B7*2 and CYP2C8*4 was compared with their corresponding wild-type enzymes. Diclofenac 40-50 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 54-60 29203276-7 2018 Enzyme kinetic analysis revealed that recombinant UGT2B7*2 showed an almost 6-fold lower intrinsic clearance of diclofenac glucuronidation compared to UGT2B7*1. Diclofenac 112-122 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 50-56 29203276-9 2018 Therefore, a decreased hepatic exposure to diclofenac acyl glucuronide is expected in patients with the UGT2B7*2 genotype. 1-O-(2-((2',6'-dichlorophenyl)amino)phenylacetyl)glucopyranuronic acid 43-70 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 104-110 29425147-0 2018 Inhibitory Effect of Sauchinone on UDP-Glucuronosyltransferase (UGT) 2B7 Activity. sauchinone 21-31 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 35-72 29425147-7 2018 In in vivo interaction study using mice, sauchinone inhibited UGT2B7-mediated zidovudine metabolism, resulting in increased systemic exposure of zidovudine when sauchinone and zidovudine were co-administered together. sauchinone 41-51 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 62-68 29425147-7 2018 In in vivo interaction study using mice, sauchinone inhibited UGT2B7-mediated zidovudine metabolism, resulting in increased systemic exposure of zidovudine when sauchinone and zidovudine were co-administered together. Zidovudine 78-88 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 62-68 29425147-7 2018 In in vivo interaction study using mice, sauchinone inhibited UGT2B7-mediated zidovudine metabolism, resulting in increased systemic exposure of zidovudine when sauchinone and zidovudine were co-administered together. Zidovudine 145-155 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 62-68 29425147-7 2018 In in vivo interaction study using mice, sauchinone inhibited UGT2B7-mediated zidovudine metabolism, resulting in increased systemic exposure of zidovudine when sauchinone and zidovudine were co-administered together. sauchinone 161-171 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 62-68 29425147-7 2018 In in vivo interaction study using mice, sauchinone inhibited UGT2B7-mediated zidovudine metabolism, resulting in increased systemic exposure of zidovudine when sauchinone and zidovudine were co-administered together. Zidovudine 145-155 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 62-68 29425147-8 2018 Our results indicated that there is potential HDI between sauchinone and drugs undergoing UGT2B7-mediated metabolism, possibly contributing to the safe use of sauchinone and drug combinations. sauchinone 58-68 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 90-96 29425147-8 2018 Our results indicated that there is potential HDI between sauchinone and drugs undergoing UGT2B7-mediated metabolism, possibly contributing to the safe use of sauchinone and drug combinations. sauchinone 159-169 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 90-96 29240983-0 2018 Human UGT2B7 is the major isoform responsible for the glucuronidation of clopidogrel carboxylate. clopidogrel carboxylate 73-96 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 6-12 29240983-6 2018 The formation of CAG was significantly inhibited by azidothymidine and gemfibrozil (well-characterized UGT2B7 substrates) in a concentration-dependent manner, or by fluconazole (a typical UGT2B7-selective inhibitor) in a time-dependent manner, for both HLMs and rUGT2B7, respectively. GUANOSINE 5'-TRIPHOSPHATE P3-[1-(2-NITROPHENYL)ETHYL ESTER] 17-20 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 103-109 29240983-6 2018 The formation of CAG was significantly inhibited by azidothymidine and gemfibrozil (well-characterized UGT2B7 substrates) in a concentration-dependent manner, or by fluconazole (a typical UGT2B7-selective inhibitor) in a time-dependent manner, for both HLMs and rUGT2B7, respectively. GUANOSINE 5'-TRIPHOSPHATE P3-[1-(2-NITROPHENYL)ETHYL ESTER] 17-20 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 188-194 29240983-6 2018 The formation of CAG was significantly inhibited by azidothymidine and gemfibrozil (well-characterized UGT2B7 substrates) in a concentration-dependent manner, or by fluconazole (a typical UGT2B7-selective inhibitor) in a time-dependent manner, for both HLMs and rUGT2B7, respectively. Zidovudine 52-66 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 103-109 29240983-6 2018 The formation of CAG was significantly inhibited by azidothymidine and gemfibrozil (well-characterized UGT2B7 substrates) in a concentration-dependent manner, or by fluconazole (a typical UGT2B7-selective inhibitor) in a time-dependent manner, for both HLMs and rUGT2B7, respectively. Zidovudine 52-66 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 188-194 28958730-0 2018 Correlations between UGT2B7*2 gene polymorphisms and plasma concentrations of carbamazepine and valproic acid in epilepsy patients. Carbamazepine 78-91 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 21-27 28958730-0 2018 Correlations between UGT2B7*2 gene polymorphisms and plasma concentrations of carbamazepine and valproic acid in epilepsy patients. Valproic Acid 96-109 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 21-27 28958730-7 2018 CONCLUSION: The UGT2B7*2 gene polymorphisms significantly affect the standard blood concentrations of VPA, but not CBZ. Valproic Acid 102-105 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 16-22 29241692-1 2018 This study aimed to investigate the liver microsomal inhibitory effects of silybin, silychristin, andrographolide, and curcumin by using morphine as an in vitro UGT2B7 probe substrate, and predict the magnitude of the herb-drug interaction arising from these herbal constituents" inhibition in vivo. Silybin 75-82 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 161-167 29241692-1 2018 This study aimed to investigate the liver microsomal inhibitory effects of silybin, silychristin, andrographolide, and curcumin by using morphine as an in vitro UGT2B7 probe substrate, and predict the magnitude of the herb-drug interaction arising from these herbal constituents" inhibition in vivo. Curcumin 119-127 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 161-167 29241692-1 2018 This study aimed to investigate the liver microsomal inhibitory effects of silybin, silychristin, andrographolide, and curcumin by using morphine as an in vitro UGT2B7 probe substrate, and predict the magnitude of the herb-drug interaction arising from these herbal constituents" inhibition in vivo. Morphine 137-145 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 161-167 29138287-11 2018 To conclude, clopidogrel carboxylic acid is metabolized mainly by UGT2B7 and UGT2B4 in the liver and by UGT2B17 in the small intestinal wall. clopidogrel carboxylic acid 13-40 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 66-72 27412850-7 2017 Reaction phenotyping utilising selective enzyme inhibitors and recombinant human UGT and CYP enzymes revealed UGT2B7 and UGT1A1, and CYP2C9 and CYP3A4 as the major enzymes involved in the metabolism of PAAH. paah 202-206 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 110-116 29395496-1 2018 OBJECTIVE: To evaluate the impact of maternal UGT1A4 and UGT2B7 genetic polymorphisms and sex of foetus on gestation-induced changes in lamotrigine (LTG) clearance during pregnancy and post-partum (PP). Lamotrigine 136-147 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 57-63 29375383-9 2017 Moreover, enzyme kinetics for R(+)-NAF, UGT2B7 (mean Km, 21 muM; mean Vmax, 1043 pmol/min/mg) showed significantly higher activity than observed for UGT2B4 and UGT1A9. r(+)-naf 30-38 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 40-46 29375383-10 2017 UGT2B4 (mean Km, 55 muM; mean Vmax, 1976 pmol/min/mg) and UGT2B7 (mean Km, 38 muM; mean Vmax, 1331 pmol/min/mg) showed significantly higher catalysis of glucuronidation of S(-)-NAF than UGT1A9. naftopidil 172-180 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 58-64 29375383-12 2017 These data indicate that UGT2B7 was the principal enzyme mediating glucuronidation of R(+)-NAF and S(-)-NAF. r(+)-naf 86-94 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 25-31 29375383-12 2017 These data indicate that UGT2B7 was the principal enzyme mediating glucuronidation of R(+)-NAF and S(-)-NAF. naftopidil 99-107 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 25-31 27855567-6 2017 In human in vitro systems, pradigastat is metabolized slowly to a stable acyl glucuronide (M18.4), catalyzed mainly by UDP-glucuronosyltransferases (UGT) 1A1, UGT1A3 and UGT2B7. acyl glucuronide 73-89 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 170-176 28500425-9 2017 Strong correlations were observed between the glucuronidation activities of 4-tOP and diclofenac (a probe for UGT2B7) or 4-hydroxybiphenyl (a probe for UGT2B15) with 0.79-0.88 of Spearman correlation coefficient (r s) values. 4-tert-octylphenol 76-81 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 110-116 28500425-9 2017 Strong correlations were observed between the glucuronidation activities of 4-tOP and diclofenac (a probe for UGT2B7) or 4-hydroxybiphenyl (a probe for UGT2B15) with 0.79-0.88 of Spearman correlation coefficient (r s) values. Diclofenac 86-96 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 110-116 28583088-10 2017 Finally, we found that liver-specific CHRNA4 transcription was highly correlated with genes involved in the nicotine metabolism, including CYP2A6, UGT2B7, and FMO3. Nicotine 108-116 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 147-153 28865089-7 2017 mRNA expression of UGT2B7 was suppressed by enzalutamide and its metabolite. enzalutamide 44-56 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 19-25 27692933-5 2017 Oxycodone-glucuronide was mainly produced by UGT2B7 (Km=762+-153muM, Vmax=344+-20 peak area/min/mg) and to a lesser extent by UGT2B4 (Km=2454+-497muM, Vmax=201+-19 peak area/min/mg). oxycodone-glucuronide 0-21 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 45-51 27692933-7 2017 Incubations of HLM with phase I and phase II drug probes showed that oxycodone mainly decreased the in vitro activities of CYP2D6, CYP3A4/5, UGT1A3, UGT1A6 and UGT2B subfamily with an important impact on UGT2B7. Oxycodone 69-78 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 204-210 28552915-0 2017 The regioselective glucuronidation of morphine by dimerized human UGT2B7, 1A1, 1A9 and their allelic variants. Morphine 38-46 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 66-72 28552915-1 2017 Uridine diphosphate-glucuronosyltransferase (UGT) 2B7 is expressed mostly in the human liver, lung and kidney and can transfer endogenous glucuronide group into its substrate and impact the pharmacological effects of several drugs such as estriol, AZT and morphine. Glucuronides 138-149 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-53 28552915-1 2017 Uridine diphosphate-glucuronosyltransferase (UGT) 2B7 is expressed mostly in the human liver, lung and kidney and can transfer endogenous glucuronide group into its substrate and impact the pharmacological effects of several drugs such as estriol, AZT and morphine. Estriol 239-246 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-53 28552915-1 2017 Uridine diphosphate-glucuronosyltransferase (UGT) 2B7 is expressed mostly in the human liver, lung and kidney and can transfer endogenous glucuronide group into its substrate and impact the pharmacological effects of several drugs such as estriol, AZT and morphine. Zidovudine 248-251 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-53 28552915-1 2017 Uridine diphosphate-glucuronosyltransferase (UGT) 2B7 is expressed mostly in the human liver, lung and kidney and can transfer endogenous glucuronide group into its substrate and impact the pharmacological effects of several drugs such as estriol, AZT and morphine. Morphine 256-264 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-53 28552915-3 2017 The current study was designed to identify this mechanism using morphine as the substrate of UGT2B7. Morphine 64-72 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 93-99 28552915-12 2017 The UGT1A9*2-UGT2B7*1 double enzyme has the lowest M3G:M6G ratio, reflecting that more M6G would form in morphine glucuronide metabolism. Morphine 105-113 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 13-19 28552915-12 2017 The UGT1A9*2-UGT2B7*1 double enzyme has the lowest M3G:M6G ratio, reflecting that more M6G would form in morphine glucuronide metabolism. Glucuronides 114-125 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 13-19 28552915-13 2017 This study demonstrates that UGT2B7 common SNPs and their dimers with UGT1A1 and UGT1A9 and their allelic variants can regioselectively affect the generation of two metabolites of morphine via altering the CLint ratios of M3G to M6G. Morphine 180-188 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 29-35 28063968-3 2017 The aim of this study was to evaluate the association between OCT1, ABCB1, and UGT2B7 variants, and morphine pharmacokinetics and -dynamics in healthy volunteers. Morphine 100-108 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 79-85 28246004-4 2017 Among them, UGT1A1, UGT1A3, UGT1A6, UGT1A9 and UGT2B7 contributed 95.6% to genistein glucuronidation in human liver, with significant correlation between gene expression of the five UGTs and the glucuronidation of genistein. Genistein 75-84 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-53 28418861-0 2017 Brain-derived neurotrophic factor involved epigenetic repression of UGT2B7 in colorectal carcinoma: A mechanism to alter morphine glucuronidation in tumor. Morphine 121-129 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 68-74 28418861-3 2017 Accordingly, morphine in CRC cells will stimulate the expression of its main metabolic enzyme, UGT2B7 during tolerance generation by activating the positive signals in histone 3, especially for trimethylated lysine 27 (H3K4Me3) and acetylated lysine 4 (H3K27Ac). Morphine 13-21 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 95-101 28418861-3 2017 Accordingly, morphine in CRC cells will stimulate the expression of its main metabolic enzyme, UGT2B7 during tolerance generation by activating the positive signals in histone 3, especially for trimethylated lysine 27 (H3K4Me3) and acetylated lysine 4 (H3K27Ac). Lysine 208-214 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 95-101 28418861-3 2017 Accordingly, morphine in CRC cells will stimulate the expression of its main metabolic enzyme, UGT2B7 during tolerance generation by activating the positive signals in histone 3, especially for trimethylated lysine 27 (H3K4Me3) and acetylated lysine 4 (H3K27Ac). Lysine 243-249 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 95-101 28418861-8 2017 Our findings imply that enzymatic activity enhancement and substrate regioselective catalysis alteration of UGT2B7 may release morphine tolerance under the cure of tumor-induced pain. Morphine 127-135 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 108-114 27359323-8 2017 In silico docking method was used to try to elucidate the inhibition mechanism of vitamin A toward UGT2B7. Vitamin A 82-91 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 99-105 27359323-9 2017 The results showed the significant contribution of hydrogen bonds and hydrophobic interaction on the UGT2B7 inhibition by vitamin A. Hydrogen 51-59 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 101-107 27359323-9 2017 The results showed the significant contribution of hydrogen bonds and hydrophobic interaction on the UGT2B7 inhibition by vitamin A. Vitamin A 122-131 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 101-107 27180825-15 2017 Glucuronidation of belinostat was markedly inhibited by emodin and apigenin (two potent inhibitors of UGT1A1), and by quinidine and diclofenac sodium (two selective inhibitors of UGT2B7). belinostat 19-29 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 179-185 28287454-6 2017 These in vitro results indicate that AM-2201 needs to be examined for potential pharmacokinetic drug interactions in vivo due to its potent inhibition of CYP2C8, CYP2C9, CYP3A4, UGT1A3, and UGT2B7 enzyme activities. 1-(5-fluoropentyl)-3-(1-naphthoyl)indole 37-44 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 190-196 27612916-6 2016 This amino acid change was predicted to create a putative N-glycosylation motif NX(S/T) subsequently validated upon endoglycosidase H treatment of microsomal fractions and inhibition of N-glycosylation of endogenously produced UGT2B7 with tunicamycin in human embryonic kidney (HEK293) cells. Nitrogen 58-59 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 227-233 28049954-3 2017 Three genetic loci (SLCO1B1, CYP3A4, and UGT2B7) were reported to affect ticagrelor pharmacokinetics. Ticagrelor 73-83 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 41-47 27612916-6 2016 This amino acid change was predicted to create a putative N-glycosylation motif NX(S/T) subsequently validated upon endoglycosidase H treatment of microsomal fractions and inhibition of N-glycosylation of endogenously produced UGT2B7 with tunicamycin in human embryonic kidney (HEK293) cells. Nitrogen 80-81 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 227-233 27612916-0 2016 A Rare UGT2B7 Variant Creates a Novel N-Glycosylation Site at Codon 121 with Impaired Enzyme Activity. Nitrogen 32-33 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 7-13 27612916-6 2016 This amino acid change was predicted to create a putative N-glycosylation motif NX(S/T) subsequently validated upon endoglycosidase H treatment of microsomal fractions and inhibition of N-glycosylation of endogenously produced UGT2B7 with tunicamycin in human embryonic kidney (HEK293) cells. Tunicamycin 239-250 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 227-233 27612916-7 2016 The presence of an additional N-linked glycan on the UGT2B7 enzyme, likely affecting proper protein folding, resulted in a significant decrease of 49% and 40% in the formation of zidovudine and mycophenolic acid glucuronides, respectively. n-linked glycan 30-45 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 53-59 27612916-5 2016 This low-frequency variation, found in two individuals of a population of 305 healthy volunteers, leads to the translation of an asparagine instead of an aspartic acid (UGT2B7 p.D121N). Asparagine 129-139 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 169-175 27612916-5 2016 This low-frequency variation, found in two individuals of a population of 305 healthy volunteers, leads to the translation of an asparagine instead of an aspartic acid (UGT2B7 p.D121N). Aspartic Acid 154-167 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 169-175 27612916-7 2016 The presence of an additional N-linked glycan on the UGT2B7 enzyme, likely affecting proper protein folding, resulted in a significant decrease of 49% and 40% in the formation of zidovudine and mycophenolic acid glucuronides, respectively. Zidovudine 179-189 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 53-59 27612916-7 2016 The presence of an additional N-linked glycan on the UGT2B7 enzyme, likely affecting proper protein folding, resulted in a significant decrease of 49% and 40% in the formation of zidovudine and mycophenolic acid glucuronides, respectively. mycophenolic acid glucuronide 194-224 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 53-59 27916843-5 2016 Deglycosylation of AST to CAG could strongly increase the inhibitory effects towards almost all of the tested UGT isoforms, with an IC50 of 0.84 muM and 11.28 muM for UGT1A8 and UGT2B7, respectively. GUANOSINE 5'-TRIPHOSPHATE P3-[1-(2-NITROPHENYL)ETHYL ESTER] 26-29 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 178-184 27916843-8 2016 From the second plot drawn with the slopes from the Lineweaver-Burk plot versus the concentrations of CAG, the inhibition constant (Ki) was calculated to be 0.034 muM and 20.98 muM for the inhibition of UGT1A8 and UGT2B7, respectively. GUANOSINE 5'-TRIPHOSPHATE P3-[1-(2-NITROPHENYL)ETHYL ESTER] 102-105 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 214-220 27899892-5 2016 We found a statistically significant increase (nominal p < 0.05) in the expression of UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT2B7, and UGT2B17, as well as glucuronidation activities of serotonin, testosterone, and vorinostat during the first 25 years of life. Vorinostat 220-230 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 129-135 27899892-5 2016 We found a statistically significant increase (nominal p < 0.05) in the expression of UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT2B7, and UGT2B17, as well as glucuronidation activities of serotonin, testosterone, and vorinostat during the first 25 years of life. Serotonin 191-200 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 129-135 27899892-5 2016 We found a statistically significant increase (nominal p < 0.05) in the expression of UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT2B7, and UGT2B17, as well as glucuronidation activities of serotonin, testosterone, and vorinostat during the first 25 years of life. Testosterone 202-214 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 129-135 27847477-0 2016 Reverse of Acute and Chronic Morphine Tolerance by Lithocholic Acid via Down-Regulating UGT2B7. Morphine 29-37 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 88-94 27176228-8 2016 On the other hand, DES displayed non-competitive inhibition against UGT2B7 in HLM, with the Ki value of 9.8 muM. Diethylstilbestrol 19-22 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 68-74 27847477-3 2016 In vivo assay, UGT2B7 was significantly repressed in the livers of acute or chronic morphine tolerance mice pretreated with LCA (10, 50, and 100 mg/kg, p.o.). Morphine 84-92 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 15-21 27847477-0 2016 Reverse of Acute and Chronic Morphine Tolerance by Lithocholic Acid via Down-Regulating UGT2B7. Lithocholic Acid 51-67 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 88-94 27847477-3 2016 In vivo assay, UGT2B7 was significantly repressed in the livers of acute or chronic morphine tolerance mice pretreated with LCA (10, 50, and 100 mg/kg, p.o.). Lithocholic Acid 124-127 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 15-21 27847477-2 2016 Our research showed that LCA can effectively inhibit uridine 5"-diphospho-glucuronosyltransferase 2B7 (UGT2B7) in morphine tolerance-like human normal liver cells, HL-7702, then increase mu-opioid receptor (MOR) and calcium-calmodulin dependent protein kinase IIalpha (CaMKIIalpha) expression. Lithocholic Acid 25-28 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 53-101 27847477-4 2016 To investigate the connections between LCA function performance and change of UGT2B7 enzymatic activity in mice livers, two morphine metabolites, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) were quantified by solid phase extraction (SPE)-HPLC-MS/MS. Lithocholic Acid 39-42 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 78-84 27847477-7 2016 As a consequence, UGT2B7 depression mediated by LCA can affect its selective catalysis ability to morphine, that may be responsible to acute or chronic morphine tolerance alleviation. Lithocholic Acid 48-51 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 18-24 27847477-2 2016 Our research showed that LCA can effectively inhibit uridine 5"-diphospho-glucuronosyltransferase 2B7 (UGT2B7) in morphine tolerance-like human normal liver cells, HL-7702, then increase mu-opioid receptor (MOR) and calcium-calmodulin dependent protein kinase IIalpha (CaMKIIalpha) expression. Lithocholic Acid 25-28 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 103-109 27847477-7 2016 As a consequence, UGT2B7 depression mediated by LCA can affect its selective catalysis ability to morphine, that may be responsible to acute or chronic morphine tolerance alleviation. Morphine 98-106 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 18-24 27847477-2 2016 Our research showed that LCA can effectively inhibit uridine 5"-diphospho-glucuronosyltransferase 2B7 (UGT2B7) in morphine tolerance-like human normal liver cells, HL-7702, then increase mu-opioid receptor (MOR) and calcium-calmodulin dependent protein kinase IIalpha (CaMKIIalpha) expression. Morphine 114-122 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 53-101 27847477-7 2016 As a consequence, UGT2B7 depression mediated by LCA can affect its selective catalysis ability to morphine, that may be responsible to acute or chronic morphine tolerance alleviation. Morphine 152-160 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 18-24 27847477-2 2016 Our research showed that LCA can effectively inhibit uridine 5"-diphospho-glucuronosyltransferase 2B7 (UGT2B7) in morphine tolerance-like human normal liver cells, HL-7702, then increase mu-opioid receptor (MOR) and calcium-calmodulin dependent protein kinase IIalpha (CaMKIIalpha) expression. Morphine 114-122 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 103-109 27795544-1 2016 BACKGROUND This study aimed to analyze the relationship of UGT2B7 and UGT1A4 polymorphisms with metabolism of valproic acid (VPA) and lamotrigine (LTG) in epileptic children. Lamotrigine 134-145 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 59-65 26808419-7 2016 The respective rates of DEF (UGT1A6), PRO (UGT1A9) and AZT (UGT2B7) glucuronidation by KCM were 1.4-, 5.2- and 10.5-fold higher than those for KMM. Zidovudine 55-58 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 60-66 27795544-1 2016 BACKGROUND This study aimed to analyze the relationship of UGT2B7 and UGT1A4 polymorphisms with metabolism of valproic acid (VPA) and lamotrigine (LTG) in epileptic children. Valproic Acid 110-123 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 59-65 27795544-1 2016 BACKGROUND This study aimed to analyze the relationship of UGT2B7 and UGT1A4 polymorphisms with metabolism of valproic acid (VPA) and lamotrigine (LTG) in epileptic children. Valproic Acid 125-128 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 59-65 27474751-6 2016 UGT2B7 protein levels were repressed in both HuH-7 and Hep3B cells in the presence of increasing miR-216b-5p concentrations, corresponding with significant (P < 0.001 and P = 0.011, respectively) decreases in glucuronidation activity against the UGT2B7-specific substrate epirubicin. mir-216b-5p 97-108 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 27474751-6 2016 UGT2B7 protein levels were repressed in both HuH-7 and Hep3B cells in the presence of increasing miR-216b-5p concentrations, corresponding with significant (P < 0.001 and P = 0.011, respectively) decreases in glucuronidation activity against the UGT2B7-specific substrate epirubicin. mir-216b-5p 97-108 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 249-255 27474751-6 2016 UGT2B7 protein levels were repressed in both HuH-7 and Hep3B cells in the presence of increasing miR-216b-5p concentrations, corresponding with significant (P < 0.001 and P = 0.011, respectively) decreases in glucuronidation activity against the UGT2B7-specific substrate epirubicin. Epirubicin 275-285 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 27474751-7 2016 Inhibition of endogenous miR-216b-5p levels significantly increased UGT2B7 mRNA levels in HuH-7 (P = 0.021) and Hep3B (P = 0.0068) cells, and increased epirubicin glucuronidation by 85% (P = 0.057) and 50% (P = 0.012) for HuH-7 and Hep3B cells, respectively. mir-216b-5p 25-36 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 68-74 27372715-6 2016 UDP-glucuronyltransferase (UGT) initial activity screening showed that UGT1A1, UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B15, and UGT2B17 formed desomorphine glucuronide. desomorphine glucuronide 148-172 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 112-118 26480899-6 2016 Incubation experiments have preliminarily shown that the glucuronidation of 19-norandrosterone is principally carried out by UGT2B7 (39%) and UGT2B17 (31%). 19-norandrosterone 76-94 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 125-131 27469576-3 2016 Haloperidol is mainly metabolized by Phase I CYP2D6 and to the lesser extent by CYP3A4 and by Phase II UGT2B7 enzymes. Haloperidol 0-11 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 103-109 27795544-1 2016 BACKGROUND This study aimed to analyze the relationship of UGT2B7 and UGT1A4 polymorphisms with metabolism of valproic acid (VPA) and lamotrigine (LTG) in epileptic children. Lamotrigine 147-150 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 59-65 27695274-7 2016 Both UGT1A1 and UGT2B7 were inhibited by the ethanol and aqueous extracts with IC50 values ranging between 9.59-22.76 mug/mL and 110.71-526.65 mug/Ml, respectively. Ethanol 45-52 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 16-22 26802129-7 2016 UGT2B7 catalyzed the stereoselective formation of glucuronides of hydroxybupropion, (S,S)-hydrobupropion, (S,R)- and (R,S)-hydrobupropion; UGT1A9 catalyzed the formation of (R,R)-hydrobupropion glucuronide. Glucuronides 50-62 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 26717295-0 2016 Effects of UGT2B7 Genetic Polymorphisms on Serum Concentrations of Valproic Acid in Chinese Children With Epilepsy Comedicated With Lamotrigine. Valproic Acid 67-80 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 11-17 26717295-0 2016 Effects of UGT2B7 Genetic Polymorphisms on Serum Concentrations of Valproic Acid in Chinese Children With Epilepsy Comedicated With Lamotrigine. Lamotrigine 132-143 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 11-17 26717295-4 2016 In this study, we seek to evaluate the effects of genetic polymorphisms of the UGT2B7 gene on serum VPA concentrations in epileptic children comedicated with lamotrigine (LTG). Lamotrigine 158-169 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 79-85 26717295-4 2016 In this study, we seek to evaluate the effects of genetic polymorphisms of the UGT2B7 gene on serum VPA concentrations in epileptic children comedicated with lamotrigine (LTG). Lamotrigine 171-174 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 79-85 26717295-11 2016 CONCLUSIONS: These results suggest that the UGT2B7 -161C > T or 802C > T mutations affect VPA pharmacokinetics, which are potentially enhanced by age and concomitant LTG administration. Lamotrigine 172-175 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 44-50 26790665-7 2016 RESULTS: We derived a formula to predict LTG concentrations that considers the daily dose of LTG, body weight, valproic acid concentration, phenytoin co-administration, and the co-administration of phenobarbital and/or carbamazepine as well as UGT1A4 142T>G and UGT2B7 -161C>T polymorphisms (adjusted coefficients of determination R (2) = 0.734). Lamotrigine 41-44 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 265-271 27232006-0 2016 UGT1A6- and UGT2B7-related valproic acid pharmacogenomics according to age groups and total drug concentration levels. Valproic Acid 27-40 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 12-18 26452313-0 2016 A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer. Epirubicin 60-70 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 2-37 26452313-1 2016 BACKGROUND: Epirubicin is metabolized by uridine glucuronosyltransferase 2B7 (UGT2B7), an enzyme rich in single nucleotide polymorphisms (SNPs). Epirubicin 12-22 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 41-76 26452313-1 2016 BACKGROUND: Epirubicin is metabolized by uridine glucuronosyltransferase 2B7 (UGT2B7), an enzyme rich in single nucleotide polymorphisms (SNPs). Epirubicin 12-22 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 78-84 26452313-2 2016 We studied whether the -161 C > T germline SNP in UGT2B7 was related to epirubicin metabolism and whether differences exist in the toxicity and efficacy of epirubicin-based chemotherapy among patients who were TT homozygotes, CT heterozygotes, and CC homozygotes. Epirubicin 75-85 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 53-59 26452313-9 2016 CONCLUSION: The results of the present prospective pharmacogenetic study suggest that the UGT2B7 -161 C > T SNP correlate with drug metabolism, toxicity, and efficacy in patients receiving epirubicin chemotherapy. Epirubicin 192-202 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 90-96 26452313-10 2016 Further studies of this UGT2B7 SNP as a predictor of epirubicin toxicity and efficacy are warranted. Epirubicin 53-63 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 24-30 26802129-7 2016 UGT2B7 catalyzed the stereoselective formation of glucuronides of hydroxybupropion, (S,S)-hydrobupropion, (S,R)- and (R,S)-hydrobupropion; UGT1A9 catalyzed the formation of (R,R)-hydrobupropion glucuronide. hydroxybupropion 66-82 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 26802129-7 2016 UGT2B7 catalyzed the stereoselective formation of glucuronides of hydroxybupropion, (S,S)-hydrobupropion, (S,R)- and (R,S)-hydrobupropion; UGT1A9 catalyzed the formation of (R,R)-hydrobupropion glucuronide. hydrobupropion 84-104 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 26802129-7 2016 UGT2B7 catalyzed the stereoselective formation of glucuronides of hydroxybupropion, (S,S)-hydrobupropion, (S,R)- and (R,S)-hydrobupropion; UGT1A9 catalyzed the formation of (R,R)-hydrobupropion glucuronide. Strontium 106-112 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 26802129-7 2016 UGT2B7 catalyzed the stereoselective formation of glucuronides of hydroxybupropion, (S,S)-hydrobupropion, (S,R)- and (R,S)-hydrobupropion; UGT1A9 catalyzed the formation of (R,R)-hydrobupropion glucuronide. (r,s)-hydrobupropion 117-137 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 26802129-7 2016 UGT2B7 catalyzed the stereoselective formation of glucuronides of hydroxybupropion, (S,S)-hydrobupropion, (S,R)- and (R,S)-hydrobupropion; UGT1A9 catalyzed the formation of (R,R)-hydrobupropion glucuronide. (r,r)-hydrobupropion glucuronide 173-205 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 26708612-6 2016 The Lineweaver-Burk plot showed that the intersection point was located in the vertical axis, indicating the competitive inhibition of (R)-carprofen on UGT2B7 in the incubation system with BSA, which is consistent with the inhibition kinetic type of (R)-carprofen on UGT2B7 in the incubation system without BSA. carprofen 135-148 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 152-158 26751618-7 2016 The jejunal content of UGT2B7 was positively associated with morphine AUC0-inf (rs = 0.4, p = 0.03). Morphine 61-69 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 23-29 26708612-6 2016 The Lineweaver-Burk plot showed that the intersection point was located in the vertical axis, indicating the competitive inhibition of (R)-carprofen on UGT2B7 in the incubation system with BSA, which is consistent with the inhibition kinetic type of (R)-carprofen on UGT2B7 in the incubation system without BSA. carprofen 135-148 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 267-273 26708612-6 2016 The Lineweaver-Burk plot showed that the intersection point was located in the vertical axis, indicating the competitive inhibition of (R)-carprofen on UGT2B7 in the incubation system with BSA, which is consistent with the inhibition kinetic type of (R)-carprofen on UGT2B7 in the incubation system without BSA. carprofen 250-263 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 152-158 26708612-9 2016 For (S)-carprofen, the intersection point was located in the horizontal axis in the Lineweaver-Burk plot for the incubation system with BSA, indicating the noncompetitive inhibition of (S)-carprofen on the activity of UGT2B7. carprofen 4-17 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 218-224 26708612-9 2016 For (S)-carprofen, the intersection point was located in the horizontal axis in the Lineweaver-Burk plot for the incubation system with BSA, indicating the noncompetitive inhibition of (S)-carprofen on the activity of UGT2B7. carprofen 185-198 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 218-224 26779253-4 2015 The drug metabolizing enzyme (DME), CYP2B6, is primarily responsible for EFV metabolism with minor contributions by CYP1A2, CYP2A6, CYP3A4, CYP3A5, and UGT2B7. dme 30-33 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 152-158 26547877-6 2016 100 microM of DNOP inhibited the activities of UGT1A3, UGT1A9, and UGT2B7 by 41.8% (p < 0.01), 45.6% (p < 0.01), and 48.8% (p < 0.01), respectively. di-n-octyl phthalate 14-18 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 67-73 26407805-8 2015 Both kinetic analysis and chemical inhibition assays demonstrated that UGT1A9, UGT2B7 and UGT2B17 played important roles in AR-4"-O-glucuronidation in HLM. arctigenin 124-126 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 79-85 26690104-6 2015 Glucuronidation of 4(S)-hydroxy-evogliptin (M2) to 4(S)-hydroxyevogliptin glucuronide (M4) was catalyzed by the enzymes UGT2B4 and UGT2B7. 4(s)-hydroxy-evogliptin 19-42 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 131-137 26690104-6 2015 Glucuronidation of 4(S)-hydroxy-evogliptin (M2) to 4(S)-hydroxyevogliptin glucuronide (M4) was catalyzed by the enzymes UGT2B4 and UGT2B7. 4(s)-hydroxyevogliptin glucuronide 51-85 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 131-137 28256933-0 2016 Association between UGT2B7 gene polymorphisms and fentanyl sensitivity in patients undergoing painful orthognathic surgery. Fentanyl 50-58 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 20-26 28256933-2 2016 The metabolism of morphine by glucuronidation is known to be influenced by polymorphisms of the UGT2B7 gene. Morphine 18-26 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 96-102 28256933-5 2016 We analyzed associations between fentanyl sensitivity and polymorphisms of the UGT2B7 gene to clarify the hereditary determinants of individual differences in fentanyl sensitivity. Fentanyl 33-41 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 79-85 28256933-5 2016 We analyzed associations between fentanyl sensitivity and polymorphisms of the UGT2B7 gene to clarify the hereditary determinants of individual differences in fentanyl sensitivity. Fentanyl 159-167 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 79-85 28256933-6 2016 Results This study examined whether single-nucleotide polymorphisms (SNPs) of the UGT2B7 gene affect cold pain sensitivity and the analgesic effects of fentanyl, evaluated by a standardized pain test and fentanyl requirements in healthy Japanese subjects who underwent uniform surgical procedures. single-nucleotide 36-53 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 82-88 28256933-6 2016 Results This study examined whether single-nucleotide polymorphisms (SNPs) of the UGT2B7 gene affect cold pain sensitivity and the analgesic effects of fentanyl, evaluated by a standardized pain test and fentanyl requirements in healthy Japanese subjects who underwent uniform surgical procedures. Fentanyl 204-212 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 82-88 28256933-7 2016 The rs7439366 SNP of UGT2B7 is reportedly associated with the metabolism and analgesic effects of morphine. Morphine 98-106 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 21-27 28256933-10 2016 Two SNPs of UGT2B7, rs4587017 and rs1002849, were also found to be novel SNPs that may influence the analgesic effects of fentanyl in the cold pressor-induced pain test. Fentanyl 122-130 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 12-18 28256933-11 2016 Conclusions Fentanyl sensitivity for cold pressor-induced pain was associated with the rs7439366, rs4587017, and rs1002849 SNPs of the UGT2B7 gene. Fentanyl 12-20 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 135-141 26407805-10 2015 CONCLUSION: UGT1A9, UGT2B7 and UGT2B17 were the major isoforms responsible for the 4"-O-glucuronidation of AR in HLM, while UGT2B7 and UGT2B17 were the major contributors to this biotransformation in HIM. 4"-o 83-87 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 20-26 26407805-10 2015 CONCLUSION: UGT1A9, UGT2B7 and UGT2B17 were the major isoforms responsible for the 4"-O-glucuronidation of AR in HLM, while UGT2B7 and UGT2B17 were the major contributors to this biotransformation in HIM. arctigenin 107-109 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 20-26 26407805-10 2015 CONCLUSION: UGT1A9, UGT2B7 and UGT2B17 were the major isoforms responsible for the 4"-O-glucuronidation of AR in HLM, while UGT2B7 and UGT2B17 were the major contributors to this biotransformation in HIM. arctigenin 107-109 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 124-130 26303110-0 2015 Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7 -161C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children. Lamotrigine 130-141 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 71-77 26303110-0 2015 Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7 -161C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children. Lamotrigine 130-141 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 95-101 26303110-1 2015 PURPOSE: To investigate the impact of valproic acid (VPA) and genetic polymorphism of the major metabolizing enzyme (UGT1A4, UGT2B7) of lamotrigine (LTG) and VPA on LTG concentration in Chinese epileptic children. Lamotrigine 136-147 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 125-131 26495850-0 2015 Correction: Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients. Tamoxifen 90-99 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 59-65 26220143-0 2015 Glucuronidation of estrone and 16alpha-hydroxyestrone by human UGT enzymes: The key roles of UGT1A10 and UGT2B7. Estrone 19-26 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 105-111 26220143-7 2015 Kinetic analyses revealed very low Km value for 16alpha-hydroxyestrone glucuronidation by UGT2B7, below 4 muM, suggesting higher affinity than commonly found among UGTs and their substrates. 16alpha-hydroxyestrone glucuronidation 48-86 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 90-96 26431339-9 2015 Sensitivity analysis suggested changes in CYP2C9 activity, and to a lesser extent UGT2B7, as the primary factor contributing to differences in indomethacin disposition between pregnancy and non-pregnancy. Indomethacin 143-155 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 82-88 26234632-9 2015 The N-terminal domain is less likely to be associated with UDP-sugar selectivity, although, a conserved residue, Arg-259 (UGT2B7 numbering) in the UGT 1 and 2 families may influence UDP-sugar selectivity. Arginine 113-116 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 122-128 26234632-9 2015 The N-terminal domain is less likely to be associated with UDP-sugar selectivity, although, a conserved residue, Arg-259 (UGT2B7 numbering) in the UGT 1 and 2 families may influence UDP-sugar selectivity. Uridine Diphosphate Sugars 182-191 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 122-128 26289097-9 2015 The N-terminal domain is less likely to be associated with UDP-sugar selectivity, although, a conserved residue, Arg-259 (UGT2B7 numbering) in the UGT 1 and 2 families may influence UDP-sugar selectivity. Arginine 113-116 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 122-128 26289097-9 2015 The N-terminal domain is less likely to be associated with UDP-sugar selectivity, although, a conserved residue, Arg-259 (UGT2B7 numbering) in the UGT 1 and 2 families may influence UDP-sugar selectivity. Uridine Diphosphate Sugars 182-191 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 122-128 26176234-0 2015 Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients. Tamoxifen 78-87 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-53 26163112-8 2015 Glucuronidation of homoegonol to M5 was mediated by UGT1A1, UGT1A3, UGT1A4, and UGT2B7 enzymes, whereas M4 was formed from 4-O-demethylhomoegonol by UGT1A1, UGT1A8, UGT1A10, and UGT2B15 enzymes. homoegonol 19-29 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 80-86 25935875-12 2015 CONCLUSION: In patients with ACS, ticagrelor pharmacokinetics is influenced by three genetic loci (SLCO1B1, UGT2B7, and CYP3A4). Ticagrelor 34-44 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 108-114 26088889-0 2015 The influence of UGT2B7 genotype on valproic acid pharmacokinetics in Chinese epilepsy patients. Valproic Acid 36-49 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 17-23 26088889-1 2015 PURPOSE: The aim of this study was to investigate the distribution and frequency of genetic polymorphisms in uridine diphosphate glucuronosyltransferase-2B7 (UGT2B7) in epilepsy patients and to evaluate the effect of these on the metabolism of valproic acid (VPA). Valproic Acid 244-257 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 158-164 26088889-1 2015 PURPOSE: The aim of this study was to investigate the distribution and frequency of genetic polymorphisms in uridine diphosphate glucuronosyltransferase-2B7 (UGT2B7) in epilepsy patients and to evaluate the effect of these on the metabolism of valproic acid (VPA). Valproic Acid 259-262 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 158-164 26176234-4 2015 This descriptive study examines correlations between concentrations of tamoxifen"s glucuronide metabolites and genotypes UGT1A4 Pro24Thr, UGT1A4 Leu48Val, UGT2B7 His268Tyr, UGT2B15 Asp85YTyr UGT2B15 Lys523Thr and UGT2B17del in 132 patients with estrogen receptor-positive breast cancer under treatment with tamoxifen. Tamoxifen 71-80 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 155-161 25713207-1 2015 We recently reported induction of UGT2B7 by its substrate epirubicin, a cytotoxic anthracycline anticancer drug, via activation of p53 and subsequent recruitment of p53 to the UGT2B7 promoter in hepatocellular carcinoma HepG2 cells. Epirubicin 58-68 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 34-40 25903196-4 2015 The inhibition difference capability was observed for the inhibition of (R)-zaltoprofen and (S)-zaltoprofen towards UGT1A8 and UGT2B7, but not for other tested UGT isoforms. (R)-Zaltoprofen 72-87 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 127-133 25770680-0 2015 Homo- and hetero-dimerization of human UDP-glucuronosyltransferase 2B7 (UGT2B7) wild type and its allelic variants affect zidovudine glucuronidation activity. Zidovudine 122-132 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 39-70 25770680-0 2015 Homo- and hetero-dimerization of human UDP-glucuronosyltransferase 2B7 (UGT2B7) wild type and its allelic variants affect zidovudine glucuronidation activity. Zidovudine 122-132 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 72-78 25770680-3 2015 UGT2B7 is one of the most important UGTs that glucuronidates abundant endobiotics and xenobiotics, such as estriol, morphine, and anticancer drugs. Estriol 107-114 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 25770680-3 2015 UGT2B7 is one of the most important UGTs that glucuronidates abundant endobiotics and xenobiotics, such as estriol, morphine, and anticancer drugs. Morphine 116-124 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 25770680-12 2015 These findings provide insights into the consequences of amino acid substitution in UGT2B7 on zidovudine glucuronidation and the association between protein-protein interaction and glucuronidation activity. Zidovudine 94-104 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 84-90 25713207-8 2015 Finally, chromatin immunoprecipitation assays demonstrated p53 recruitment to the UGT2B7 p53 site upon exposure to mitomycin C, the most potent UGT2B7 inducer among the nine tested drugs. Mitomycin 115-126 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 82-88 25713207-8 2015 Finally, chromatin immunoprecipitation assays demonstrated p53 recruitment to the UGT2B7 p53 site upon exposure to mitomycin C, the most potent UGT2B7 inducer among the nine tested drugs. Mitomycin 115-126 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 144-150 25713207-10 2015 The cytotoxic drug-induced UGT2B7 activity in target liver cancer cells or possibly in normal liver cells may affect the therapeutic efficacy of co-administered cytotoxic drugs (e.g., epirubicin) and noncytotoxic drugs (e.g., morphine), which are UGT2B7 substrates. Epirubicin 184-194 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 27-33 25713207-10 2015 The cytotoxic drug-induced UGT2B7 activity in target liver cancer cells or possibly in normal liver cells may affect the therapeutic efficacy of co-administered cytotoxic drugs (e.g., epirubicin) and noncytotoxic drugs (e.g., morphine), which are UGT2B7 substrates. Morphine 226-234 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 27-33 24927789-7 2015 UGT2B4 predominantly catalyzed the formation of DON-15-O-glucuronide (DON-15GlcA), while for UGT2B7 the DON-3-O-glucuronide (DON-3GlcA) metabolite prevailed. don-3-o-glucuronide 104-123 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 93-99 24927789-7 2015 UGT2B4 predominantly catalyzed the formation of DON-15-O-glucuronide (DON-15GlcA), while for UGT2B7 the DON-3-O-glucuronide (DON-3GlcA) metabolite prevailed. don-3glca 125-134 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 93-99 25903196-4 2015 The inhibition difference capability was observed for the inhibition of (R)-zaltoprofen and (S)-zaltoprofen towards UGT1A8 and UGT2B7, but not for other tested UGT isoforms. pyranoprofen 92-107 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 127-133 25903196-5 2015 (R)-zaltoprofen exhibited noncompetitive inhibition towards UGT1A8 and competitive inhibition towards UGT2B7. (R)-Zaltoprofen 0-15 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 102-108 25903196-8 2015 Based on the reported maximum plasma concentration of (R)-zaltoprofen in vivo, a high drug-drug interaction between (R)-zaltoprofen and the drugs mainly undergoing UGT1A7, UGT1A8, and UGT2B7-catalyzed glucuronidation was indicated. (R)-Zaltoprofen 116-131 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 184-190 25522350-5 2015 Piroxicam and niflumic acid inhibited UGT1A9 activity (IC50 = 73.8 mum and 0.38 mum, respectively) and naproxen selectively inhibited UGT2B7 activity (IC50 = 53.1 mum), whereas it did not inhibit the other UGTs tested (IC50 > 200 mum). Naproxen 103-111 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 134-140 25713207-1 2015 We recently reported induction of UGT2B7 by its substrate epirubicin, a cytotoxic anthracycline anticancer drug, via activation of p53 and subsequent recruitment of p53 to the UGT2B7 promoter in hepatocellular carcinoma HepG2 cells. Epirubicin 58-68 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 176-182 25713207-1 2015 We recently reported induction of UGT2B7 by its substrate epirubicin, a cytotoxic anthracycline anticancer drug, via activation of p53 and subsequent recruitment of p53 to the UGT2B7 promoter in hepatocellular carcinoma HepG2 cells. Anthracyclines 82-95 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 34-40 25713207-3 2015 We first demonstrated by reverse transcriptase quantitative real-time polymerase chain reaction that, as observed with epirubicin, nine cytotoxic drugs including three anthracyclines (doxorubicin, daunorubicin, and idarubicin) and six nonanthracyclines (mitomycin C, 5-fluorouracil, camptothecin, 7-ethyl-10-hydroxycamptothecin, topotecan, and etoposide) significantly increased UGT2B7 mRNA levels. Epirubicin 119-129 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 379-385 25496264-0 2015 Regioselective glucuronidation of gingerols by human liver microsomes and expressed UDP-glucuronosyltransferase enzymes: reaction kinetics and activity correlation analyses for UGT1A9 and UGT2B7. gingerol 34-43 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 188-194 25650382-9 2015 UGT2B7 activity is the most repressed in tumors relative to normal tissues, with a 96-fold decrease in zidovudine metabolism, whereas propofol and sorafenib glucuronidation is decreased by 7.6- and 5.2-fold, respectively. Zidovudine 103-113 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 25496264-7 2015 UGT1A8 (an intestinal enzyme), UGT1A9 and UGT2B7 were the enzymes showing the highest activity towards gingerols. gingerol 103-112 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 42-48 25496264-9 2015 UGT2B7 was the only enzyme that generated glucuronides at both 4"-OH and 5-OH sites, although a strong position preference was observed with 4"-OH (>=80.2%). Glucuronides 42-54 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 25496264-9 2015 UGT2B7 was the only enzyme that generated glucuronides at both 4"-OH and 5-OH sites, although a strong position preference was observed with 4"-OH (>=80.2%). 4"-oh 63-68 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 25496264-9 2015 UGT2B7 was the only enzyme that generated glucuronides at both 4"-OH and 5-OH sites, although a strong position preference was observed with 4"-OH (>=80.2%). 5-oh 73-77 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 25496264-9 2015 UGT2B7 was the only enzyme that generated glucuronides at both 4"-OH and 5-OH sites, although a strong position preference was observed with 4"-OH (>=80.2%). 4"-oh 141-146 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 25496264-10 2015 Further, activity correlation analyses indicated that UGT2B7 and UGT1A9 were primarily responsible for 4"-O-glucuronidation and 5-O-glucuronidation of gingerols in the liver, respectively. 4"-o 103-107 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 54-60 25496264-10 2015 Further, activity correlation analyses indicated that UGT2B7 and UGT1A9 were primarily responsible for 4"-O-glucuronidation and 5-O-glucuronidation of gingerols in the liver, respectively. 5-o 128-131 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 54-60 25496264-10 2015 Further, activity correlation analyses indicated that UGT2B7 and UGT1A9 were primarily responsible for 4"-O-glucuronidation and 5-O-glucuronidation of gingerols in the liver, respectively. gingerol 151-160 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 54-60 25502512-0 2015 Enantioselective inhibition of carprofen towards UDP-glucuronosyltransferase (UGT) 2B7. carprofen 31-40 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 49-86 25502512-4 2015 The results showed that (S)-carprofen exhibited stronger inhibition potential than (R)-carprofen towards UGT2B7. carprofen 24-37 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 105-111 25502512-4 2015 The results showed that (S)-carprofen exhibited stronger inhibition potential than (R)-carprofen towards UGT2B7. carprofen 83-96 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 105-111 25502512-6 2015 Furthermore, the inhibition kinetic behavior was compared for the inhibition of (S)-carprofen and (R)-carprofen towards UGT2B7. carprofen 80-93 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 120-126 25502512-6 2015 Furthermore, the inhibition kinetic behavior was compared for the inhibition of (S)-carprofen and (R)-carprofen towards UGT2B7. carprofen 98-111 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 120-126 25502512-7 2015 A Lineweaver-Burk plot showed that both (S)-carprofen and (R)-carprofen exhibited competitive inhibition towards UGT2B7-catalyzed 4-MU glucuronidation. carprofen 40-53 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 113-119 25502512-7 2015 A Lineweaver-Burk plot showed that both (S)-carprofen and (R)-carprofen exhibited competitive inhibition towards UGT2B7-catalyzed 4-MU glucuronidation. carprofen 58-71 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 113-119 25502512-10 2015 In conclusion, enantioselective inhibition of carprofen towards UDP-glucuronosyltransferase (UGT) 2B7 was demonstrated in the present study. carprofen 46-55 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 64-101 25502512-12 2015 Therefore, clinical monitoring of the plasma concentration of (S)-carprofen is more important than (R)-carprofen to avoid a possible drug-drug interaction between carprofen and the drugs mainly undergoing UGT2B7-catalyzed metabolism. carprofen 62-75 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 205-211 25502512-12 2015 Therefore, clinical monitoring of the plasma concentration of (S)-carprofen is more important than (R)-carprofen to avoid a possible drug-drug interaction between carprofen and the drugs mainly undergoing UGT2B7-catalyzed metabolism. carprofen 66-75 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 205-211 26419090-8 2015 All UGTs were capable of metabolizing ethanol through glucuronidation; UGT1A9 and UGT2B7 exhibited the highest formation rates. Ethanol 38-45 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 82-88 25052959-4 2015 HS-23 showed negligible inhibition of CYP1A2, CYP2C8, CYP2D6, UGT1A1, UGT1A4, UGT1A9, and UGT2B7 activities in human liver microsomes. hs-23 0-5 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 90-96 25760534-4 2015 While other UGT members such as UGT1A8, UGT2B7, and UGT2B15 showed glucuronidation activity toward trovafloxacin, the metabolic velocity was extremely low. trovafloxacin 99-112 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 40-46 26419090-12 2015 Inhibition was reversible and competitive for most enzymes; mechanism-based inhibition was evident for UGT2B7 and SULT2A1 with regard to quercetin and for SULT1E1 with regard to kaempferol. Quercetin 137-146 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 103-109 25476790-5 2014 The polymorphic effects of UGT1A9 (I399C>T) and UGT2B7*2 (802C>T), the major enzymes involved in the metabolism of DHA, on the pharmacokinetic profiles of DHA and its metabolite was also studied. artenimol 121-124 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 51-57 25823783-0 2015 SCN1A, ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy. Oxcarbazepine 78-91 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 17-23 26053558-10 2015 We found aprepitant to be a moderate inhibitor of UGT2B7 with a Ki of ~10 microM for 4-MU, morphine and zidovudine. Morphine 91-99 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 50-56 26053558-10 2015 We found aprepitant to be a moderate inhibitor of UGT2B7 with a Ki of ~10 microM for 4-MU, morphine and zidovudine. Zidovudine 104-114 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 50-56 26053558-12 2015 Given the likelihood for first-pass metabolism by intestinal UGT2B7, this is of particular concern for oral aprepitant co-administered with oral substrates of UGT2B7, such as zidovudine and morphine. Zidovudine 175-185 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 61-67 26053558-12 2015 Given the likelihood for first-pass metabolism by intestinal UGT2B7, this is of particular concern for oral aprepitant co-administered with oral substrates of UGT2B7, such as zidovudine and morphine. Morphine 190-198 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 61-67 24256307-0 2015 Influence of uridine diphosphate-glucuronyltransferase 2B7 (UGT2B7) variants on postoperative buprenorphine analgesia. Buprenorphine 94-107 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 60-66 24256307-3 2015 This study investigates a possible difference in the response to postoperative buprenorphine analgesia related to the presence of different isoforms (cytosine or thymine substitution at nucleotide 802) of UGT2B7 gene. Buprenorphine 79-92 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 205-211 24256307-3 2015 This study investigates a possible difference in the response to postoperative buprenorphine analgesia related to the presence of different isoforms (cytosine or thymine substitution at nucleotide 802) of UGT2B7 gene. Cytosine 150-158 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 205-211 24256307-3 2015 This study investigates a possible difference in the response to postoperative buprenorphine analgesia related to the presence of different isoforms (cytosine or thymine substitution at nucleotide 802) of UGT2B7 gene. Thymine 162-169 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 205-211 24256307-13 2015 CONCLUSIONS: The presence of the SNP 802C>T UGT2B7 (UGT2B7*2/*2) is associated with a worse analgesic response to transdermal buprenorphine in the postoperative period of thoracic surgery. Buprenorphine 129-142 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-53 24256307-13 2015 CONCLUSIONS: The presence of the SNP 802C>T UGT2B7 (UGT2B7*2/*2) is associated with a worse analgesic response to transdermal buprenorphine in the postoperative period of thoracic surgery. Buprenorphine 129-142 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 55-61 25540593-0 2014 Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms. Mycophenolic Acid 0-17 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 117-123 25540593-0 2014 Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms. Mycophenolic Acid 78-91 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 117-123 24631340-4 2014 High specific inhibition of andrographolide derivatives towards UGT2B7 was observed. andrographolide 28-43 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 64-70 25249502-9 2014 A correlation between genotype and 20-HETE glucuronidation revealed that UGT2B7 802C>T, UGT1A9 -118T9>T10, and UGT1A9 1399T>C significantly altered 20-HETE glucuronide formation (P < 0.05-0.001). 20-hydroxy-5,8,11,14-eicosatetraenoic acid 35-42 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 73-79 25249502-9 2014 A correlation between genotype and 20-HETE glucuronidation revealed that UGT2B7 802C>T, UGT1A9 -118T9>T10, and UGT1A9 1399T>C significantly altered 20-HETE glucuronide formation (P < 0.05-0.001). Glucuronides 165-176 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 73-79 25199627-5 2014 First, BaP-induced expression of key metabolic enzymes was analysed; expression levels of the activating CYP1A1 and CYP1B1 were increased, while the detoxifying enzymes UGT1A6 and UGT2B7 were significantly reduced by hypoxia. Benzo(a)pyrene 7-10 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 180-186 25219630-8 2014 Also, capsaicin glucuronidation was strongly correlated with zidovudine glucuronidation (r = 0.765; p < 0.01) and with UGT2B7 protein levels (r = 0.721; p < 0.01). Capsaicin 6-15 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 122-128 24706503-0 2014 The effect of UGT2B7*2 polymorphism on the pharmacokinetics of OROS hydromorphone in Taiwanese subjects. oros hydromorphone 63-82 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 14-20 24954688-6 2014 p-Cresol was the most potent individual inhibitor, producing >50% inhibition of CYP2E1, CYP3A4, UGT1A1, UGT1A9 and UGT2B7 at a concentration of 100 muM. 4-cresol 0-8 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 118-124 24631340-0 2014 Herb-drug interaction prediction based on the high specific inhibition of andrographolide derivatives towards UDP-glucuronosyltransferase (UGT) 2B7. andrographolide 74-89 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 110-147 24703092-3 2014 The aim of this study was to investigate the significance of UGT2B7, OPRM1 and ABCB1 polymorphisms for interindividual variability in morphine-induced analgesia in patients undergoing hysterectomy. Morphine 134-142 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 61-67 24703092-8 2014 Patients homozygous for UGT2B7 802C needed significantly lower dose of morphine for pain relief. Morphine 71-79 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 24-30 24703092-10 2014 The dose of morphine in patients included in this study was significantly related to variation in UGT2B7 T802C. Morphine 12-20 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 98-104 24526241-0 2014 Commonly used excipients modulate UDP-glucuronosyltransferase 2b7 activity to improve nalbuphine oral bioavailability in humans. Nalbuphine 86-96 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 34-65 24526241-2 2014 The major aim of this study was to develop an oral NAL formulation employing known excipients as UDP-glucuronosyltransferase 2B7 (UGT2B7) inhibitors to improve its oral bioavailability. Nalbuphine 51-54 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 97-128 24526241-2 2014 The major aim of this study was to develop an oral NAL formulation employing known excipients as UDP-glucuronosyltransferase 2B7 (UGT2B7) inhibitors to improve its oral bioavailability. Nalbuphine 51-54 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 130-136 24631340-7 2014 Additionally, both the in vitro inhibition data and computational modeling results provide important information for the modification of andrographolide derivatives as selective inhibitors of UGT2B7. andrographolide 137-152 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 192-198 24631340-8 2014 Taken together, data obtained from the present study indicated the potential herb-drug interaction between Andrographis paniculata and the drugs mainly undergoing UGT2B7-catalyzed metabolic elimination, and the andrographolide derivatives as potential candidates for the selective inhibitors of UGT2B7. andrographolide 211-226 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 295-301 24292225-10 2014 The expression of thymidine kinase 1 (TK1) and UDP-glucuronosyltransferase 2B7 (UGT2B7) genes that regulate the metabolic activation and deactivation of AZT, respectively, was increased in HepG2 cells but decreased in THLE2 cells after treatment with AZT. Zidovudine 153-156 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-78 24459244-0 2014 Morphine glucuronidation and glucosidation represent complementary metabolic pathways that are both catalyzed by UDP-glucuronosyltransferase 2B7: kinetic, inhibition, and molecular modeling studies. Morphine 0-8 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 113-144 24459244-7 2014 Studies with UGT enzyme-selective inhibitors and recombinant UGT enzymes, along with effects of BSA on morphine glycosidation kinetics, were consistent with a major role of UGT2B7 in both morphine glucuronidation and glucosidation. Morphine 188-196 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 173-179 24459244-8 2014 Molecular modeling identified key amino acids involved in the binding of UDP-GlcUA and UDP-Glc to UGT2B7. Uridine Diphosphate Glucuronic Acid 73-82 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 98-104 24459244-8 2014 Molecular modeling identified key amino acids involved in the binding of UDP-GlcUA and UDP-Glc to UGT2B7. Uridine Diphosphate Glucose 73-80 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 98-104 24459244-10 2014 Overall, the data indicate that morphine glucuronidation and glucosidation occur as complementary metabolic pathways catalyzed by a common enzyme (UGT2B7). Morphine 32-40 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 147-153 24459244-11 2014 Glucuronidation is the dominant metabolic pathway because the binding affinity of UDP-GlcUA to UGT2B7 is higher than that of UDP-Glc. Uridine Diphosphate Glucuronic Acid 82-91 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 95-101 24459244-11 2014 Glucuronidation is the dominant metabolic pathway because the binding affinity of UDP-GlcUA to UGT2B7 is higher than that of UDP-Glc. Uridine Diphosphate Glucose 82-89 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 95-101 24292225-10 2014 The expression of thymidine kinase 1 (TK1) and UDP-glucuronosyltransferase 2B7 (UGT2B7) genes that regulate the metabolic activation and deactivation of AZT, respectively, was increased in HepG2 cells but decreased in THLE2 cells after treatment with AZT. Zidovudine 153-156 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 80-86 24292225-10 2014 The expression of thymidine kinase 1 (TK1) and UDP-glucuronosyltransferase 2B7 (UGT2B7) genes that regulate the metabolic activation and deactivation of AZT, respectively, was increased in HepG2 cells but decreased in THLE2 cells after treatment with AZT. Zidovudine 251-254 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-78 24292225-10 2014 The expression of thymidine kinase 1 (TK1) and UDP-glucuronosyltransferase 2B7 (UGT2B7) genes that regulate the metabolic activation and deactivation of AZT, respectively, was increased in HepG2 cells but decreased in THLE2 cells after treatment with AZT. Zidovudine 251-254 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 80-86 24296138-6 2014 Inhibition studies with selected UGT2B7 substrates indicate that diclofenac displayed a relatively strong inhibition (Ki, 4.2 muM) against steviol glucuronidation in human liver microsomes. Diclofenac 65-75 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 33-39 24296138-7 2014 Taken together, the identification of the involvement of UGT2B7 in steviol glucuronidation would provide a mechanistic basis for the evaluation of the interaction between steviol and diclofenac. steviol 67-74 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 57-63 24296138-7 2014 Taken together, the identification of the involvement of UGT2B7 in steviol glucuronidation would provide a mechanistic basis for the evaluation of the interaction between steviol and diclofenac. steviol 171-178 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 57-63 24296138-7 2014 Taken together, the identification of the involvement of UGT2B7 in steviol glucuronidation would provide a mechanistic basis for the evaluation of the interaction between steviol and diclofenac. Diclofenac 183-193 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 57-63 25340733-0 2014 Effect of UGT2B7 -900G>A (-842G>A; rs7438135) on morphine glucuronidation in preterm newborns: results from a pilot cohort. Morphine 55-63 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 10-16 24406279-5 2014 On the other hand, in order to explain the differences in the clinical response to CBZ, genetic polymorphisms in phase I (CYP3A4, CYP3A5 and EPHX1) and phase II (UGT2B7) metabolising enzymes have been assessed; additionally, the influence of transporters (ABCB1 and ABCC2), receptors (PXR) and other drug targets (voltage- gated Na+ channels) in CBZ clinical response has been evaluated. Carbamazepine 83-86 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 162-168 24406279-5 2014 On the other hand, in order to explain the differences in the clinical response to CBZ, genetic polymorphisms in phase I (CYP3A4, CYP3A5 and EPHX1) and phase II (UGT2B7) metabolising enzymes have been assessed; additionally, the influence of transporters (ABCB1 and ABCC2), receptors (PXR) and other drug targets (voltage- gated Na+ channels) in CBZ clinical response has been evaluated. Carbamazepine 346-349 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 162-168 25340733-1 2014 AIM: Assess association between UGT2B7 polymorphism -900G>A (rs7438135, also known as -842G>A) with morphine kinetics in preterm newborns undergoing mechanical ventilation. Morphine 106-114 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 32-38 25340733-4 2014 RESULTS: Morphine plasma concentrations at 20 min post intubation were associated with postnatal age (p=0.017) and UGT2B7 -900G>A (p=0.036). Morphine 9-17 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 115-121 25340733-5 2014 UGT2B7 -900A allele carriers (n=13) had lower morphine levels compared with UGT2B7 -900G/G patients (n=2). Morphine 46-54 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 25340733-8 2014 CONCLUSION: Our small pilot study illustrates that in addition to gestational and postnatal age, the UGT2B7 -900G>A polymorphism significantly alters morphine pharmacokinetics in preterm infants. Morphine 153-161 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 101-107 24400440-7 2013 The inhibition kinetic parameters (Ki) were calculated to be 0.5 microM, 3.5 microM, 2.8 microM, 29.7 microM for UGT2B7-mediated 4-MU glucuronidation, UGT1A9-mediated 4-MU glucuronidation, UGT2B7-mediated AZT glucuronidation, and UGT1A9-mediated propofol glucuronidation, respectively. Propofol 246-254 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 113-119 24349450-7 2013 We also found that BPAF glucuronidation could be mediated through several human recombinant UDP-glucuronosyltransferases (UGTs) including UGT1A1, UGT1A3, UGT1A8, UGT1A9, UGT2B4, UGT2B7, UGT2B15 and UGT2B17, among which UGT2B7 showed the highest efficiency of glucuronidation. 4,4'-hexafluorisopropylidene diphenol 19-23 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 178-184 24349450-7 2013 We also found that BPAF glucuronidation could be mediated through several human recombinant UDP-glucuronosyltransferases (UGTs) including UGT1A1, UGT1A3, UGT1A8, UGT1A9, UGT2B4, UGT2B7, UGT2B15 and UGT2B17, among which UGT2B7 showed the highest efficiency of glucuronidation. 4,4'-hexafluorisopropylidene diphenol 19-23 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 219-225 25278738-7 2013 SNPs in the genes encoding the morphine phase II metabolic enzyme, UGT2B7, were associated with withdrawal symptom scores. Morphine 31-39 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 67-73 23847592-2 2013 Conjugation of anabolic steroids during phase II metabolism, mainly driven by UDP-glucuronosyltransferase (UGT) 2B7, 2B15, and 2B17, has been shown to be impaired in vitro by a range of compounds including xenobiotics and pharmaceuticals. Steroids 24-32 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 78-121 24400440-2 2013 The nonspecific probe substrate 4-methylumbelliferone (4-MU) and recombinant UGT enzymes (UGT1A9, UGT2B7) were firstly used to evaluate the inhibition of arbidol towards UGT1A9 and UGT2B7. umifenovir 154-161 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 98-104 24400440-2 2013 The nonspecific probe substrate 4-methylumbelliferone (4-MU) and recombinant UGT enzymes (UGT1A9, UGT2B7) were firstly used to evaluate the inhibition of arbidol towards UGT1A9 and UGT2B7. umifenovir 154-161 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 181-187 24400440-3 2013 Furthermore, specific substrates of UGT1A9 and UGT2B7 propofol and zidovudine (AZT) were used to determine the inhibition of arbidol towards UGT1A9 and UGT2B7. umifenovir 125-132 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 152-158 24400440-6 2013 Arbidol was demonstrated to exhibit competitive inhibition towards UGT1A9 and UGT2B7 without substate-dependent behaviour. umifenovir 0-7 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 78-84 24400440-7 2013 The inhibition kinetic parameters (Ki) were calculated to be 0.5 microM, 3.5 microM, 2.8 microM, 29.7 microM for UGT2B7-mediated 4-MU glucuronidation, UGT1A9-mediated 4-MU glucuronidation, UGT2B7-mediated AZT glucuronidation, and UGT1A9-mediated propofol glucuronidation, respectively. Zidovudine 205-208 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 113-119 24400440-9 2013 Given that arbidol exhibits strong inhibition towards UGT1A9 and UGT2B7, clinical monitoring should be given when arbidol was co-administered with drugs mainly undergoing UGT1A9, UGT2B7-mediated metabolism. umifenovir 11-18 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 65-71 23948605-6 2013 Bisphenol A exhibited the competitive inhibition towards UGT2B4, and noncompetitive inhibition towards UGT2B7, 2B15 and 2B17. bisphenol A 0-11 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 103-109 23756370-5 2013 The chenodeoxycholic acid-3G (CDCA-3G) concentration was associated with the UGT2B7 802C>T polymorphism. Chenodeoxycholic Acid 4-25 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 77-83 23756370-5 2013 The chenodeoxycholic acid-3G (CDCA-3G) concentration was associated with the UGT2B7 802C>T polymorphism. Chenodeoxycholic Acid 30-34 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 77-83 23756370-6 2013 Glucuronidation assays confirmed the predominant role of UGT2B7 and UGT1A4 in CDCA-3G formation. Chenodeoxycholic Acid 78-82 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 57-63 23756370-7 2013 Fenofibrate exposure increased the serum levels of five BA-G species, including CDCA-3G, and upregulated expression of UGT1A4, but not UGT2B7, in hepatic cells. Fenofibrate 0-11 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 135-141 23981985-0 2013 Effect of UGT2B7 genetic variants on serum valproic acid concentration. Valproic Acid 43-56 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 10-16 23981985-1 2013 OBJECTIVE: To investigate the effect of UGT2B7 A268G and UGT2B7 G211T genetic polymorphism on serum drug concentration of valproic acid (VPA). Valproic Acid 122-135 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 40-46 23981985-1 2013 OBJECTIVE: To investigate the effect of UGT2B7 A268G and UGT2B7 G211T genetic polymorphism on serum drug concentration of valproic acid (VPA). Valproic Acid 122-135 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 57-63 23981985-1 2013 OBJECTIVE: To investigate the effect of UGT2B7 A268G and UGT2B7 G211T genetic polymorphism on serum drug concentration of valproic acid (VPA). Valproic Acid 137-140 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 40-46 23981985-1 2013 OBJECTIVE: To investigate the effect of UGT2B7 A268G and UGT2B7 G211T genetic polymorphism on serum drug concentration of valproic acid (VPA). Valproic Acid 137-140 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 57-63 23562620-0 2013 Evaluation of UGT protein interactions in human hepatocytes: effect of siRNA down regulation of UGT1A9 and UGT2B7 on propofol glucuronidation in human hepatocytes. Propofol 117-125 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 107-113 24400440-9 2013 Given that arbidol exhibits strong inhibition towards UGT1A9 and UGT2B7, clinical monitoring should be given when arbidol was co-administered with drugs mainly undergoing UGT1A9, UGT2B7-mediated metabolism. umifenovir 11-18 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 179-185 24400440-9 2013 Given that arbidol exhibits strong inhibition towards UGT1A9 and UGT2B7, clinical monitoring should be given when arbidol was co-administered with drugs mainly undergoing UGT1A9, UGT2B7-mediated metabolism. umifenovir 114-121 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 65-71 23965986-0 2013 The letrozole phase 1 metabolite carbinol as a novel probe drug for UGT2B7. Letrozole 4-13 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 68-74 23965986-0 2013 The letrozole phase 1 metabolite carbinol as a novel probe drug for UGT2B7. Methanol 33-41 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 68-74 23965986-8 2013 We identified UGT2B7 as the predominant UGT isoform involved in carbinol glucuronidation. Methanol 64-72 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 14-20 23965986-10 2013 In the set of 148 human livers, carbinol glucuronidation activity significantly correlated with UGT2B7 protein as determined by Western blotting (r(s) = 0.5088, P < 0.0001). Methanol 32-40 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 96-102 23965986-13 2013 Taken together, these findings suggest carbinol as a novel in vitro probe substrate for UGT2B7. Methanol 39-47 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 88-94 23362865-8 2013 Modulation by drug substrates (e.g. NSAIDs) of the intrarenal activity of UGT1A9 and UGT2B7 has the potential to perturb the metabolism of renal mediators including aldosterone, prostaglandins and 20-hydroxyeicosatetraenoic acid, thus disrupting renal homeostasis. Aldosterone 165-176 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 85-91 23362865-8 2013 Modulation by drug substrates (e.g. NSAIDs) of the intrarenal activity of UGT1A9 and UGT2B7 has the potential to perturb the metabolism of renal mediators including aldosterone, prostaglandins and 20-hydroxyeicosatetraenoic acid, thus disrupting renal homeostasis. Prostaglandins 178-192 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 85-91 23362865-8 2013 Modulation by drug substrates (e.g. NSAIDs) of the intrarenal activity of UGT1A9 and UGT2B7 has the potential to perturb the metabolism of renal mediators including aldosterone, prostaglandins and 20-hydroxyeicosatetraenoic acid, thus disrupting renal homeostasis. 20-hydroxy-5,8,11,14-eicosatetraenoic acid 197-228 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 85-91 23148031-3 2013 Furthermore, the inhibition kinetic type and parameters were determined for the inhibition of glycyrrhetinic acid towards UGT1A3 and UGT2B7. Glycyrrhetinic Acid 94-113 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 133-139 23148031-4 2013 Data fitting using Dixon and Lineweaver-Burk plots demonstrated that the inhibition of UGT1A3 and UGT2B7 by glycyrrhetinic acid was best fit to competitive and noncompetitive type, respectively. Glycyrrhetinic Acid 108-127 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 98-104 23148031-5 2013 The second plot using the slopes from Lineweaver-Burk plots versus glycyrrhetinic acid concentrations was employed to calculate the inhibition kinetic parameters (K(i)), and the values were calculated to be 0.2 and 1.7 muM for UGT1A3 and UGT2B7, respectively. Glycyrrhetinic Acid 67-86 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 238-244 24648760-0 2013 Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients. Tamoxifen 66-75 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 22-28 24648760-1 2013 PURPOSE: The objective of this study was to evaluate the impact of CYP2D6 and UGT2B7 polymorphisms on tamoxifen (TAM) pharmacokinetics in Thai breast cancer patients. Tamoxifen 102-111 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 78-84 24648760-1 2013 PURPOSE: The objective of this study was to evaluate the impact of CYP2D6 and UGT2B7 polymorphisms on tamoxifen (TAM) pharmacokinetics in Thai breast cancer patients. Tamoxifen 113-116 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 78-84 24648760-10 2013 CONCLUSION: Results from this study confirmed the impacts of CYP2D6 polymorphisms on the pharmacokinetics of TAM, while UGT2B7 polymorphisms tended to have impact on TAM metabolism in patients with homozygous CYP2D6*10. Tamoxifen 166-169 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 120-126 23527766-10 2013 UGT2B7 was also able to form (R)bicalutamide-G. (r)bicalutamide 29-44 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 23527766-11 2013 Kinetic parameters of the recombinant UGT2B7, UGT1A8 and UGT1A9 enzymes support a predominant role of the UGT1A9 isoform in bicalutamide metabolism. bicalutamide 124-136 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 38-44 23805127-0 2013 Implication of Human UGT2B7, 2B15, and 2B17 in 19-Norandrosterone Metabolism. 19-norandrosterone 47-65 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 21-27 23670235-5 2013 RESULTS: UGT1A1, UGT1A4, UGT1A8, UGT2B7, and SULT1A1 were found to be involved in the formation of inactive ABT-751 glucuronide (ABT-751G) and sulfate (ABT-751S). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 108-111 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 33-39 23670235-5 2013 RESULTS: UGT1A1, UGT1A4, UGT1A8, UGT2B7, and SULT1A1 were found to be involved in the formation of inactive ABT-751 glucuronide (ABT-751G) and sulfate (ABT-751S). Glucuronides 116-127 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 33-39 23670235-5 2013 RESULTS: UGT1A1, UGT1A4, UGT1A8, UGT2B7, and SULT1A1 were found to be involved in the formation of inactive ABT-751 glucuronide (ABT-751G) and sulfate (ABT-751S). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 129-132 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 33-39 23670235-5 2013 RESULTS: UGT1A1, UGT1A4, UGT1A8, UGT2B7, and SULT1A1 were found to be involved in the formation of inactive ABT-751 glucuronide (ABT-751G) and sulfate (ABT-751S). Sulfates 143-150 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 33-39 23670235-5 2013 RESULTS: UGT1A1, UGT1A4, UGT1A8, UGT2B7, and SULT1A1 were found to be involved in the formation of inactive ABT-751 glucuronide (ABT-751G) and sulfate (ABT-751S). 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 129-132 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 33-39 23571427-5 2013 Screening assays with 12 available human recombinant UDP-glucuronosyltransferases (UGTs) demonstrated that UGT1A9 was the predominant UGT isoform involved in R-ornidazole glucuronidation, whereas S-ornidazole glucuronidation was almost exclusively catalyzed by UGT2B7. r-ornidazole 158-170 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 261-267 23805127-6 2013 Inhibition assays using human liver microsomes (HLM) incubated with 19-norandrosterone and selective inhibitors confirmed that UGT2B7 and UGT2B15 are involved in 19-norandrosterone glucuronidation, since the presence of the specific UGT2B7 and UGT2B15 inhibitors gemfibrozil and valproic acid inhibited the 19-norandrosterone glucuronidation by 35 and 45%, respectively. -norandrosterone 70-86 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 233-239 23805127-6 2013 Inhibition assays using human liver microsomes (HLM) incubated with 19-norandrosterone and selective inhibitors confirmed that UGT2B7 and UGT2B15 are involved in 19-norandrosterone glucuronidation, since the presence of the specific UGT2B7 and UGT2B15 inhibitors gemfibrozil and valproic acid inhibited the 19-norandrosterone glucuronidation by 35 and 45%, respectively. Gemfibrozil 263-274 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 127-133 23805127-6 2013 Inhibition assays using human liver microsomes (HLM) incubated with 19-norandrosterone and selective inhibitors confirmed that UGT2B7 and UGT2B15 are involved in 19-norandrosterone glucuronidation, since the presence of the specific UGT2B7 and UGT2B15 inhibitors gemfibrozil and valproic acid inhibited the 19-norandrosterone glucuronidation by 35 and 45%, respectively. Valproic Acid 279-292 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 127-133 23805127-6 2013 Inhibition assays using human liver microsomes (HLM) incubated with 19-norandrosterone and selective inhibitors confirmed that UGT2B7 and UGT2B15 are involved in 19-norandrosterone glucuronidation, since the presence of the specific UGT2B7 and UGT2B15 inhibitors gemfibrozil and valproic acid inhibited the 19-norandrosterone glucuronidation by 35 and 45%, respectively. 19-norandrosterone 162-180 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 127-133 23805127-4 2013 An in vitro study using recombinant enzymes expressed in insect cells showed that UGT1A4 and UGT2B7 are the two main enzymes responsible of 19-norandrosterone glucuronidation. 19-norandrosterone 140-158 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 93-99 23805127-10 2013 Only UGT2B7 mRNA expression was significantly increased (1.8-folds) after incubation with nandrolone decanoate. Nandrolone Decanoate 90-110 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 5-11 23805127-6 2013 Inhibition assays using human liver microsomes (HLM) incubated with 19-norandrosterone and selective inhibitors confirmed that UGT2B7 and UGT2B15 are involved in 19-norandrosterone glucuronidation, since the presence of the specific UGT2B7 and UGT2B15 inhibitors gemfibrozil and valproic acid inhibited the 19-norandrosterone glucuronidation by 35 and 45%, respectively. 19-norandrosterone 68-86 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 127-133 23805127-11 2013 These results show that the UGT2B7 and UGT2B15 are involved in 19-norandrosterone glucuronidation and that the UGT2B15 polymorphism (D85Y) is the only UGT genetic variation that influences the glucuronidation activity. 19-norandrosterone 63-81 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 28-34 23805127-6 2013 Inhibition assays using human liver microsomes (HLM) incubated with 19-norandrosterone and selective inhibitors confirmed that UGT2B7 and UGT2B15 are involved in 19-norandrosterone glucuronidation, since the presence of the specific UGT2B7 and UGT2B15 inhibitors gemfibrozil and valproic acid inhibited the 19-norandrosterone glucuronidation by 35 and 45%, respectively. 19-norandrosterone 68-86 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 233-239 23805127-6 2013 Inhibition assays using human liver microsomes (HLM) incubated with 19-norandrosterone and selective inhibitors confirmed that UGT2B7 and UGT2B15 are involved in 19-norandrosterone glucuronidation, since the presence of the specific UGT2B7 and UGT2B15 inhibitors gemfibrozil and valproic acid inhibited the 19-norandrosterone glucuronidation by 35 and 45%, respectively. -norandrosterone 70-86 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 127-133 23288867-2 2013 UGT1A10 is highly active in the conjugation of the 3-OH in all these estriols, whereas UGT2B7 is the most active UGT toward one of the ring D hydroxyls, the 16-OH in estriol and 16-epiestriol, but the 17-OH in 17-epiestriol. 16-oh 157-162 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 87-93 23263737-0 2013 Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients. Lamotrigine 86-97 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 17-23 23263737-2 2013 Lamotrigine is primarily metabolized by UGT1A4 and UGT2B7, both of which show genetic polymorphisms. Lamotrigine 0-11 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 51-57 23263737-9 2013 The use of enzyme inducers, valproic acid, and the UGT2B7-161 C>T SNP were found to significantly influence lamotrigine apparent clearance (CL/F). Lamotrigine 111-122 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 51-57 23263737-9 2013 The use of enzyme inducers, valproic acid, and the UGT2B7-161 C>T SNP were found to significantly influence lamotrigine apparent clearance (CL/F). Fluorine 146-147 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 51-57 23263737-10 2013 Lamotrigine CL/F in patients carrying the UGT2B7 -161 CT or TT SNP was 18% lower than that in patients carrying the UGT2B7 -161 CC SNP. lamotrigine cl/f 0-16 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 42-48 23263737-10 2013 Lamotrigine CL/F in patients carrying the UGT2B7 -161 CT or TT SNP was 18% lower than that in patients carrying the UGT2B7 -161 CC SNP. lamotrigine cl/f 0-16 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 116-122 23052409-7 2013 Subjects with UGT1A9-440TC had enhanced MPA exposure while carriers of UGT2B7 211T had higher concentrations of the toxic metabolite, AcMPAG. mycophenolic acid acyl glucuronide 134-140 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 71-77 23052409-8 2013 CONCLUSIONS: The current results indicate that UGT1A9 and UGT2B7 genotypes could significantly alter MPA pharmacokinetics in healthy Chinese volunteers after a single oral dose of MMF. Mycophenolic Acid 180-183 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 58-64 23090703-2 2013 This study was performed to examine whether common polymorphisms in UGT1A1, UGT2B7, CYP2C19 and ABCB1 affect the PK of labetalol. Labetalol 119-128 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 76-82 23509226-15 2013 Both UGT1A4 and UGT2B7 were responsible for Z-3-hydroxy-apatinib-O-glucuronide (M9-1) formation. z-3-hydroxy-apatinib-o-glucuronide 44-78 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 16-22 23726609-1 2013 BACKGROUND: Uridine diphosphate glucuronosyltransferase (UGT2B7) is responsible for conversion of mycophenolic acid to mycophenolic acyl-glucuronide (acylMPAG). Mycophenolic Acid 98-115 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 57-63 23726609-1 2013 BACKGROUND: Uridine diphosphate glucuronosyltransferase (UGT2B7) is responsible for conversion of mycophenolic acid to mycophenolic acyl-glucuronide (acylMPAG). mycophenolic acyl-glucuronide 119-148 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 57-63 23726609-1 2013 BACKGROUND: Uridine diphosphate glucuronosyltransferase (UGT2B7) is responsible for conversion of mycophenolic acid to mycophenolic acyl-glucuronide (acylMPAG). acylmpag 150-158 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 57-63 23052409-0 2013 Polymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteers. Mycophenolic Acid 69-86 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 28-34 23230132-0 2013 Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse. Ethanol 65-72 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 55-61 23288867-2 2013 UGT1A10 is highly active in the conjugation of the 3-OH in all these estriols, whereas UGT2B7 is the most active UGT toward one of the ring D hydroxyls, the 16-OH in estriol and 16-epiestriol, but the 17-OH in 17-epiestriol. Estriol 69-76 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 87-93 23288867-2 2013 UGT1A10 is highly active in the conjugation of the 3-OH in all these estriols, whereas UGT2B7 is the most active UGT toward one of the ring D hydroxyls, the 16-OH in estriol and 16-epiestriol, but the 17-OH in 17-epiestriol. Epiestriol 178-191 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 87-93 23288867-2 2013 UGT1A10 is highly active in the conjugation of the 3-OH in all these estriols, whereas UGT2B7 is the most active UGT toward one of the ring D hydroxyls, the 16-OH in estriol and 16-epiestriol, but the 17-OH in 17-epiestriol. 17-oh 201-206 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 87-93 23288867-2 2013 UGT1A10 is highly active in the conjugation of the 3-OH in all these estriols, whereas UGT2B7 is the most active UGT toward one of the ring D hydroxyls, the 16-OH in estriol and 16-epiestriol, but the 17-OH in 17-epiestriol. 17-Epiestriol 210-223 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 87-93 23206182-3 2013 RESULT: In this study, a significant allele frequency was observed for CYP2D6*3 polymorphism in patients under rivastigmine combination therapy (A>del = 0.50 [patients] and A>del = 0.20 [controls]), UGT2B7 (T = 0.17 [patients] and 0.33 [Controls], and UGT1A9*5 A = 0.58 [patients] and 0.26 [Controls]). Rivastigmine 111-123 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 199-205 23206182-5 2013 CONCLUSION: Poor metabolizer subjects of UGT2B7 polymorphism in patients under rivastigmine combination therapy have higher drug levels with a poor response to the drug treatments. Rivastigmine 79-91 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 41-47 23142425-9 2013 Subjects carrying the UGT2B7 268 His/Tyr or Tyr/Tyr genotype had significantly lower total NNAL than those carrying His/His genotype. Histidine 33-36 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 22-28 22813462-5 2013 Among the tested UGT isoforms, UGT1A3 and UGT2B7 were inhibited by thienorphine, with other UGT isoforms negligibly influenced. thienorphine 67-79 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 42-48 23142425-9 2013 Subjects carrying the UGT2B7 268 His/Tyr or Tyr/Tyr genotype had significantly lower total NNAL than those carrying His/His genotype. Tyrosine 37-40 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 22-28 22265884-3 2012 Testing the human UDP-glucuronosyltransferases (UGTs) of subfamilies 1A, 2A and 2B at pH 7.4 revealed that UGT1A10, UGT2B7 and UGT2B17 are the most active enzymes in diclofenac glucuronidation, while the highest indomethacin glucuronidation rates (corrected for relative expression levels) were exhibited by UGT2A1, UGT1A10 and UGT2B7. Diclofenac 166-176 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 116-122 23252947-2 2013 MATERIALS & METHODS: Twenty-five SNPs within seven CBZ pathway genes, namely CYP3A4, CYP3A5, EPHX1, NR1I2, UGT2B7, ABCB1 and ABCC2, were analyzed for association with CBZ pharmacokinetics in 90 epilepsy patients. Adenosine Monophosphate 11-14 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 111-117 23252947-2 2013 MATERIALS & METHODS: Twenty-five SNPs within seven CBZ pathway genes, namely CYP3A4, CYP3A5, EPHX1, NR1I2, UGT2B7, ABCB1 and ABCC2, were analyzed for association with CBZ pharmacokinetics in 90 epilepsy patients. Carbamazepine 55-58 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 111-117 23134532-6 2012 UGT1A7, UGT1A8, and UGT1A9 are the predominant isoforms responsible for the formation of M2 while UGT2B7 is the main isoform for M1, suggesting a regioselective glucuronidation of reduced quinone by UGTs. quinone 188-195 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 98-104 23131697-0 2012 UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients. Mycophenolic Acid 47-64 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 8-14 22265884-3 2012 Testing the human UDP-glucuronosyltransferases (UGTs) of subfamilies 1A, 2A and 2B at pH 7.4 revealed that UGT1A10, UGT2B7 and UGT2B17 are the most active enzymes in diclofenac glucuronidation, while the highest indomethacin glucuronidation rates (corrected for relative expression levels) were exhibited by UGT2A1, UGT1A10 and UGT2B7. Indomethacin 212-224 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 116-122 22476391-1 2012 PURPOSE: The aim of this study was to investigate the genetic polymorphisms of UGT1A3, UGT1A6, and UGT2B7 in Chinese epilepsy patients and their potential influence on the pharmacokinetics of valproic acid (VPA). Valproic Acid 192-205 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 99-105 22820246-3 2012 (ii) Hepatotoxic lithocholic acid (LCA) is oxidized to hyodeoxycholic acid, the latter conjugated by UGT2B4 and UGT2B7. Lithocholic Acid 17-33 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 112-118 22820246-3 2012 (ii) Hepatotoxic lithocholic acid (LCA) is oxidized to hyodeoxycholic acid, the latter conjugated by UGT2B4 and UGT2B7. Lithocholic Acid 35-38 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 112-118 22820246-3 2012 (ii) Hepatotoxic lithocholic acid (LCA) is oxidized to hyodeoxycholic acid, the latter conjugated by UGT2B4 and UGT2B7. hyodeoxycholic acid 55-74 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 112-118 22476391-1 2012 PURPOSE: The aim of this study was to investigate the genetic polymorphisms of UGT1A3, UGT1A6, and UGT2B7 in Chinese epilepsy patients and their potential influence on the pharmacokinetics of valproic acid (VPA). Valproic Acid 207-210 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 99-105 23016456-4 2012 Among the tested UGT isoforms, UGT1A1, UGT1A3, UGT2B7 and UGT2B15 were strongly inhibited by tacro in a concentration-dependent manner. Tacrolimus 93-98 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-53 22957438-3 2012 The results showed that 100 microM of glimepiride inhibited UGT1A1, UGT1A3, UGT1A6, UGT1A9, UGT2B7 and UGT2B15 by 54.7%, 43.1%, 100%, 70.5%, 32.7 and 37.2%, respectively. glimepiride 38-49 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 92-98 22435749-3 2012 Unique tryptic peptides of UGT1A1 and UGT2B7 in tryptically digested HLMs were simultaneously quantified by liquid chromatography (LC) equipped with tandem mass spectrometry (MS) using corresponding stable isotope-labelled peptides as internal standards. Peptides 223-231 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 38-44 22435749-8 2012 Both morphine 3-O- and 6-O-glucuronidation significantly correlated with UGT2B7 level. Morphine 5-13 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 73-79 22435749-8 2012 Both morphine 3-O- and 6-O-glucuronidation significantly correlated with UGT2B7 level. 3-o 14-17 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 73-79 22435749-8 2012 Both morphine 3-O- and 6-O-glucuronidation significantly correlated with UGT2B7 level. 6-o 23-26 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 73-79 22435749-9 2012 However, the intercept of the linear regression clearly indicates that morphine glucuronidation was mediated by other UGT isoforms in addition to UGT2B7. Morphine 71-79 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 146-152 22874791-2 2012 The present study aims to investigate the inhibition of demethylzeylasteral (an important active component isolated from Tripterygium wilfordii Hook F.) towards three important UGT isoforms UGT1A6, UGT1A9 and UGT2B7. demethylzeylasteral 56-75 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 209-215 22644026-2 2012 Lersivirine, a weak inducer of the cytochrome P450 (CYP) enzyme CYP3A4, is metabolized by CYP3A4 and UDP glucuronosyltransferase 2B7 (UGT2B7). UK 453,061 0-11 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 101-132 22644026-2 2012 Lersivirine, a weak inducer of the cytochrome P450 (CYP) enzyme CYP3A4, is metabolized by CYP3A4 and UDP glucuronosyltransferase 2B7 (UGT2B7). UK 453,061 0-11 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 134-140 22644026-10 2012 Lersivirine should not be coadministered with rifampin, which is a potent inducer of CYP3A4, UGT2B7, and P-glycoprotein activity and thus substantially lowers lersivirine exposure. UK 453,061 0-11 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 93-99 22644026-10 2012 Lersivirine should not be coadministered with rifampin, which is a potent inducer of CYP3A4, UGT2B7, and P-glycoprotein activity and thus substantially lowers lersivirine exposure. Rifampin 46-54 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 93-99 22564759-7 2012 UGT2B7, 2B15, and 2B17 were involved in glucuronidation of HMEA and SULT1A1 and SULT1A3 and SULT1A3 and SULT1E1 in the sulfation of DHEA and HMEA, respectively. 3,4-dihydroxyethylamphetamine 132-136 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 22564759-7 2012 UGT2B7, 2B15, and 2B17 were involved in glucuronidation of HMEA and SULT1A1 and SULT1A3 and SULT1A3 and SULT1E1 in the sulfation of DHEA and HMEA, respectively. 4-hydroxy-3-methoxyethylamphetamine 141-145 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 22564759-7 2012 UGT2B7, 2B15, and 2B17 were involved in glucuronidation of HMEA and SULT1A1 and SULT1A3 and SULT1A3 and SULT1E1 in the sulfation of DHEA and HMEA, respectively. 4-hydroxy-3-methoxyethylamphetamine 59-63 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 22676193-0 2012 UGT2B7 genetic polymorphisms are associated with the withdrawal symptoms in methadone maintenance patients. Methadone 76-85 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 22838952-3 2012 UGTs metabolizing valproic acid in the liver are UGT1A3, UGT1A4, UGT1A6, UGT1A9 and UGT2B7, with UGT1A6 and UGT2B7 being the most prominent. Valproic Acid 18-31 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 84-90 22838952-3 2012 UGTs metabolizing valproic acid in the liver are UGT1A3, UGT1A4, UGT1A6, UGT1A9 and UGT2B7, with UGT1A6 and UGT2B7 being the most prominent. Valproic Acid 18-31 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 108-114 22676193-1 2012 AIM: To test whether the genetic polymorphisms within the gene encoding the UGT2B7 gene may have an impact on methadone treatment. Methadone 110-119 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 76-82 22676193-2 2012 MATERIALS & METHODS: Twelve SNPs in UGT2B7 were selected. Adenosine Monophosphate 11-14 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 40-46 22040521-1 2012 AIMS: To investigate the effect of inhibitors of cytochrome P450 (CYP) 3A4 and glucuronidation (UGT2B7) on the pharmacokinetics of lersivirine (UK-453,061), a next generation non-nucleoside reverse transcriptase inhibitor with a unique resistance profile, and to investigate the safety and tolerability of co-administration of lersivirine with these inhibitors. UK 453,061 131-142 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 96-102 22430884-5 2012 On the contrary, up to 35% of SCD patients may have unfavorable ABCB1 and UGT2B7 genotypes for a good morphine exposure.Obviously, pharmacokinetic studies with precise phenotype/genotype correlations are required to draw definitive conclusions. Morphine 102-110 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 74-80 22092298-0 2012 Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. Methadone 0-9 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 30-40 22040521-10 2012 CONCLUSIONS: Inhibition of CYP3A4 and UGT2B7 by ketoconazole increased lersivirine exposure. Ketoconazole 48-60 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 38-44 22040521-10 2012 CONCLUSIONS: Inhibition of CYP3A4 and UGT2B7 by ketoconazole increased lersivirine exposure. UK 453,061 71-82 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 38-44 22040521-11 2012 Inhibition of UGT2B7-mediated glucuronidation by VPA had a modest effect on lersivirine exposure. Valproic Acid 49-52 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 14-20 22040521-11 2012 Inhibition of UGT2B7-mediated glucuronidation by VPA had a modest effect on lersivirine exposure. UK 453,061 76-87 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 14-20 22294686-10 2012 The CL(int) value of AcMPAG formation from MPA, which was catalyzed by human UGT2B7, in HLH was increased by 1.8-fold in the presence of PMSF. mycophenolic acid acyl glucuronide 21-27 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 77-83 22331994-1 2012 Long-chain unsaturated fatty acids inhibit several cytochrome P450 and UDP-glucuronosyltransferase (UGT) enzymes involved in drug metabolism, including CYP2C8, CYP2C9, UGT1A9, UGT2B4, and UGT2B7. long-chain unsaturated fatty acids 0-34 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 188-194 22259019-6 2012 With recombinant UGT enzymes, lorcaserin N-carbamoyl glucuronidation was predominantly catalyzed by three UGT2Bs (UGT2B7, UGT2B15, and UGT2B17), whereas two UGT1As (UGT1A6 and UGT1A9) played a minor role. lorcaserin 30-40 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 114-120 22259019-8 2012 The rank order of catalytic efficiency of human UGT enzymes for lorcaserin N-carbamoyl glucuronidation was UGT2B15 > UGT2B7 > UGT2B17 > UGT1A9 > UGT1A6. lorcaserin 64-74 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 120-126 22259019-9 2012 Inhibition of lorcaserin N-carbamoyl glucuronidation activities of UGT2B7, UGT2B15, and UGT2B17 in human liver microsomes by mefenamic acid, bisphenol A, and eugenol further substantiated the involvement of these UGT2B isoforms. lorcaserin 14-24 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 67-73 22259019-9 2012 Inhibition of lorcaserin N-carbamoyl glucuronidation activities of UGT2B7, UGT2B15, and UGT2B17 in human liver microsomes by mefenamic acid, bisphenol A, and eugenol further substantiated the involvement of these UGT2B isoforms. Mefenamic Acid 125-139 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 67-73 22259019-9 2012 Inhibition of lorcaserin N-carbamoyl glucuronidation activities of UGT2B7, UGT2B15, and UGT2B17 in human liver microsomes by mefenamic acid, bisphenol A, and eugenol further substantiated the involvement of these UGT2B isoforms. bisphenol A 141-152 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 67-73 22259019-9 2012 Inhibition of lorcaserin N-carbamoyl glucuronidation activities of UGT2B7, UGT2B15, and UGT2B17 in human liver microsomes by mefenamic acid, bisphenol A, and eugenol further substantiated the involvement of these UGT2B isoforms. Eugenol 158-165 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 67-73 22462748-1 2012 AIM: Hepatic enzymes, CYP2B6 and UGT2B7 play a major role in the metabolism of the widely used antiretroviral drugs efavirenz, nevirapine and zidovudine. Nevirapine 127-137 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 33-39 22462748-1 2012 AIM: Hepatic enzymes, CYP2B6 and UGT2B7 play a major role in the metabolism of the widely used antiretroviral drugs efavirenz, nevirapine and zidovudine. Zidovudine 142-152 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 33-39 22395643-0 2012 CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. Tamoxifen 53-62 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 11-17 22395643-9 2012 A near-null association was observed between UGT2B7 genotype and recurrence in tamoxifen-treated patients. Tamoxifen 79-88 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 45-51 22294686-10 2012 The CL(int) value of AcMPAG formation from MPA, which was catalyzed by human UGT2B7, in HLH was increased by 1.8-fold in the presence of PMSF. Phenylmethylsulfonyl Fluoride 137-141 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 77-83 22123705-3 2012 Previous studies have demonstrated that lersivirine is metabolized by glucuronidation via UGT2B7 and by cytochrome P450 3A4 (CYP3A4). UK 453,061 40-51 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 90-96 22188362-0 2012 Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Carbamazepine 88-101 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 39-45 22028316-3 2012 The haloperidol N-glucuronidation was catalyzed solely by UGT1A4, whereas the haloperidol O-glucuronidation was catalyzed by UGT1A4, UGT1A9, and UGT2B7. Haloperidol 78-89 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 145-151 22028316-6 2012 Because the haloperidol O-glucuronidation in a panel of 17 HLM was significantly correlated (r = 0.732, p < 0.01) with zidovudine O-glucuronidation, a probe activity of UGT2B7, and the activity in the pooled HLM was prominently inhibited (58% of control) by gemfibrozil, an inhibitor of UGT2B7, we surmised that the reaction would mainly be catalyzed by UGT2B7. Haloperidol 12-23 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 172-178 22028316-6 2012 Because the haloperidol O-glucuronidation in a panel of 17 HLM was significantly correlated (r = 0.732, p < 0.01) with zidovudine O-glucuronidation, a probe activity of UGT2B7, and the activity in the pooled HLM was prominently inhibited (58% of control) by gemfibrozil, an inhibitor of UGT2B7, we surmised that the reaction would mainly be catalyzed by UGT2B7. Haloperidol 12-23 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 290-296 22028316-6 2012 Because the haloperidol O-glucuronidation in a panel of 17 HLM was significantly correlated (r = 0.732, p < 0.01) with zidovudine O-glucuronidation, a probe activity of UGT2B7, and the activity in the pooled HLM was prominently inhibited (58% of control) by gemfibrozil, an inhibitor of UGT2B7, we surmised that the reaction would mainly be catalyzed by UGT2B7. Haloperidol 12-23 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 290-296 22028316-6 2012 Because the haloperidol O-glucuronidation in a panel of 17 HLM was significantly correlated (r = 0.732, p < 0.01) with zidovudine O-glucuronidation, a probe activity of UGT2B7, and the activity in the pooled HLM was prominently inhibited (58% of control) by gemfibrozil, an inhibitor of UGT2B7, we surmised that the reaction would mainly be catalyzed by UGT2B7. Zidovudine 122-132 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 172-178 22028316-6 2012 Because the haloperidol O-glucuronidation in a panel of 17 HLM was significantly correlated (r = 0.732, p < 0.01) with zidovudine O-glucuronidation, a probe activity of UGT2B7, and the activity in the pooled HLM was prominently inhibited (58% of control) by gemfibrozil, an inhibitor of UGT2B7, we surmised that the reaction would mainly be catalyzed by UGT2B7. Zidovudine 122-132 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 290-296 22028316-6 2012 Because the haloperidol O-glucuronidation in a panel of 17 HLM was significantly correlated (r = 0.732, p < 0.01) with zidovudine O-glucuronidation, a probe activity of UGT2B7, and the activity in the pooled HLM was prominently inhibited (58% of control) by gemfibrozil, an inhibitor of UGT2B7, we surmised that the reaction would mainly be catalyzed by UGT2B7. Zidovudine 122-132 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 290-296 22028316-6 2012 Because the haloperidol O-glucuronidation in a panel of 17 HLM was significantly correlated (r = 0.732, p < 0.01) with zidovudine O-glucuronidation, a probe activity of UGT2B7, and the activity in the pooled HLM was prominently inhibited (58% of control) by gemfibrozil, an inhibitor of UGT2B7, we surmised that the reaction would mainly be catalyzed by UGT2B7. Gemfibrozil 261-272 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 172-178 22293344-4 2012 The aim of this study was to clarify the mechanism of these phenomena in HLM and human intestinal microsomes (HIM) and its relevance to uridine 5"-diphosphate (UDP)-glucuronosyl transferase (UGT) 1A1, UGT2B4 and UGT2B7, which mainly metabolize carvedilol directly in phase II enzymes. Uridine Diphosphate 136-158 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 212-218 22293344-7 2012 UGT2B7 was responsible for (S)-carvedilol glucuronidation in HLM. Carvedilol 27-41 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 22240840-0 2012 The effects of N-glycosylation on the glucuronidation of zidovudine and morphine by UGT2B7 expressed in HEK293 cells. Nitrogen 15-16 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 84-90 22240840-0 2012 The effects of N-glycosylation on the glucuronidation of zidovudine and morphine by UGT2B7 expressed in HEK293 cells. Zidovudine 57-67 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 84-90 22240840-0 2012 The effects of N-glycosylation on the glucuronidation of zidovudine and morphine by UGT2B7 expressed in HEK293 cells. Morphine 72-80 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 84-90 22240840-5 2012 An immunoblot analysis of whole cell lysate (S9) fractions with or without treatment with an endoglycosidase revealed that UGT2B7 was N-glycosylated at Asn-68 and Asn-315 but not Asn-67. Nitrogen 134-135 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 123-129 22240840-5 2012 An immunoblot analysis of whole cell lysate (S9) fractions with or without treatment with an endoglycosidase revealed that UGT2B7 was N-glycosylated at Asn-68 and Asn-315 but not Asn-67. Asparagine 152-155 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 123-129 22240840-5 2012 An immunoblot analysis of whole cell lysate (S9) fractions with or without treatment with an endoglycosidase revealed that UGT2B7 was N-glycosylated at Asn-68 and Asn-315 but not Asn-67. Asparagine 163-166 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 123-129 22240840-5 2012 An immunoblot analysis of whole cell lysate (S9) fractions with or without treatment with an endoglycosidase revealed that UGT2B7 was N-glycosylated at Asn-68 and Asn-315 but not Asn-67. Asparagine 163-166 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 123-129 22240840-7 2012 These results suggest that N-glycosylation differentially affects the glucuronidation of AZT and morphine by human UGT2B7. Nitrogen 27-28 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 115-121 22240840-7 2012 These results suggest that N-glycosylation differentially affects the glucuronidation of AZT and morphine by human UGT2B7. Zidovudine 89-92 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 115-121 22240840-7 2012 These results suggest that N-glycosylation differentially affects the glucuronidation of AZT and morphine by human UGT2B7. Morphine 97-105 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 115-121 23118789-5 2012 Different from icariin, icariside II was a potent inhibitor of UGT1A4, UGT1A7, UGT1A9, and UGT2B7, and icaritin was a potent inhibitor of UGT1A7 and UGT1A9. baohuoside I 24-36 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 91-97 22188362-5 2012 In addition, the multiple regression model of concentration-dose ratio of CBZ also revealed that genetic variants in SCN1A, EPHX1 and UGT2B7 genes interactively affect the concentration-dose ratio of CBZ (adjusted r(2) = 55%). Carbamazepine 74-77 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 134-140 22188362-5 2012 In addition, the multiple regression model of concentration-dose ratio of CBZ also revealed that genetic variants in SCN1A, EPHX1 and UGT2B7 genes interactively affect the concentration-dose ratio of CBZ (adjusted r(2) = 55%). Carbamazepine 200-203 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 134-140 21930117-3 2011 It was demonstrated that co-expressed, solubilized UGT2B7 proteins differentially tagged with hemagglutinin (UGT2B7-HA) and c-MYC (UGT2B7-cMYC) co-immunoprecipitated as active homodimers that catalyzed 4-methylumbelliferone glucuronidation. Hymecromone 202-223 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 51-57 23110092-8 2012 Treatment of WM3211 or metastatic melanoma cell lines with anti-cancer agents (including vemurafenib) induced expression of UGT2B7, UGT2B10 and UGT2B15 demonstrating that melanoma cells retain the ability to re-express these same three UGTs. Vemurafenib 89-100 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 124-130 23110092-10 2012 Furthermore, knockdown of UGT2B7 in WM115 cells sensitized these cells to treatment by adriamycin and epirubicin indicating that UGT2B7 is involved in resistance to these drugs. Doxorubicin 87-97 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 26-32 23110092-10 2012 Furthermore, knockdown of UGT2B7 in WM115 cells sensitized these cells to treatment by adriamycin and epirubicin indicating that UGT2B7 is involved in resistance to these drugs. Doxorubicin 87-97 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 129-135 23110092-10 2012 Furthermore, knockdown of UGT2B7 in WM115 cells sensitized these cells to treatment by adriamycin and epirubicin indicating that UGT2B7 is involved in resistance to these drugs. Epirubicin 102-112 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 26-32 23110092-10 2012 Furthermore, knockdown of UGT2B7 in WM115 cells sensitized these cells to treatment by adriamycin and epirubicin indicating that UGT2B7 is involved in resistance to these drugs. Epirubicin 102-112 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 129-135 21899827-6 2011 Nevertheless, the glucuronidation of ent-etiocholanolone and ent-androsterone by both UGT2B7 and UGT2B17 differs considerably from their respective activity toward the corresponding endogenous androgens, whereas UGT2A1-catalyzed conjugation is much less affected by the stereochemistry differences. ent-Etiocholanolone 37-56 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 86-92 21862693-0 2011 Production of ibuprofen acyl glucosides by human UGT2B7. ibuprofen acyl glucosides 14-39 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 49-55 21862693-7 2011 It was interesting to note that pronounced differences between the two polymorphic UGT2B7 variants were observed with respect to acyl glucoside production. acyl glucoside 129-143 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 83-89 21856742-3 2011 Nonetheless, using the specific substrates entacapone and zidovudine (AZT) for UGT1A9 and UGT2B7, respectively, and using an improved ultrafiltration method for measuring drug binding to BSA and to biological membranes, we found that the presence of BSA during the glucuronidation reaction leads to a large increase in the V(max) value of UGT1A9, in addition to lowering its K(m) value. entacapone 43-53 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 90-96 21856742-3 2011 Nonetheless, using the specific substrates entacapone and zidovudine (AZT) for UGT1A9 and UGT2B7, respectively, and using an improved ultrafiltration method for measuring drug binding to BSA and to biological membranes, we found that the presence of BSA during the glucuronidation reaction leads to a large increase in the V(max) value of UGT1A9, in addition to lowering its K(m) value. Zidovudine 58-68 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 90-96 21856742-3 2011 Nonetheless, using the specific substrates entacapone and zidovudine (AZT) for UGT1A9 and UGT2B7, respectively, and using an improved ultrafiltration method for measuring drug binding to BSA and to biological membranes, we found that the presence of BSA during the glucuronidation reaction leads to a large increase in the V(max) value of UGT1A9, in addition to lowering its K(m) value. Zidovudine 70-73 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 90-96 21856293-0 2011 Characterizing the effect of UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen. Flurbiprofen 139-151 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 29-66 21856293-3 2011 This study examines the role of the genetic variants of UGT2B7 and 1A9 enzymes involved in the formation of acyl glucuronides (FPFGs). acyl glucuronides 108-125 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 56-62 21899827-6 2011 Nevertheless, the glucuronidation of ent-etiocholanolone and ent-androsterone by both UGT2B7 and UGT2B17 differs considerably from their respective activity toward the corresponding endogenous androgens, whereas UGT2A1-catalyzed conjugation is much less affected by the stereochemistry differences. ent-androsterone 61-77 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 86-92 21673130-10 2011 In conclusion, glucuronidation of eslicarbazepine results from the contribution of UGT1A4, UGT1A9, UGT2B4, UGT2B7, and UGT2B17, but the high-affinity component of the UGT2B4 isozyme may play a major role at therapeutic plasma concentrations of unbound eslicarbazepine. eslicarbazepine 34-49 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 107-113 21780761-6 2011 Three glucuronide conjugates were observed in activity assays with UGTs 1A1 and 1A10, while two glucuronides were formed by UGTs 1A7, 1A8, and 1A9, and one glucuronide was made by UGT1A4 and UGT2B7. Glucuronides 6-17 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 191-197 21622626-8 2011 Kinetic studies using recombinant human UGT isoforms identified UGT2B7 as the most important UGT isoform for glucuronidation of sesamin monocatechol. Sesamin monocatechol 128-148 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 64-70 21622626-10 2011 These results strongly suggest that UGT2B7 plays an important role in glucuronidation of sesamin monocatechol. Sesamin monocatechol 89-109 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 36-42 21846671-8 2011 The Wilcoxon matched pairs test indicated that the change in 8-hydroxyefavirenz concentration and efavirenz MR over time was significant in females and in CYP2B6*1 and UGT2B7*1 carriers. 8-hydroxyefavirenz 61-79 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 168-174 21622626-14 2011 On the basis of these results, we concluded that CYP2C9, UGT2B7, and COMT played essential roles in the metabolism of sesamin in the human liver. sesamin 118-125 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 57-63 21511943-10 2011 The four oxidative metabolites were formed by multiple human P450 enzymes, and N-glucuronide was formed by UGT1A3 and UGT2B7. n-glucuronide 79-92 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 118-124 21438849-15 2011 The current evaluation of glucuronide metabolites of BUP and norBUP are suggestive of combined inhibition of Uridine diphosphate (UDP)-glucuronosyltransferase of the 1A family and cytochrome P450 3A4 that spares UGT2B7 leading to a shunting of BUP away from production of norBUP and toward BUP-3G as seen by a statistically significant increase in the AUC of BUP-3G. Glucuronides 26-37 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 212-218 21245288-5 2011 Higher NFA concentrations (50-100 muM) inhibited UGT1A1 and UGT2B15 but had little effect on the activities of UGT1A3, UGT1A4, UGT1A6, UGT2B4, UGT2B7, and UGT2B17. Niflumic Acid 7-10 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 143-149 21658222-0 2011 Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer. Epirubicin 67-77 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 10-16 21658222-3 2011 The present study aimed to describe the impact of the UGT2B7(His268Tyr) polymorphism on invasive disease-free survival in breast cancer patients after epirubicin treatment. Epirubicin 151-161 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 54-60 21658222-9 2011 RESULTS: Among the 205 epirubicin-treated patients, carriers of two UGT2B7(268Tyr) alleles had a mean invasive disease-free survival of 8.6 (95% confidence interval (CI) 7.9 to 9.3) years as compared to 7.5 (95% CI 6.9 to 8.0) years in carriers of at least one UGT2B7(268His) allele (adjusted hazard ratio (HR) = 2.64 (95% CI 1.22 to 5.71); P = 0.014). Epirubicin 23-33 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 68-74 21658222-9 2011 RESULTS: Among the 205 epirubicin-treated patients, carriers of two UGT2B7(268Tyr) alleles had a mean invasive disease-free survival of 8.6 (95% confidence interval (CI) 7.9 to 9.3) years as compared to 7.5 (95% CI 6.9 to 8.0) years in carriers of at least one UGT2B7(268His) allele (adjusted hazard ratio (HR) = 2.64 (95% CI 1.22 to 5.71); P = 0.014). Epirubicin 23-33 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 261-267 21658222-10 2011 In addition, the impact of the UGT2B7(His268Tyr) polymorphism became even more pronounced in patients subsequently treated with tamoxifen (adjusted HR = 5.22 (95% CI 1.67 to 26.04); P = 0.015) whereas no such difference in invasive disease-free survival was observed in patients not receiving epirubicin. Tamoxifen 128-137 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 31-37 21658222-10 2011 In addition, the impact of the UGT2B7(His268Tyr) polymorphism became even more pronounced in patients subsequently treated with tamoxifen (adjusted HR = 5.22 (95% CI 1.67 to 26.04); P = 0.015) whereas no such difference in invasive disease-free survival was observed in patients not receiving epirubicin. Epirubicin 293-303 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 31-37 21658222-11 2011 CONCLUSIONS: Breast cancer patients carrying the UGT2B7(268Tyr/Tyr) genotype may benefit most from adjuvant epirubicin-based chemotherapy. Tyrosine 59-62 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 49-55 21658222-11 2011 CONCLUSIONS: Breast cancer patients carrying the UGT2B7(268Tyr/Tyr) genotype may benefit most from adjuvant epirubicin-based chemotherapy. Epirubicin 108-118 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 49-55 21415305-5 2011 Liver UGT2B7 expression levels were decreased when TgUGT2B7 mice were treated with the CAR ligand 1,4-b-s-[2-(3,5,-dichloropyridyloxy)] (TCPOBOP) but not the PXR ligand pregnenolone 16alpha-carbonitrile. 1,4-b-s-[2-(3,5,-dichloropyridyloxy)] 98-135 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 6-12 21415305-5 2011 Liver UGT2B7 expression levels were decreased when TgUGT2B7 mice were treated with the CAR ligand 1,4-b-s-[2-(3,5,-dichloropyridyloxy)] (TCPOBOP) but not the PXR ligand pregnenolone 16alpha-carbonitrile. 1,4-bis(2-(3,5-dichloropyridyloxy))benzene 137-144 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 6-12 21415305-5 2011 Liver UGT2B7 expression levels were decreased when TgUGT2B7 mice were treated with the CAR ligand 1,4-b-s-[2-(3,5,-dichloropyridyloxy)] (TCPOBOP) but not the PXR ligand pregnenolone 16alpha-carbonitrile. Pregnenolone Carbonitrile 169-202 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 6-12 21319958-2 2011 Among 12 recombinant UGT isoforms tested, only UGT2B7 showed catalytic activity in the formation of EFV-N-glucuronide (EFV-G) as previously reported. efv-n-glucuronide 100-117 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-53 21319958-2 2011 Among 12 recombinant UGT isoforms tested, only UGT2B7 showed catalytic activity in the formation of EFV-N-glucuronide (EFV-G) as previously reported. efv-g 119-124 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-53 21319958-5 2011 The formation of EFV-G showed a significant correlation (r = 0.920; p < 0.0001) with UGT2B7-catalysed azidothymidine glucuronidation in 17 different human liver microsomes. Zidovudine 105-119 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 88-94 21319958-6 2011 Furthermore, fluconazole, a known UGT2B7 inhibitor, potently inhibited the formation of EFV-G up to 80%. Fluconazole 13-24 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 34-40 21319958-6 2011 Furthermore, fluconazole, a known UGT2B7 inhibitor, potently inhibited the formation of EFV-G up to 80%. efv-g 88-93 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 34-40 21427202-7 2011 The active hydroxylamine metabolite of PR-104A, PR-104H, was also glucuronidated by UGT2B7, although with slightly lower specificity and much lower rates. Hydroxylamine 11-24 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 84-90 21381897-8 2011 The present results demonstrated complex interactions between IFN-alpha2b and hepatocytes and the observed down-regulation of CYP1A2, OAT2 and UGT2B7 is consistent with reports of drug interactions between IFN-alpha2b and drugs such as theophylline, clozapine and gemfibrozil. Theophylline 236-248 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 143-149 21381897-8 2011 The present results demonstrated complex interactions between IFN-alpha2b and hepatocytes and the observed down-regulation of CYP1A2, OAT2 and UGT2B7 is consistent with reports of drug interactions between IFN-alpha2b and drugs such as theophylline, clozapine and gemfibrozil. Clozapine 250-259 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 143-149 21381897-8 2011 The present results demonstrated complex interactions between IFN-alpha2b and hepatocytes and the observed down-regulation of CYP1A2, OAT2 and UGT2B7 is consistent with reports of drug interactions between IFN-alpha2b and drugs such as theophylline, clozapine and gemfibrozil. Gemfibrozil 264-275 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 143-149 21123165-6 2011 This finding is supported by markedly lower glucuronidation of the UGT2B7 probe zidovudine, UGT2B7 protein, and UGT2B7 mRNA in diabetic tissues. Zidovudine 80-90 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 67-73 21123165-9 2011 These findings suggest that diabetes mellitus is associated with significantly reduced UGT2B7 mRNA expression, protein level, and enzymatic activity of human liver and kidney, explaining in part the relatively low circulating concentrations of AcMPAG in diabetic patients. mycophenolic acid acyl glucuronide 244-250 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 87-93 21123165-0 2011 Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. mycophenolic acid acyl glucuronide 130-164 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 44-75 20797434-8 2010 UGT2B7, on the other hand, glucuronidated both O-desmethyltramadol enantiomers, with slight preference for 1S,2S-O-desmethyltramadol. O-demethyltramadol 47-66 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 21284263-0 2010 Strong inhibitory effect of medroxyprogesterone acetate (MPA) on UDP-glucuronosyltransferase (UGT) 2B7 might induce drug-drug interactions. Medroxyprogesterone Acetate 28-55 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 65-102 20797434-8 2010 UGT2B7, on the other hand, glucuronidated both O-desmethyltramadol enantiomers, with slight preference for 1S,2S-O-desmethyltramadol. 1s,2s-o-desmethyltramadol 107-132 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 20797434-10 2010 The apparent K(m) or S(50) values were high: 1.2mM+-0.23 for 1R,2R-O-desmethyltramadol with UGT1A8 and 1.84+-1.2 and 4.6+-2.0mM for 1S,2S- and 1R,2R-O-desmethyltramadol enantiomers with UGT2B7, respectively. 2r-o-desmethyltramadol 64-86 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 186-192 20713656-5 2010 Consistent with these observations, the UGT1A4 inhibitor hecogenin and the UGT2B7 substrate diclofenac potently inhibited the N- and O-glucuronidation of 1"-hydroxymidazolam in HLMs, respectively. Nitrogen 126-127 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 75-81 20713656-5 2010 Consistent with these observations, the UGT1A4 inhibitor hecogenin and the UGT2B7 substrate diclofenac potently inhibited the N- and O-glucuronidation of 1"-hydroxymidazolam in HLMs, respectively. 1-hydroxymethylmidazolam 154-173 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 75-81 20713656-5 2010 Consistent with these observations, the UGT1A4 inhibitor hecogenin and the UGT2B7 substrate diclofenac potently inhibited the N- and O-glucuronidation of 1"-hydroxymidazolam in HLMs, respectively. Diclofenac 92-102 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 75-81 20713656-6 2010 A correlation analysis of UGT enzymatic activity and the formation rate of glucuronide metabolites from 1"- and 4-hydroxymidazolam in 25 HLMs showed that hydroxymidazolam glucuronidation is correlated with UGT1A4-mediated lamotrigine glucuronidation and UGT2B7-mediated diclofenac glucuronidation activity. Glucuronides 75-86 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 254-260 20713656-6 2010 A correlation analysis of UGT enzymatic activity and the formation rate of glucuronide metabolites from 1"- and 4-hydroxymidazolam in 25 HLMs showed that hydroxymidazolam glucuronidation is correlated with UGT1A4-mediated lamotrigine glucuronidation and UGT2B7-mediated diclofenac glucuronidation activity. 1"- and 4-hydroxymidazolam 104-130 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 254-260 20713656-6 2010 A correlation analysis of UGT enzymatic activity and the formation rate of glucuronide metabolites from 1"- and 4-hydroxymidazolam in 25 HLMs showed that hydroxymidazolam glucuronidation is correlated with UGT1A4-mediated lamotrigine glucuronidation and UGT2B7-mediated diclofenac glucuronidation activity. hydroxymidazolam 114-130 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 254-260 20397195-6 2010 UGT1A1, 1A3 and 1A8 had the highest activities and gave rise to the phenolic glucuronide, whereas glucuronidation of the aliphatic hydroxyl group was mostly mediated by UGT2B7 with low activity. aliphatic hydroxyl 121-139 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 169-175 20973683-10 2010 CONCLUSION: UGT2B7 is a promising gene candidate that may influence MPA pharmacokinetics clinically; however, larger clinical pharmacogenetic studies in thoracic transplant subpopulations are warranted to corroborate the role of AcMPAG and UGT2B7 variants in optimizing mycophenolate mofetil therapy. mycophenolic acid acyl glucuronide 229-235 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 12-18 20973683-10 2010 CONCLUSION: UGT2B7 is a promising gene candidate that may influence MPA pharmacokinetics clinically; however, larger clinical pharmacogenetic studies in thoracic transplant subpopulations are warranted to corroborate the role of AcMPAG and UGT2B7 variants in optimizing mycophenolate mofetil therapy. Mycophenolic Acid 270-291 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 12-18 20551237-8 2010 Three UDP-glucuronosyltransferases (UGTs), namely, UGT1A9, UGT2B7, and UGT2B15, exhibited glucuronidation of dabigatran. Dabigatran 109-119 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 59-65 27713373-7 2010 Similarly, the UDP-glucuronosyltransferase 2B7 genotype may affect the pharmacokinetics of lamotrigine. Lamotrigine 91-102 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 15-46 20304966-0 2010 Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction. Spironolactone 0-14 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 37-43 20484152-9 2010 Whereas fluconazole and ketoconazole inhibited UGT2B4- and UGT2B7-catalyzed COD glucuronidation to a similar extent, inhibition by dextropropoxyphene and methadone resulted largely from an effect on UGT2B4. Fluconazole 8-19 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 59-65 20484152-9 2010 Whereas fluconazole and ketoconazole inhibited UGT2B4- and UGT2B7-catalyzed COD glucuronidation to a similar extent, inhibition by dextropropoxyphene and methadone resulted largely from an effect on UGT2B4. Ketoconazole 24-36 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 59-65 20484152-9 2010 Whereas fluconazole and ketoconazole inhibited UGT2B4- and UGT2B7-catalyzed COD glucuronidation to a similar extent, inhibition by dextropropoxyphene and methadone resulted largely from an effect on UGT2B4. Methadone 154-163 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 59-65 20304966-0 2010 Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction. Canrenone 19-28 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 37-43 20304966-0 2010 Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction. Aldosterone 88-99 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 37-43 20304966-2 2010 Because ALDO is eliminated via UGT2B7-catalyzed 18beta-glucuronidation, this study aimed to determine whether spironolactone and its primary metabolites, canrenone and canrenoic acid, inhibit ALDO 18beta-glucuronidation by recombinant UGT2B7 and by human liver (HLM) and human kidney cortical (HKCM) microsomes. 18beta 48-54 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 31-37 20304966-2 2010 Because ALDO is eliminated via UGT2B7-catalyzed 18beta-glucuronidation, this study aimed to determine whether spironolactone and its primary metabolites, canrenone and canrenoic acid, inhibit ALDO 18beta-glucuronidation by recombinant UGT2B7 and by human liver (HLM) and human kidney cortical (HKCM) microsomes. Spironolactone 110-124 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 31-37 20304966-2 2010 Because ALDO is eliminated via UGT2B7-catalyzed 18beta-glucuronidation, this study aimed to determine whether spironolactone and its primary metabolites, canrenone and canrenoic acid, inhibit ALDO 18beta-glucuronidation by recombinant UGT2B7 and by human liver (HLM) and human kidney cortical (HKCM) microsomes. Canrenone 154-163 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 31-37 20304966-2 2010 Because ALDO is eliminated via UGT2B7-catalyzed 18beta-glucuronidation, this study aimed to determine whether spironolactone and its primary metabolites, canrenone and canrenoic acid, inhibit ALDO 18beta-glucuronidation by recombinant UGT2B7 and by human liver (HLM) and human kidney cortical (HKCM) microsomes. Aldosterone 8-12 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 31-37 20304966-5 2010 Inhibitor constant (K(i)) values for spironolactone and canrenone inhibition of ALDO 18beta-glucuronidation were subsequently determined with HLM, HKCM, and UGT2B7 as the enzyme sources. Canrenone 56-65 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 157-163 20304966-6 2010 Spironolactone and canrenone were competitive inhibitors of ALDO 18beta-glucuronidation by HLM, HKCM, and UGT2B7. Spironolactone 0-14 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 106-112 20304966-6 2010 Spironolactone and canrenone were competitive inhibitors of ALDO 18beta-glucuronidation by HLM, HKCM, and UGT2B7. Canrenone 19-28 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 106-112 20304966-8 2010 K(i) values for spironolactone and canrenone inhibition of ALDO 18beta-glucuronidation by recombinant UGT2B7 were 23 and 11 microM, respectively. Spironolactone 16-30 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 102-108 20304966-8 2010 K(i) values for spironolactone and canrenone inhibition of ALDO 18beta-glucuronidation by recombinant UGT2B7 were 23 and 11 microM, respectively. Canrenone 35-44 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 102-108 20304966-10 2010 The data indicate that the elevated ALDO concentrations observed in patients treated with spironolactone may be due, at least in part, to a pharmacokinetic interaction, and spironolactone and canrenone should be considered to be potential inhibitors of the UGT2B7-mediated metabolic clearance of drugs in both liver and kidney. Spironolactone 90-104 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 257-263 20304966-10 2010 The data indicate that the elevated ALDO concentrations observed in patients treated with spironolactone may be due, at least in part, to a pharmacokinetic interaction, and spironolactone and canrenone should be considered to be potential inhibitors of the UGT2B7-mediated metabolic clearance of drugs in both liver and kidney. Spironolactone 173-187 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 257-263 20304966-10 2010 The data indicate that the elevated ALDO concentrations observed in patients treated with spironolactone may be due, at least in part, to a pharmacokinetic interaction, and spironolactone and canrenone should be considered to be potential inhibitors of the UGT2B7-mediated metabolic clearance of drugs in both liver and kidney. Canrenone 192-201 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 257-263 20297805-4 2010 The results also indicated that UGT1A1, UGT1A7, UGT1A8, UGT1A9, UGT1A10 and UGT2B7 are the most important six UGT isoforms for metabolizing the chosen flavones. Flavones 151-159 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 76-82 20200232-10 2010 Among the human UGT enzymes tested, only UGT2B7 had detectable glucuronidation activity for BMP. 2,2-bis(bromomethyl)-1,3-propanediol 92-95 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 41-47 19644937-1 2010 Stereoselective metabolism of propranolol side-chain glucuronidation was studied for two recombinant human uridine diphosphate glucuronosyltransferases (UGTs), UGT1A9 and UGT2B7. Propranolol 30-41 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 171-177 20304965-8 2010 UGT1A4 was the main enzyme involved in the metabolism of all compounds except for fluconazole, which was mainly metabolized by UGT2B7, probably mediating its O-glucuronide metabolism. Fluconazole 82-93 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 127-133 20304965-8 2010 UGT1A4 was the main enzyme involved in the metabolism of all compounds except for fluconazole, which was mainly metabolized by UGT2B7, probably mediating its O-glucuronide metabolism. o-glucuronide 158-171 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 127-133 19644937-6 2010 The high concentration of racemic propranolol (>0.57 mmol/l) and individual enantiomers (>0.69 mmol/l) exhibited substrate inhibition of glucuronidation for UGT2B7, but only the S-enantiomer (>0.44 mmol/l) in racemic propranolol exhibited substrate inhibition for UGT1A9. Propranolol 34-45 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 163-169 20216122-0 2010 UGT2B7_-161C>T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study. Lamotrigine 50-61 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-7 20124396-9 2010 In vitro studies showed that UGT2B7 and CYP3A4 are responsible for the majority of lersivirine metabolism in humans. UK 453,061 83-94 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 29-35 20111869-4 2010 Amitriptyline and temazepam are inhibitors of NBUP glucuronidation (UGT1A3, HLMs), whereas BUP glucuronidation was affected by amitriptyline (HLMs), oxazepam, and temazepam (UGT2B7). Amitriptyline 0-13 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 174-180 20071451-2 2010 Morphine, a probe drug for UGT2B7, is metabolized to morphine-3-beta-glucuronide (M3G) and morphine-6-beta-glucuronide (M6G) in humans. Morphine 0-8 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 27-33 20071451-2 2010 Morphine, a probe drug for UGT2B7, is metabolized to morphine-3-beta-glucuronide (M3G) and morphine-6-beta-glucuronide (M6G) in humans. morphine-3-beta-glucuronide 53-80 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 27-33 20071451-2 2010 Morphine, a probe drug for UGT2B7, is metabolized to morphine-3-beta-glucuronide (M3G) and morphine-6-beta-glucuronide (M6G) in humans. morphine-6-glucuronide 91-118 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 27-33 20216122-1 2010 Lamotrigine (LTG) is metabolized by UGT1A4 but UGT2B7 also contributes to its glucuronidation. Lamotrigine 0-11 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-53 20216122-2 2010 The aim of this study was to determine whether UGT2B7_- 161C>T and UGT2B7_372A>G polymorphisms contribute to the intersubject variability in LTG concentration-to-dose ratio (LTG-CDR) in epileptic patients. Lamotrigine 147-150 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-54 20216122-2 2010 The aim of this study was to determine whether UGT2B7_- 161C>T and UGT2B7_372A>G polymorphisms contribute to the intersubject variability in LTG concentration-to-dose ratio (LTG-CDR) in epileptic patients. Lamotrigine 147-150 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-53 19730281-0 2009 Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid. Mycophenolic Acid 109-126 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 34-40 20145913-4 2010 The assays are based on analysis and quantification by high-performance liquid chromatography-tandem mass spectrometry of glucuronides formed from selective probe substrates, namely, beta-estradiol (UGT1A1, 3-glucuronide), 1-naphthol (UGT1A6), propofol (UGT1A9), and naloxone (UGT2B7). Glucuronides 122-134 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 277-283 20145913-4 2010 The assays are based on analysis and quantification by high-performance liquid chromatography-tandem mass spectrometry of glucuronides formed from selective probe substrates, namely, beta-estradiol (UGT1A1, 3-glucuronide), 1-naphthol (UGT1A6), propofol (UGT1A9), and naloxone (UGT2B7). Estradiol 183-197 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 277-283 20145913-8 2010 Under these conditions, selective inhibition of UGT2B7 by fluconazole and low amitriptyline concentrations were observed, whereas diclofenac and quinidine were shown as non-enzyme-selective inhibitors of UGTs. Fluconazole 58-69 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 48-54 20145913-8 2010 Under these conditions, selective inhibition of UGT2B7 by fluconazole and low amitriptyline concentrations were observed, whereas diclofenac and quinidine were shown as non-enzyme-selective inhibitors of UGTs. Amitriptyline 78-91 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 48-54 20008037-0 2010 Identification of human UGT2B7 as the major isoform involved in the O-glucuronidation of chloramphenicol. Chloramphenicol 89-104 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 24-30 20008037-4 2010 Reaction phenotyping for the glucuronidation of CP with 12 expressed human liver UGT isoforms has identified UGT2B7 as having the highest activity for 3-O- and 1-O-CP glucuronidation with minor contributions from UGT1A6 and UGT1A9. 3-o 151-154 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 109-115 20008037-4 2010 Reaction phenotyping for the glucuronidation of CP with 12 expressed human liver UGT isoforms has identified UGT2B7 as having the highest activity for 3-O- and 1-O-CP glucuronidation with minor contributions from UGT1A6 and UGT1A9. 1-hexadecyl-2-acetyl-glycero-3-phosphocholine 160-163 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 109-115 20008037-7 2010 Azidothymidine (AZT) and hyodeoxycholic acid (substrates of UGT2B7) inhibited 3-O- and 1-O-CP glucuronidation in pooled HLMs. Zidovudine 0-14 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 60-66 20008037-7 2010 Azidothymidine (AZT) and hyodeoxycholic acid (substrates of UGT2B7) inhibited 3-O- and 1-O-CP glucuronidation in pooled HLMs. hyodeoxycholic acid 25-44 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 60-66 20008037-7 2010 Azidothymidine (AZT) and hyodeoxycholic acid (substrates of UGT2B7) inhibited 3-O- and 1-O-CP glucuronidation in pooled HLMs. 3-o 78-81 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 60-66 20008037-7 2010 Azidothymidine (AZT) and hyodeoxycholic acid (substrates of UGT2B7) inhibited 3-O- and 1-O-CP glucuronidation in pooled HLMs. Chloramphenicol 1-O-|A-D-Glucuronide 87-93 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 60-66 20008037-9 2010 These results suggest that UGT2B7 is the primary human hepatic UDP-glucuronosyltransferase isoform catalyzing 3-O- and 1-O-CP glucuronidation with minor contributions from UGT1A6 and UGT1A9. 3-o 110-113 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 27-33 20008037-9 2010 These results suggest that UGT2B7 is the primary human hepatic UDP-glucuronosyltransferase isoform catalyzing 3-O- and 1-O-CP glucuronidation with minor contributions from UGT1A6 and UGT1A9. 1-hexadecyl-2-acetyl-glycero-3-phosphocholine 119-122 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 27-33 19821783-5 2010 The 1.8-a resolution apo crystal structure of the UDP-glucuronic acid binding domain of human UGT2B7 (2B7CT) is the only structure of a mammalian UGT target determined to date. Uridine Diphosphate Glucuronic Acid 50-69 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 94-100 19466410-0 2010 Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Morphine 47-55 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 15-21 19466410-2 2010 METHODS: We examined the relation of morphine-related adverse events to polymorphisms in UDP-glucuronosyltransferase (UGT) 2B7, ATP-binding cassette, sub-family B, number 1 (ABCB1), and mu-opioid receptor 1 genes in 32 Japanese cancer patients receiving oral controlled-release morphine sulfate tablets. Morphine 37-45 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 89-126 19850672-5 2010 Erlotinib exhibited selective potent competitive inhibition against 4-MU glucuronidation by UGT1A1, and gefitinib demonstrated a wide range of inhibition against UGT-mediated 4-MU glucuronidation, particularly against UGT1A1, UGT1A7, UGT1A9, and UGT2B7. Erlotinib Hydrochloride 0-9 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 246-252 19850672-5 2010 Erlotinib exhibited selective potent competitive inhibition against 4-MU glucuronidation by UGT1A1, and gefitinib demonstrated a wide range of inhibition against UGT-mediated 4-MU glucuronidation, particularly against UGT1A1, UGT1A7, UGT1A9, and UGT2B7. Gefitinib 104-113 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 246-252 19475557-8 2010 Coexpression of the UGT1As significantly decreased K(m) and increased V(max) of zidovudine O-glucuronidation by UGT2B7. Zidovudine 80-90 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 112-118 19475557-9 2010 Coexpression of UGT2B7 also affected the kinetics of estradiol 3-O-glucuronidation by UGT1A1, imipramine N-glucuronidation by UGT1A4, serotonin O-glucuronidation by UGT1A6, and propofol O-glucuronidation by UGT1A9. estradiol 3-o 53-66 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 16-22 19661211-3 2009 UGT2B7 conjugated all four androgens at the 3-OH but not at the 17-OH that is available in both diols. diols 96-101 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 19661211-4 2009 UGT2B7 exhibited a higher glucuronidation rate toward the steroids with a flat backbone, androsterone and 5alpha-diol, compared with etiocholanolone and 5beta-diol, which have a bent backbone. Steroids 58-66 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 19661211-4 2009 UGT2B7 exhibited a higher glucuronidation rate toward the steroids with a flat backbone, androsterone and 5alpha-diol, compared with etiocholanolone and 5beta-diol, which have a bent backbone. Androsterone 89-101 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 19661211-4 2009 UGT2B7 exhibited a higher glucuronidation rate toward the steroids with a flat backbone, androsterone and 5alpha-diol, compared with etiocholanolone and 5beta-diol, which have a bent backbone. Androstane-3,17-diol 106-117 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 19661211-4 2009 UGT2B7 exhibited a higher glucuronidation rate toward the steroids with a flat backbone, androsterone and 5alpha-diol, compared with etiocholanolone and 5beta-diol, which have a bent backbone. Etiocholanolone 133-148 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 19661211-4 2009 UGT2B7 exhibited a higher glucuronidation rate toward the steroids with a flat backbone, androsterone and 5alpha-diol, compared with etiocholanolone and 5beta-diol, which have a bent backbone. Androstane-3,17-diol 153-163 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 19661212-6 2009 UGT2B7.1 (His(268)) and UGT2B7.2 (Tyr(268)) enzyme activity was similar, whereas UGT1A3.2 (R(11)A(47)), UGT1A3.3 (Trp(11)), and UGT1A9.3 (Thr(33)) showed 61 to 96% reduced V(max)/K(m) values compared with the respective (1) reference proteins. Histidine 10-13 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 19661212-9 2009 This was confirmed by a strong correlation of FA-G formation with UGT2B7 protein content and inhibition by fluconazole, a known UGT2B7 selective inhibitor. Fluconazole 107-118 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 128-134 19475557-9 2010 Coexpression of UGT2B7 also affected the kinetics of estradiol 3-O-glucuronidation by UGT1A1, imipramine N-glucuronidation by UGT1A4, serotonin O-glucuronidation by UGT1A6, and propofol O-glucuronidation by UGT1A9. imipramine n 94-106 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 16-22 19475557-9 2010 Coexpression of UGT2B7 also affected the kinetics of estradiol 3-O-glucuronidation by UGT1A1, imipramine N-glucuronidation by UGT1A4, serotonin O-glucuronidation by UGT1A6, and propofol O-glucuronidation by UGT1A9. Serotonin 134-143 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 16-22 19475557-9 2010 Coexpression of UGT2B7 also affected the kinetics of estradiol 3-O-glucuronidation by UGT1A1, imipramine N-glucuronidation by UGT1A4, serotonin O-glucuronidation by UGT1A6, and propofol O-glucuronidation by UGT1A9. Propofol 177-185 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 16-22 19730281-1 2009 The aim of this study was to determine the relationship between single nucleotide polymorphisms in multidrug resistance protein 2 (MRP2) and uridine diphosphate glucuronosyltransferase (UGT) 2B7 and the severity of gastrointestinal (GI) symptoms in patients receiving mycophenolic acid (MPA). Mycophenolic Acid 268-285 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 141-194 19730281-8 2009 When the genotypes for MRP2 and UGT2B7 were considered together, patients with the variant forms of MRP2 and UGT2B7 had significantly lower overall GSRS scores (CC-CC vs. CT-CT/TT, 22.5 +/- 4.3 vs. 30.1 +/- 10.1, P = 0.04) and diarrhea subscale scores compared to wild type (CC-CC vs. CT-CT/TT, 3.4 +/- 0.7 vs. 6.2 +/- 4.4, P = 0.03). cc-cc 161-166 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 32-38 19730281-8 2009 When the genotypes for MRP2 and UGT2B7 were considered together, patients with the variant forms of MRP2 and UGT2B7 had significantly lower overall GSRS scores (CC-CC vs. CT-CT/TT, 22.5 +/- 4.3 vs. 30.1 +/- 10.1, P = 0.04) and diarrhea subscale scores compared to wild type (CC-CC vs. CT-CT/TT, 3.4 +/- 0.7 vs. 6.2 +/- 4.4, P = 0.03). cc-cc 161-166 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 109-115 19730281-8 2009 When the genotypes for MRP2 and UGT2B7 were considered together, patients with the variant forms of MRP2 and UGT2B7 had significantly lower overall GSRS scores (CC-CC vs. CT-CT/TT, 22.5 +/- 4.3 vs. 30.1 +/- 10.1, P = 0.04) and diarrhea subscale scores compared to wild type (CC-CC vs. CT-CT/TT, 3.4 +/- 0.7 vs. 6.2 +/- 4.4, P = 0.03). ct-ct 171-176 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 32-38 19730281-8 2009 When the genotypes for MRP2 and UGT2B7 were considered together, patients with the variant forms of MRP2 and UGT2B7 had significantly lower overall GSRS scores (CC-CC vs. CT-CT/TT, 22.5 +/- 4.3 vs. 30.1 +/- 10.1, P = 0.04) and diarrhea subscale scores compared to wild type (CC-CC vs. CT-CT/TT, 3.4 +/- 0.7 vs. 6.2 +/- 4.4, P = 0.03). ct-ct 171-176 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 109-115 19740398-7 2009 Of the UGT proteins, only UGT1A10 and UGT2B7 converted ALDO to its 18beta-glucuronide. 18beta-glucuronide 67-85 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 38-44 19487247-5 2009 The conserved N-terminal domain histidine of UGT1A1, UGT1A6, UGT1A9, and UGT2B7 was mutated to proline and leucine 34 of UGT2B10 was substituted with histidine, and the capacity of the wild-type and mutant proteins to glucuronidate 4MU, 1NP, LTG, TFP, and naproxen was characterized. Histidine 32-41 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 73-79 19487247-5 2009 The conserved N-terminal domain histidine of UGT1A1, UGT1A6, UGT1A9, and UGT2B7 was mutated to proline and leucine 34 of UGT2B10 was substituted with histidine, and the capacity of the wild-type and mutant proteins to glucuronidate 4MU, 1NP, LTG, TFP, and naproxen was characterized. Proline 95-102 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 73-79 19487247-5 2009 The conserved N-terminal domain histidine of UGT1A1, UGT1A6, UGT1A9, and UGT2B7 was mutated to proline and leucine 34 of UGT2B10 was substituted with histidine, and the capacity of the wild-type and mutant proteins to glucuronidate 4MU, 1NP, LTG, TFP, and naproxen was characterized. Leucine 107-114 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 73-79 19487252-2 2009 The glucuronidation of EFV was screened with UGT1A and UGT2B enzymes expressed in a heterologous system, and UGT2B7 was shown to be the only reactive enzyme. efavirenz 23-26 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 109-115 19487247-5 2009 The conserved N-terminal domain histidine of UGT1A1, UGT1A6, UGT1A9, and UGT2B7 was mutated to proline and leucine 34 of UGT2B10 was substituted with histidine, and the capacity of the wild-type and mutant proteins to glucuronidate 4MU, 1NP, LTG, TFP, and naproxen was characterized. glucuronidate 218-231 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 73-79 19487247-5 2009 The conserved N-terminal domain histidine of UGT1A1, UGT1A6, UGT1A9, and UGT2B7 was mutated to proline and leucine 34 of UGT2B10 was substituted with histidine, and the capacity of the wild-type and mutant proteins to glucuronidate 4MU, 1NP, LTG, TFP, and naproxen was characterized. Histidine 150-159 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 73-79 19487247-5 2009 The conserved N-terminal domain histidine of UGT1A1, UGT1A6, UGT1A9, and UGT2B7 was mutated to proline and leucine 34 of UGT2B10 was substituted with histidine, and the capacity of the wild-type and mutant proteins to glucuronidate 4MU, 1NP, LTG, TFP, and naproxen was characterized. Naproxen 256-264 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 73-79 19487252-3 2009 The apparent K(m) value of UGT2B7 (21 microM) is similar to the value observed for human liver microsomes (24 microM), whereas the variant allozyme UGT2B7*2 (Tyr(268)) displayed similar kinetic parameters. Tyrosine 158-161 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 148-154 19022937-10 2009 Although UGT2B7 and UGT2B17 exhibited high, although converse, stereoselectivity in testosterone and epitestosterone glucuronidation, UGT2A1, an extrahepatic enzyme that is expressed mainly in the nasal epithelium, catalyzed the glucuronidation of both steroids at considerable rates and similar kinetics. Steroids 253-261 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 9-15 19487252-4 2009 Because 3"-azido-3"-deoxythymidine (AZT), one of the most current nucleotide reverse transcriptase inhibitors prescribed in combination with EFV, is also conjugated by UGT2B7, the potential metabolic interaction between EFV and AZT has been studied using human liver microsomes. Zidovudine 8-34 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 168-174 19487252-4 2009 Because 3"-azido-3"-deoxythymidine (AZT), one of the most current nucleotide reverse transcriptase inhibitors prescribed in combination with EFV, is also conjugated by UGT2B7, the potential metabolic interaction between EFV and AZT has been studied using human liver microsomes. Zidovudine 36-39 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 168-174 19487252-4 2009 Because 3"-azido-3"-deoxythymidine (AZT), one of the most current nucleotide reverse transcriptase inhibitors prescribed in combination with EFV, is also conjugated by UGT2B7, the potential metabolic interaction between EFV and AZT has been studied using human liver microsomes. efavirenz 141-144 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 168-174 19487252-4 2009 Because 3"-azido-3"-deoxythymidine (AZT), one of the most current nucleotide reverse transcriptase inhibitors prescribed in combination with EFV, is also conjugated by UGT2B7, the potential metabolic interaction between EFV and AZT has been studied using human liver microsomes. efavirenz 220-223 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 168-174 19487252-4 2009 Because 3"-azido-3"-deoxythymidine (AZT), one of the most current nucleotide reverse transcriptase inhibitors prescribed in combination with EFV, is also conjugated by UGT2B7, the potential metabolic interaction between EFV and AZT has been studied using human liver microsomes. Zidovudine 228-231 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 168-174 19244109-6 2009 For active hepatic UGTs, the UGT2B7(268Tyr) variant exhibited significant (P < 0.01) 2- and 5-fold decreases in activity against the trans isomers of 4-OH-TAM and endoxifen, respectively, compared with wild-type UGT2B7(268His). hydroxytamoxifen 153-161 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 29-35 19244109-6 2009 For active hepatic UGTs, the UGT2B7(268Tyr) variant exhibited significant (P < 0.01) 2- and 5-fold decreases in activity against the trans isomers of 4-OH-TAM and endoxifen, respectively, compared with wild-type UGT2B7(268His). hydroxytamoxifen 153-161 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 215-221 19244109-6 2009 For active hepatic UGTs, the UGT2B7(268Tyr) variant exhibited significant (P < 0.01) 2- and 5-fold decreases in activity against the trans isomers of 4-OH-TAM and endoxifen, respectively, compared with wild-type UGT2B7(268His). 4-hydroxy-N-desmethyltamoxifen 166-175 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 29-35 19244109-8 2009 These results suggest that functional polymorphisms in TAM-metabolizing UGTs, including UGT2B7 and potentially UGT1A8, may be important in interindividual variability in TAM metabolism and response to TAM therapy. Tamoxifen 55-58 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 88-94 19244109-8 2009 These results suggest that functional polymorphisms in TAM-metabolizing UGTs, including UGT2B7 and potentially UGT1A8, may be important in interindividual variability in TAM metabolism and response to TAM therapy. Tamoxifen 170-173 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 88-94 19244109-8 2009 These results suggest that functional polymorphisms in TAM-metabolizing UGTs, including UGT2B7 and potentially UGT1A8, may be important in interindividual variability in TAM metabolism and response to TAM therapy. Tamoxifen 170-173 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 88-94 19628728-0 2009 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. Zidovudine 179-189 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 143-149 19628728-6 2009 In conclusion, generic NRTI pharmacokinetics in HIV/TB-coinfected Ghanaians are similar to other populations, whereas the UGT2B7*1c polymorphism may explain in part relatively high interindividual variability in zidovudine clearance. Zidovudine 212-222 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 122-128 19462483-14 2009 These results suggest that Salvinorin A maybe a substrate of UGT2B7, CYP2D6, CYP1A1, CYP2E1, and CYP2C18. salvinorin A 27-39 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 61-67 19158361-3 2009 To address this issue, we examined in more detail the CYP3A4-UGT2B7 association by means of immunoprecipitation, overlay assay, and cross-linking involving 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide. Ethyldimethylaminopropyl Carbodiimide 156-203 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 61-67 19022937-9 2009 Epitestosterone glucuronidation is catalyzed mainly by UGT2B7, and the K(m) of this reaction is significantly lower than the K(m) of UGT2B17 for testosterone. Epitestosterone 0-15 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 55-61 19022937-9 2009 Epitestosterone glucuronidation is catalyzed mainly by UGT2B7, and the K(m) of this reaction is significantly lower than the K(m) of UGT2B17 for testosterone. Testosterone 3-15 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 55-61 19022937-10 2009 Although UGT2B7 and UGT2B17 exhibited high, although converse, stereoselectivity in testosterone and epitestosterone glucuronidation, UGT2A1, an extrahepatic enzyme that is expressed mainly in the nasal epithelium, catalyzed the glucuronidation of both steroids at considerable rates and similar kinetics. Testosterone 84-96 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 9-15 19022937-10 2009 Although UGT2B7 and UGT2B17 exhibited high, although converse, stereoselectivity in testosterone and epitestosterone glucuronidation, UGT2A1, an extrahepatic enzyme that is expressed mainly in the nasal epithelium, catalyzed the glucuronidation of both steroids at considerable rates and similar kinetics. Epitestosterone 101-116 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 9-15 19224506-2 2009 Three enzymes (UDP-glucuronosyltransferases) are responsible for transfering the glucuronic group from glucuronic acid to androgens: UGT2B7, UGT2B15 and UGT2B17. Glucuronic Acid 103-118 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 133-139 20045984-5 2009 UGT2B7 is one of the major isoforms responsible for drug conjugation including morphine 3- and 3"- azido-3"-deoxythymidine (AZT) glucuronidation. morphine 3- and 3"- azido-3"-deoxythymidine 79-122 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 20045984-5 2009 UGT2B7 is one of the major isoforms responsible for drug conjugation including morphine 3- and 3"- azido-3"-deoxythymidine (AZT) glucuronidation. Zidovudine 124-127 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 20045987-7 2009 Both imipramine (typical substrate of UGT1A3 and 1A4) and flurbiprofen (typical substrate of UGT2B7) inhibit the glucuronidation of glycyrrhetinic acid. Flurbiprofen 58-70 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 93-99 20045987-7 2009 Both imipramine (typical substrate of UGT1A3 and 1A4) and flurbiprofen (typical substrate of UGT2B7) inhibit the glucuronidation of glycyrrhetinic acid. Glycyrrhetinic Acid 132-151 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 93-99 18541222-8 2008 Consistent with these observations, the UGT1A selective inhibitors phenylbutazone and sulfinpyrazone decreased FSMG formation by HLM, HKCM and HKMM by 60-80%, whereas the UGT2B7 selective inhibitor fluconazole reduced FSM glucuronidation by < or =20%. Fluconazole 198-209 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 171-177 20041016-3 2009 ET inhibited UGT1A6 (glucuronidation of p-nitrophenol) and UGT2B7 (glucuronidation of androsterone). Erythrosine 0-2 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 59-65 20041016-3 2009 ET inhibited UGT1A6 (glucuronidation of p-nitrophenol) and UGT2B7 (glucuronidation of androsterone). Androsterone 86-98 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 59-65 18990428-3 2008 BPA glucuronidation was catalyzed by UGT1A1, UGT1A3, UGT1A9, UGT2B4, UGT2B7 and UGT2B15 as well as by human liver microsomes. bisphenol A 0-3 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 69-75 18946804-1 2008 The aim was to investigate the effect of UGT1A9, UGT1A8, UGT2B7 and ABCC2 polymorphism on the pharmacokinetics of mycophenolic acid (MPA) and its metabolites phenolic glucuronide (MPAG) and acyl glucuronide (AcMPAG) in Chinese renal transplant recipients. Mycophenolic Acid 114-131 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 57-63 18946804-1 2008 The aim was to investigate the effect of UGT1A9, UGT1A8, UGT2B7 and ABCC2 polymorphism on the pharmacokinetics of mycophenolic acid (MPA) and its metabolites phenolic glucuronide (MPAG) and acyl glucuronide (AcMPAG) in Chinese renal transplant recipients. Mycophenolic Acid 133-136 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 57-63 18647858-0 2008 Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Hymecromone 45-66 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 114-145 18647858-0 2008 Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Hymecromone 45-66 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 147-153 18647858-0 2008 Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. 1-naphthol 68-78 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 114-145 18647858-0 2008 Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. 1-naphthol 68-78 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 147-153 18647858-0 2008 Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Zidovudine 84-94 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 114-145 18647858-0 2008 Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Zidovudine 84-94 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 147-153 18647858-1 2008 Interactions between the UGT2B7-catalyzed glucuronidation of zidovudine (AZT), 4-methylumbelliferone (4MU), and 1-naphthol (1NP) were analyzed using multisite and empirical kinetic models to explore the existence of multiple substrate and effector binding sites within this important drug metabolizing enzyme. Zidovudine 61-71 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 25-31 18647858-1 2008 Interactions between the UGT2B7-catalyzed glucuronidation of zidovudine (AZT), 4-methylumbelliferone (4MU), and 1-naphthol (1NP) were analyzed using multisite and empirical kinetic models to explore the existence of multiple substrate and effector binding sites within this important drug metabolizing enzyme. Zidovudine 73-76 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 25-31 18647858-1 2008 Interactions between the UGT2B7-catalyzed glucuronidation of zidovudine (AZT), 4-methylumbelliferone (4MU), and 1-naphthol (1NP) were analyzed using multisite and empirical kinetic models to explore the existence of multiple substrate and effector binding sites within this important drug metabolizing enzyme. Hymecromone 79-100 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 25-31 18647858-1 2008 Interactions between the UGT2B7-catalyzed glucuronidation of zidovudine (AZT), 4-methylumbelliferone (4MU), and 1-naphthol (1NP) were analyzed using multisite and empirical kinetic models to explore the existence of multiple substrate and effector binding sites within this important drug metabolizing enzyme. Hymecromone 102-105 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 25-31 18647858-1 2008 Interactions between the UGT2B7-catalyzed glucuronidation of zidovudine (AZT), 4-methylumbelliferone (4MU), and 1-naphthol (1NP) were analyzed using multisite and empirical kinetic models to explore the existence of multiple substrate and effector binding sites within this important drug metabolizing enzyme. 1-naphthol 112-122 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 25-31 18647858-1 2008 Interactions between the UGT2B7-catalyzed glucuronidation of zidovudine (AZT), 4-methylumbelliferone (4MU), and 1-naphthol (1NP) were analyzed using multisite and empirical kinetic models to explore the existence of multiple substrate and effector binding sites within this important drug metabolizing enzyme. 1-naphthol 124-127 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 25-31 18647858-3 2008 In contrast, UGT2B7-catalyzed AZT glucuronidation follows hyperbolic (Michaelis-Menten) kinetics. Zidovudine 30-33 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 13-19 18583161-5 2008 Our data indicate that the demonstrated effect of smoking on LTG metabolism is likely to be mediated via UDPGT2B7, as LTG is not a substrate of cytochrome P450 isoenzymes and UDPGT1A4 activity may not be affected by nicotine, but the exact mechanism underlying the demonstrated effect remains uncertain. Nicotine 216-224 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 105-113 18674515-10 2008 UGT2B7, alongside UGT1A3, glucuronidated candesartan at the tetrazole-N2 position, whereas UGTs 1A7-1A10 mainly yielded candesartan O-glucuronide. candesartan 41-52 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 18674515-10 2008 UGT2B7, alongside UGT1A3, glucuronidated candesartan at the tetrazole-N2 position, whereas UGTs 1A7-1A10 mainly yielded candesartan O-glucuronide. tetrazole-n2 60-72 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 18674515-13 2008 Kinetic analyses revealed that the main contributors to losartan glucuronidation in HLM are UGT1A1 and UGT2B7. Losartan 56-64 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 103-109 18622261-5 2008 UGT2B7 was resequenced in 12 samples [(six highest and six lowest for the formation of morphine-3-glucuronide (M3G)]. morphine-3-glucuronide 87-109 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 18622263-1 2008 OBJECTIVES: Human uridine diphosphate-glucuronosyltransferase 2B7 (UGT2B7) plays important roles in the metabolism of some clinical drugs, carcinogens, and steroid hormones. Steroids 156-163 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 18-65 18622263-1 2008 OBJECTIVES: Human uridine diphosphate-glucuronosyltransferase 2B7 (UGT2B7) plays important roles in the metabolism of some clinical drugs, carcinogens, and steroid hormones. Steroids 156-163 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 67-73 18622263-8 2008 In HepG2 cells, the UGT2B7 protein level and morphine glucuronosyltransferase activity were also significantly induced by SFN. sulforaphane 122-125 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 20-26 18641546-3 2008 This conversion of MPA to AcylMPAG is catalyzed by UDP-glucuronosyltransferase 2B7 (UGT2B7). Mycophenolic Acid 19-22 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 51-82 18641546-3 2008 This conversion of MPA to AcylMPAG is catalyzed by UDP-glucuronosyltransferase 2B7 (UGT2B7). Mycophenolic Acid 19-22 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 84-90 18641546-3 2008 This conversion of MPA to AcylMPAG is catalyzed by UDP-glucuronosyltransferase 2B7 (UGT2B7). acylmpag 26-34 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 51-82 18641546-3 2008 This conversion of MPA to AcylMPAG is catalyzed by UDP-glucuronosyltransferase 2B7 (UGT2B7). acylmpag 26-34 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 84-90 18597651-1 2008 UNLABELLED: We previously reported that polymorphisms in the UGT2B7 and UGT1A9 genes are associated with significant alteration in the disposition of mycophenolic acid (MPA) in healthy volunteers. Mycophenolic Acid 150-167 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 61-67 18573701-9 2008 In addition, the method could determine the effects of fluconazole, a known UGT2B7 selective inhibitor, on AZTG in HLMs. Fluconazole 55-66 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 76-82 18573701-9 2008 In addition, the method could determine the effects of fluconazole, a known UGT2B7 selective inhibitor, on AZTG in HLMs. aztg 107-111 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 76-82 18573701-10 2008 Therefore, this method is suitable for in vitro studies using AZTG formation as an index reaction for UGT2B7 activity. aztg 62-66 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 102-108 18573701-1 2008 A rapid and specific ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS) method was developed for the qualitative and quantitative determination of UGT2B7 activity using 3"-azido-3"-deoxythymidine (AZT) as probe substrate in human liver microsomes (HLMs). Zidovudine 193-219 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 171-177 18573701-1 2008 A rapid and specific ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS) method was developed for the qualitative and quantitative determination of UGT2B7 activity using 3"-azido-3"-deoxythymidine (AZT) as probe substrate in human liver microsomes (HLMs). Zidovudine 221-224 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 171-177 18597651-1 2008 UNLABELLED: We previously reported that polymorphisms in the UGT2B7 and UGT1A9 genes are associated with significant alteration in the disposition of mycophenolic acid (MPA) in healthy volunteers. Mycophenolic Acid 169-172 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 61-67 18268076-7 2008 After glucuronidation, predominantly catalyzed by UDP glucuronosyltransferase (UGT) isoforms UGT2B7, UGT1A9, and UGT1A3, M1 is converted into the hydroxy-glucuronide M3 in a CYP2C8-dependent reaction. hydroxy-glucuronide 146-165 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 93-99 18362158-1 2008 Bovine serum albumin (BSA) and fatty acid-free human serum albumin (HSAFAF) reduce the K(m) values for UGT2B7 substrates by sequestering inhibitory long-chain fatty acids released by incubations of human liver microsomes (HLM) and HEK293 cells expressing this enzyme. Fatty Acids 31-41 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 103-109 18362158-1 2008 Bovine serum albumin (BSA) and fatty acid-free human serum albumin (HSAFAF) reduce the K(m) values for UGT2B7 substrates by sequestering inhibitory long-chain fatty acids released by incubations of human liver microsomes (HLM) and HEK293 cells expressing this enzyme. hsafaf 68-74 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 103-109 18362158-1 2008 Bovine serum albumin (BSA) and fatty acid-free human serum albumin (HSAFAF) reduce the K(m) values for UGT2B7 substrates by sequestering inhibitory long-chain fatty acids released by incubations of human liver microsomes (HLM) and HEK293 cells expressing this enzyme. long-chain fatty acids 148-170 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 103-109 17687269-0 2008 Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Lorazepam 51-60 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 94-100 18471784-4 2008 Identification of the substrates for each member has revealed that three UGT2B enzymes are mainly responsible for DHT, ADT and 3alpha-DIOL glucuronidation: UGT2B7, UGT2B15 and UGT2B17. Dihydrotestosterone 114-117 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 156-162 18471784-4 2008 Identification of the substrates for each member has revealed that three UGT2B enzymes are mainly responsible for DHT, ADT and 3alpha-DIOL glucuronidation: UGT2B7, UGT2B15 and UGT2B17. Androsterone 119-122 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 156-162 18471784-4 2008 Identification of the substrates for each member has revealed that three UGT2B enzymes are mainly responsible for DHT, ADT and 3alpha-DIOL glucuronidation: UGT2B7, UGT2B15 and UGT2B17. 3alpha-diol 127-138 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 156-162 17687269-0 2008 Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Valproic Acid 65-78 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 94-100 17687269-4 2008 AUCs of valproate showed an increasing tendency as the number of UGT2B7*2 alleles increased, but the difference was insignificant. Valproic Acid 8-17 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 65-71 17687269-6 2008 Our study suggests that the UGT2B7 genotype probably affects lorazepam-valproate pharmacodynamic interaction, especially in subjects who have homovariant genotypes of UGT2B7 and UGT2B15, although the effects on the pharmacokinetics are less significant. Lorazepam 61-70 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 28-34 17687269-6 2008 Our study suggests that the UGT2B7 genotype probably affects lorazepam-valproate pharmacodynamic interaction, especially in subjects who have homovariant genotypes of UGT2B7 and UGT2B15, although the effects on the pharmacokinetics are less significant. Lorazepam 61-70 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 167-173 17687269-6 2008 Our study suggests that the UGT2B7 genotype probably affects lorazepam-valproate pharmacodynamic interaction, especially in subjects who have homovariant genotypes of UGT2B7 and UGT2B15, although the effects on the pharmacokinetics are less significant. Valproic Acid 71-80 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 28-34 17687269-6 2008 Our study suggests that the UGT2B7 genotype probably affects lorazepam-valproate pharmacodynamic interaction, especially in subjects who have homovariant genotypes of UGT2B7 and UGT2B15, although the effects on the pharmacokinetics are less significant. Valproic Acid 71-80 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 167-173 18187562-5 2008 Not only UGT2B7, which is well known to catalyze morphine-6-glucuronidation, but also UGT1A1 and 1A8 effectively catalyzed morphine-6-glucuronidation at relatively low morphine concentrations (<100 muM). Morphine 49-57 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 9-15 18467088-3 2008 Three UGT2B enzymes are responsible for the conjugation of DHT and its metabolites ADT and 3alpha-diol: UGT2B7, B15 and B17. Androsterone 83-86 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 104-110 18187562-5 2008 Not only UGT2B7, which is well known to catalyze morphine-6-glucuronidation, but also UGT1A1 and 1A8 effectively catalyzed morphine-6-glucuronidation at relatively low morphine concentrations (<100 muM). Morphine 123-131 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 9-15 18187562-5 2008 Not only UGT2B7, which is well known to catalyze morphine-6-glucuronidation, but also UGT1A1 and 1A8 effectively catalyzed morphine-6-glucuronidation at relatively low morphine concentrations (<100 muM). Morphine 123-131 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 9-15 18187562-9 2008 These kinetics are basically different from that of morphine-6-glucuronidation by UGT2B7, which suggested biphasic Michaelis-Menten kinetic behavior. Morphine 52-60 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 82-88 18187562-11 2008 The results strongly suggest that UGT1A1 and UGT1A8 are isozymes involved in morphine-6-glucuronidation in vivo, as is UGT2B7 in humans. Morphine 77-85 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 119-125 18467088-3 2008 Three UGT2B enzymes are responsible for the conjugation of DHT and its metabolites ADT and 3alpha-diol: UGT2B7, B15 and B17. Dihydrotestosterone 59-62 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 104-110 18315786-1 2008 OBJECTIVE: The aim of this study was to investigate drug interactions between mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil (MMF) and tacrolimus, as well as the impact of CYP3A5 and UGT2B7 genetic polymorphisms on these drug interactions in 71 Japanese renal transplant recipients. Mycophenolic Acid 97-100 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 208-214 18467088-3 2008 Three UGT2B enzymes are responsible for the conjugation of DHT and its metabolites ADT and 3alpha-diol: UGT2B7, B15 and B17. 3alpha-diol 91-102 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 104-110 18048489-8 2008 A model of the UDP-GlcUA binding site suggests that the contribution of other residues to cosubstrate binding may explain these differences between UGT1A10 and UGT2B7. Uridine Diphosphate Glucuronic Acid 15-24 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 160-166 17722074-3 2008 Emerging evidence suggests that the allelic variants in the genes involving the opioid (UGT2B7, OPRM1, and ABCB1 genes) and nonopioid system (COMT gene) can alter the efficacy of morphine. Morphine 179-187 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 88-94 17724700-0 2008 UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Morphine 90-98 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 17724700-1 2008 The purpose of the study was to determine if UDP-glucuronosyltransferase (UGT) 2B7 allelic variants encoding for UGT2B7, primary enzyme responsible for morphine glucuronidation contribute to the variability in the hepatic clearance of morphine in sickle cell disease (SCD). Morphine 152-160 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 45-82 17724700-1 2008 The purpose of the study was to determine if UDP-glucuronosyltransferase (UGT) 2B7 allelic variants encoding for UGT2B7, primary enzyme responsible for morphine glucuronidation contribute to the variability in the hepatic clearance of morphine in sickle cell disease (SCD). Morphine 152-160 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 113-119 17724700-1 2008 The purpose of the study was to determine if UDP-glucuronosyltransferase (UGT) 2B7 allelic variants encoding for UGT2B7, primary enzyme responsible for morphine glucuronidation contribute to the variability in the hepatic clearance of morphine in sickle cell disease (SCD). Morphine 235-243 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 45-82 17724700-1 2008 The purpose of the study was to determine if UDP-glucuronosyltransferase (UGT) 2B7 allelic variants encoding for UGT2B7, primary enzyme responsible for morphine glucuronidation contribute to the variability in the hepatic clearance of morphine in sickle cell disease (SCD). Morphine 235-243 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 113-119 17724700-4 2008 Presence of UGT2B7 -840G allele is associated with significantly reduced glucuronidation of morphine and thus contributes to the variability in hepatic clearance of morphine in SCD. Morphine 92-100 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 12-18 17724700-4 2008 Presence of UGT2B7 -840G allele is associated with significantly reduced glucuronidation of morphine and thus contributes to the variability in hepatic clearance of morphine in SCD. Morphine 165-173 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 12-18 18048489-2 2008 The binding site for UDP-GlcUA is localized to the C-terminal domain of UGTs on the basis of amino acid sequence homology analysis and crystal structures of glycosyltransferases, including the C-terminal domain of human UGT2B7. Uridine Diphosphate Glucuronic Acid 21-30 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 220-226 18048489-7 2008 Although D(393) (D(398) in UGT2B7) is similarly critical for UDP-GlcUA binding in both enzymes, the effects of Q(394) (Q(399) in UGT2B7) to Ala mutation on activity were significant but different between UGT1A10 and UGT2B7. Uridine Diphosphate Glucuronic Acid 61-70 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 27-33 18177842-8 2008 The calculated intrinsic 25-O-glucuronide M1 formation clearance for UGT1A4 was 14-fold higher than the next best isozyme, UGT2B7. 25-o-glucuronide 25-41 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 123-129 18974614-0 2008 Effect of retinoids on UDP-glucuronosyltransferase 2B7 mRNA expression in Caco-2 cells. Retinoids 10-19 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 23-54 18048489-7 2008 Although D(393) (D(398) in UGT2B7) is similarly critical for UDP-GlcUA binding in both enzymes, the effects of Q(394) (Q(399) in UGT2B7) to Ala mutation on activity were significant but different between UGT1A10 and UGT2B7. Alanine 140-143 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 129-135 18048489-7 2008 Although D(393) (D(398) in UGT2B7) is similarly critical for UDP-GlcUA binding in both enzymes, the effects of Q(394) (Q(399) in UGT2B7) to Ala mutation on activity were significant but different between UGT1A10 and UGT2B7. Alanine 140-143 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 129-135 17998299-10 2008 Incubations with recombinant human uridine diphosphate glucuronosyltransferases (UGTs) indicated that the O-glucuronidation was catalyzed by UGT2B4 and UGT2B7, whereas the N-glucuronidation was catalyzed by UGT1A4. Nitrogen 172-173 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 152-158 17998299-11 2008 Consistent with these observations, hecogenin, a selective inhibitor of UGT1A4, selectively inhibited the N-glucuronidation, whereas diclofenac, a potent inhibitor of UGT2B7, had a greater inhibitory effect on the O-glucuronidation than on the N-glucuronidation. Diclofenac 133-143 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 167-173 18974614-7 2008 These data lead us to hypothesize that biologically active forms of RA suppress the expression of UGT2B7 in intestinal cells. Radium 68-70 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 98-104 18974614-3 2008 In this study, the effects of all-trans retinoic acid (atRA), 9-cis RA, and the RAR agonist TTNPB, on UGT2B7 and UGT2B15 mRNA expression in Caco-2 cells have been examined. 2-octenal 34-39 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 102-108 18974614-3 2008 In this study, the effects of all-trans retinoic acid (atRA), 9-cis RA, and the RAR agonist TTNPB, on UGT2B7 and UGT2B15 mRNA expression in Caco-2 cells have been examined. Tretinoin 40-53 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 102-108 18974614-3 2008 In this study, the effects of all-trans retinoic acid (atRA), 9-cis RA, and the RAR agonist TTNPB, on UGT2B7 and UGT2B15 mRNA expression in Caco-2 cells have been examined. Tretinoin 55-59 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 102-108 18974614-3 2008 In this study, the effects of all-trans retinoic acid (atRA), 9-cis RA, and the RAR agonist TTNPB, on UGT2B7 and UGT2B15 mRNA expression in Caco-2 cells have been examined. 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid 92-97 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 102-108 18974614-4 2008 Each of these retinoids significantly suppressed UGT2B7 mRNA expression in a concentration-dependent manner with IC50 values of 3.5, 0.3, and 0.2 microM, respectively. Retinoids 14-23 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 49-55 18974614-5 2008 However, no inhibition was observed when two other UGTs, UGT2B15 or -1A6, were exposed to atRA, 9-cis RA, or TTNPB, demonstrating that the inhibitory effect of retinoids might be specific for the UGT2B7 isoform. Retinoids 160-169 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 196-202 18098064-6 2008 UGT1A1 and UGT2B7 were identified as the major UGT enzymes producing labetalol glucuronides (trace amount of glucuronide conjugate was formed by UGT1A9). labetalol glucuronides 69-91 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 11-17 18098064-6 2008 UGT1A1 and UGT2B7 were identified as the major UGT enzymes producing labetalol glucuronides (trace amount of glucuronide conjugate was formed by UGT1A9). Glucuronides 79-90 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 11-17 17670842-0 2007 The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Gemfibrozil 63-74 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 4-35 17978490-0 2007 Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity. Carvedilol 38-48 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 63-69 17978490-1 2007 Carvedilol, an alpha- and beta-adrenergic blocking drug, is mainly metabolized by CYP2D6, UGT1A1, UGT2B4 and UGT2B7. Carvedilol 0-10 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 109-115 17978490-6 2007 The aim of this study was to clarify stereoselective metabolism of carvedilol by UGT1A1 and UGT2B7 and to determine by using a recombinant enzyme-introduced mutation whether genetic mutation in UGT1A1 and UGT2B7 causes reduction in metabolic activity for carvedilol. Carvedilol 67-77 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 92-98 17978490-6 2007 The aim of this study was to clarify stereoselective metabolism of carvedilol by UGT1A1 and UGT2B7 and to determine by using a recombinant enzyme-introduced mutation whether genetic mutation in UGT1A1 and UGT2B7 causes reduction in metabolic activity for carvedilol. Carvedilol 67-77 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 205-211 17978490-7 2007 A glucuronidation assay using human liver microsomes and recombinant UGT1A1 and UGT2B7 expressed in HeLa cells demonstrated that UGT1A1 prefers metabolizing R-carvedilol to S-carvedilol. Carvedilol 157-169 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 80-86 17978490-8 2007 On the other hand, UGT2B7 prefers metabolizing S-carvedilol to R-carvedilol. Carvedilol 47-59 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 19-25 17978490-8 2007 On the other hand, UGT2B7 prefers metabolizing S-carvedilol to R-carvedilol. Carvedilol 63-75 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 19-25 17664247-5 2007 Using homogenates of individual UGT-overexpressing cell lines, UGTs 2B7 approximately 1A8 > UGT1A10 exhibited the highest overall O-glucuronidating activity against trans-4-OH-TAM as determined by Vmax/K(M), with the hepatic enzyme UGT2B7 exhibiting the highest binding affinity and lowest K(M) (3.7 microM). trans-4-oh-tam 168-182 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 235-241 17670842-6 2007 Evaluation of 12 recombinant human UGT isozymes shows gemfibrozil glucuronidation activity in UGT1A1, UGT1A3, UGT1A9, UGT2B4, UGT2B7, and UGT2B17, with UGT2B7 showing the highest activity. Gemfibrozil 54-65 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 126-132 17664247-8 2007 UGTs 1A10 approximately 1A8 > UGT2B7 exhibited the highest overall glucuronidating activities as determined by Vmax/K(M) for trans-endoxifen, with the extrahepatic enzyme UGT1A10 exhibiting the highest binding affinity and lowest K(M) (39.9 microM). trans-endoxifen 128-143 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 33-39 17670842-6 2007 Evaluation of 12 recombinant human UGT isozymes shows gemfibrozil glucuronidation activity in UGT1A1, UGT1A3, UGT1A9, UGT2B4, UGT2B7, and UGT2B17, with UGT2B7 showing the highest activity. Gemfibrozil 54-65 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 152-158 17670842-8 2007 The high affinity K(m) value was 2.5 microM, which is similar to the K(m) value of gemfibrozil glucuronidation in recombinant UGT2B7 (2.2 microM). Gemfibrozil 83-94 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 126-132 17670842-10 2007 Flurbiprofen and mefenamic acid inhibited gemfibrozil glucuronidation in HLMs with similar IC(50) values to those reported in recombinant UGT2B7. Flurbiprofen 0-12 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 138-144 17670842-10 2007 Flurbiprofen and mefenamic acid inhibited gemfibrozil glucuronidation in HLMs with similar IC(50) values to those reported in recombinant UGT2B7. Mefenamic Acid 17-31 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 138-144 17670842-11 2007 These results suggest that UGT2B7 is the main isozyme responsible for gemfibrozil glucuronidation in humans. Gemfibrozil 70-81 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 27-33 17927138-5 2007 The results also indicated that well-expressed UGT isoforms in the Caco-2 cells, UGT1A1, UGT1A3, UGT1A6, and UGT2B7, were capable of metabolizing apigenin faster than genistein and that UGT1A6 silencing did not substantially increase the level of expression of genistein-metabolizing UGT isoforms. Apigenin 146-154 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 109-115 17927138-5 2007 The results also indicated that well-expressed UGT isoforms in the Caco-2 cells, UGT1A1, UGT1A3, UGT1A6, and UGT2B7, were capable of metabolizing apigenin faster than genistein and that UGT1A6 silencing did not substantially increase the level of expression of genistein-metabolizing UGT isoforms. Genistein 167-176 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 109-115 17927138-5 2007 The results also indicated that well-expressed UGT isoforms in the Caco-2 cells, UGT1A1, UGT1A3, UGT1A6, and UGT2B7, were capable of metabolizing apigenin faster than genistein and that UGT1A6 silencing did not substantially increase the level of expression of genistein-metabolizing UGT isoforms. Genistein 261-270 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 109-115 17706742-0 2007 Eudismic analysis of tricyclic sesquiterpenoid alcohols: lead structures for the design of potent inhibitors of the human UDP-glucuronosyltransferase 2B7. sesquiterpenoid 31-46 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 122-153 17698974-4 2007 Additionally, UGT1A and UGT2B7 expression was demonstrated in the macula densa, supporting a potential role of UGTs in regulating aldosterone. Aldosterone 130-141 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 24-30 17698974-8 2007 Fluconazole inhibited the high-affinity component establishing UGT2B7 as the enzyme responsible for S-naproxen glucuronidation in cortex and medulla. Fluconazole 0-11 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 63-69 17706742-0 2007 Eudismic analysis of tricyclic sesquiterpenoid alcohols: lead structures for the design of potent inhibitors of the human UDP-glucuronosyltransferase 2B7. Alcohols 47-55 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 122-153 17706742-5 2007 The diastereomeric alcohols exhibited nearly identical affinities toward UGT2B7 indicating that the spatial arrangement of the hydroxy group had no influence on the dissociation of the enzyme-terpenoid complex. Alcohols 19-27 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 73-79 17706742-12 2007 Considering the high inhibition levels exerted by the tricyclic sesquiterpenoid alcohols, these compounds might serve as valuable lead structures for the design of potent inhibitors for UGT2B7. sesquiterpenoid alcohols 64-88 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 186-192 17867560-0 2007 Studies on the flavonoid substrates of human UDP-glucuronosyl transferase (UGT) 2B7. Flavonoids 15-24 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 45-83 17555467-8 2007 Furthermore, rates of zidovudine glucuronidation correlated well with rates of glucuronidation of the UGT2B7 substrate gemcabene, but did not correlate with UGT1A1 enzyme activities. Zidovudine 22-32 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 102-108 17555467-8 2007 Furthermore, rates of zidovudine glucuronidation correlated well with rates of glucuronidation of the UGT2B7 substrate gemcabene, but did not correlate with UGT1A1 enzyme activities. gemcabene 119-128 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 102-108 17880178-4 2007 In this study, we investigated the mechanisms of clofibric acid-induced genotoxicity in HEK293 cells expressing the human UDP-glucuronosyltransferases UGT1A3, UGT1A9, or UGT2B7, and screened three other carboxylic acid drugs for UGT-dependent genotoxicity. Clofibric Acid 49-63 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 170-176 17880178-10 2007 The glycation/glycoxidation inhibitor aminoguanidine and the glucuronidation inhibitor borneol significantly decreased clofibric-acid-mediated DNA damage in UGT2B7 transfected cells by 73.5 and 94.8%, respectively. pimagedine 38-52 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 157-163 17880178-10 2007 The glycation/glycoxidation inhibitor aminoguanidine and the glucuronidation inhibitor borneol significantly decreased clofibric-acid-mediated DNA damage in UGT2B7 transfected cells by 73.5 and 94.8%, respectively. isoborneol 87-94 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 157-163 17880178-10 2007 The glycation/glycoxidation inhibitor aminoguanidine and the glucuronidation inhibitor borneol significantly decreased clofibric-acid-mediated DNA damage in UGT2B7 transfected cells by 73.5 and 94.8%, respectively. Clofibric Acid 119-133 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 157-163 17965522-2 2007 In the present study, we examined the genotype of UGT2B7 in these 54 subjects, and investigated the effect of UGT2B7*3 on the pharmacokinetics of R- and S-carvedilol. Carvedilol 155-165 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 110-116 17579197-3 2007 OBJECTIVE: Our objective was to determine the impact of the H(268)Y polymorphism in the UGT2B7 gene on interindividual variation of serum levels of sex steroids and cortical bone dimensions. Steroids 152-160 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 88-94 17576790-4 2007 UGT2B10 was also more active than UGT1A4 in N-glucuronidation of cotinine (oxidative nicotine metabolite), whereas UGT2B7 exhibited only low nicotine glucuronidation activity and was essentially inactive toward cotinine. Nicotine 141-149 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 115-121 17579197-10 2007 CONCLUSIONS: The UGT2B7 H(268)Y polymorphism is independently associated with cortical bone size and serum sex steroid levels in young adult men. Steroids 111-118 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 17-23 17867560-3 2007 This study suggests features of the flavonoid structure necessary for it to act as a substrate of human UGT2B7. Flavonoids 36-45 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 104-110 17867560-7 2007 Increasing the number of hydroxyl groups of flavonoids will increase their glucuronidation activity towards UGT2B7, while conjugation of glycon will weaken the activity, and hydroxyl position can also have an important role in activity. Flavonoids 44-54 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 108-114 17867560-8 2007 The high glucuronidation efficiency observed with many flavonoids suggests that the contribution of UGT2B7 to the metabolism of flavonoids may be significant. Flavonoids 55-65 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 100-106 17867560-8 2007 The high glucuronidation efficiency observed with many flavonoids suggests that the contribution of UGT2B7 to the metabolism of flavonoids may be significant. Flavonoids 128-138 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 100-106 17446261-0 2007 Predominant contribution of UDP-glucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver. Flurbiprofen 94-106 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 28-59 17446261-4 2007 UGT1A1, 1A3, 1A9, 2B4, and 2B7 showed glucuronidation activity for both (R)- and (S)-glucuronide, with UGT2B7 possessing the highest activity. (r)- and (s)-glucuronide 72-96 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 103-109 17446261-10 2007 In conclusion, these findings suggest that the formation of (R)- and (S)-glucuronide from racemic flurbiprofen is catalyzed by the same UGT isozyme, namely UGT2B7. Glucuronides 69-84 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 156-162 17446261-10 2007 In conclusion, these findings suggest that the formation of (R)- and (S)-glucuronide from racemic flurbiprofen is catalyzed by the same UGT isozyme, namely UGT2B7. Flurbiprofen 98-110 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 156-162 17446261-5 2007 UGT2B7 formed the (R)-glucuronide at a rate 2.8-fold higher than that for (S)-glucuronide, whereas the other UGTs had similar formation rates. (r)-glucuronide 18-33 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 17446261-6 2007 The glucuronidation of racemic flurbiprofen by HLMs also resulted in the formation of (R)-glucuronide as the dominant form, which occurred to a degree similar to that by recombinant UGT2B7 (2.1 versus 2.8). Flurbiprofen 31-43 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 182-188 17446261-9 2007 Mefenamic acid inhibited the formation of both (R)- and (S)-glucuronide in HLMs with similar IC(50) values (2.0 and 1.7 muM, respectively), which are close to those in recombinant UGT2B7. Mefenamic Acid 0-14 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 180-186 17446261-9 2007 Mefenamic acid inhibited the formation of both (R)- and (S)-glucuronide in HLMs with similar IC(50) values (2.0 and 1.7 muM, respectively), which are close to those in recombinant UGT2B7. (r)- and (s)-glucuronide 47-71 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 180-186 17446261-10 2007 In conclusion, these findings suggest that the formation of (R)- and (S)-glucuronide from racemic flurbiprofen is catalyzed by the same UGT isozyme, namely UGT2B7. Ranolazine 60-68 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 156-162 17479992-0 2007 Potent inhibitors of the human UDP-glucuronosyltransferase 2B7 derived from the sesquiterpenoid alcohol longifolol. sesquiterpenoid 80-95 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 31-62 17359941-7 2007 The K(m) values of MGN glucuronidation in recombinant UGT1A3 and UGT2B7 microsomes were close to those in human liver microsomes. mitiglinide 19-22 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 65-71 17359941-8 2007 The formation of MGN glucuronidation by human liver microsomes was effectively inhibited by quercetin (substrate for UGT1A3) and diclofenac (substrate for UGT2B7), respectively. mitiglinide 17-20 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 155-161 17359941-8 2007 The formation of MGN glucuronidation by human liver microsomes was effectively inhibited by quercetin (substrate for UGT1A3) and diclofenac (substrate for UGT2B7), respectively. Diclofenac 129-139 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 155-161 17479992-0 2007 Potent inhibitors of the human UDP-glucuronosyltransferase 2B7 derived from the sesquiterpenoid alcohol longifolol. Alcohols 96-103 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 31-62 17479992-0 2007 Potent inhibitors of the human UDP-glucuronosyltransferase 2B7 derived from the sesquiterpenoid alcohol longifolol. Longifolol 104-114 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 31-62 17479992-1 2007 The tricyclic sesquiterpenol (+)-longifolol served as a lead structure for the design of inhibitors of the human UDP-glucuronosyltransferase (UGT) 2B7. sesquiterpenol 14-28 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 113-150 17479992-1 2007 The tricyclic sesquiterpenol (+)-longifolol served as a lead structure for the design of inhibitors of the human UDP-glucuronosyltransferase (UGT) 2B7. (+)-longifolol 29-43 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 113-150 17479992-4 2007 The phenyl-substituted secondary alcohol 16 b (beta-phenyllongifolol) displayed the highest affinity toward UGT2B7, and its inhibitory dissociation constant was 0.91 nM. Alcohols 33-40 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 108-114 17479992-4 2007 The phenyl-substituted secondary alcohol 16 b (beta-phenyllongifolol) displayed the highest affinity toward UGT2B7, and its inhibitory dissociation constant was 0.91 nM. beta-phenyllongifolol 47-68 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 108-114 17371798-0 2007 Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line. Valproic Acid 0-13 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 57-63 17223084-4 2007 Derived apparent K(m) values for testosterone and phenolphthalein glucuronidation by UGT2B7-15((61-194))-7 were similar in magnitude to those determined for UGT2B15. Testosterone 33-45 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 85-91 17371798-9 2007 Even though UGT2B7 has only about one-tenth to one-hundredth the activity of UGT2B15 and 2B17 toward active androgens and we did not found any modulation in gene expression of these enzymes, it can be hypothesized that VPA might enhance DHT catabolism in this in vitro model and induces NE differentiation. Dihydrotestosterone 237-240 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 12-18 17442341-3 2007 We report the 1.8-A resolution apo crystal structure of the UDP-glucuronic acid binding domain of human UGT isoform 2B7 (UGT2B7), which catalyzes the conjugative elimination of opioid, antiviral, and anticancer drugs. Uridine Diphosphate Glucuronic Acid 60-79 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 104-119 17442341-3 2007 We report the 1.8-A resolution apo crystal structure of the UDP-glucuronic acid binding domain of human UGT isoform 2B7 (UGT2B7), which catalyzes the conjugative elimination of opioid, antiviral, and anticancer drugs. Uridine Diphosphate Glucuronic Acid 60-79 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 121-127 17442341-5 2007 Designated UGT2B7 mutants at residues predicted to interact with the UDP-glucuronic acid cofactor exhibited significantly impaired catalytic activity, with maximum effects observed for amino acids closest to the glucuronic acid sugar transferred to the acceptor molecule. Uridine Diphosphate Glucuronic Acid 69-88 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 11-17 17442341-5 2007 Designated UGT2B7 mutants at residues predicted to interact with the UDP-glucuronic acid cofactor exhibited significantly impaired catalytic activity, with maximum effects observed for amino acids closest to the glucuronic acid sugar transferred to the acceptor molecule. glucuronic acid sugar 212-233 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 11-17 17474732-0 2007 Isoform-selective inhibition of the human UDP-glucuronosyltransferase 2B7 by isolongifolol derivatives. isolongifolol 77-90 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 42-73 17474732-7 2007 Its inhibitory activity toward 14 other UGT isoforms of subfamily 1A and 2B was determined, and the data indicated that the tricyclic secondary alcohol 26b was highly selective for UGT2B7 (true selectivity >1000). Alcohols 144-151 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 181-187 17343829-6 2007 Diverse kinetics were observed for fenamate glucuronidation by UGT2B7 and UGT1A9. Fenamates 35-43 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 63-69 17343829-7 2007 Using UGT2B7 MM kinetics were observed for flufenamic (K(m)(app) 48 microM) and niflumic acid (K(m)(app) 135 microM) glucuronidation and atypical kinetics with mefenamic acid. flufenamic 43-53 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 6-12 17343829-7 2007 Using UGT2B7 MM kinetics were observed for flufenamic (K(m)(app) 48 microM) and niflumic acid (K(m)(app) 135 microM) glucuronidation and atypical kinetics with mefenamic acid. Niflumic Acid 80-93 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 6-12 17343829-7 2007 Using UGT2B7 MM kinetics were observed for flufenamic (K(m)(app) 48 microM) and niflumic acid (K(m)(app) 135 microM) glucuronidation and atypical kinetics with mefenamic acid. Mefenamic Acid 160-174 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 6-12 17343829-8 2007 Similarity in K(m)(app) between HKCM and UGT2B7 suggests that UGT2B7 may be the predominant renal UGT isoform catalysing niflumic acid glucuronidation. Niflumic Acid 121-134 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 41-47 17343829-8 2007 Similarity in K(m)(app) between HKCM and UGT2B7 suggests that UGT2B7 may be the predominant renal UGT isoform catalysing niflumic acid glucuronidation. Niflumic Acid 121-134 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 62-68 17343829-11 2007 These data suggest that inhibitory metabolic interactions may occur between fenamates and other substrates metabolised by UGT2B7 and UGT1A9 in human kidney. Fenamates 76-85 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 122-128 17223084-3 2007 A UGT2B7-15-7 chimera that incorporated amino acids 61-194 of UGT2B15 glucuronidated the UGT2B15 substrates testosterone and phenolphthalein, but not the UGT2B7 substrates zidovudine and 11alpha-hydroxyprogesterone. Testosterone 108-120 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 2-8 17223084-3 2007 A UGT2B7-15-7 chimera that incorporated amino acids 61-194 of UGT2B15 glucuronidated the UGT2B15 substrates testosterone and phenolphthalein, but not the UGT2B7 substrates zidovudine and 11alpha-hydroxyprogesterone. Phenolphthalein 125-140 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 2-8 17223084-3 2007 A UGT2B7-15-7 chimera that incorporated amino acids 61-194 of UGT2B15 glucuronidated the UGT2B15 substrates testosterone and phenolphthalein, but not the UGT2B7 substrates zidovudine and 11alpha-hydroxyprogesterone. Zidovudine 172-182 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 2-8 17223084-3 2007 A UGT2B7-15-7 chimera that incorporated amino acids 61-194 of UGT2B15 glucuronidated the UGT2B15 substrates testosterone and phenolphthalein, but not the UGT2B7 substrates zidovudine and 11alpha-hydroxyprogesterone. 11-hydroxyprogesterone 187-214 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 2-8 17223084-4 2007 Derived apparent K(m) values for testosterone and phenolphthalein glucuronidation by UGT2B7-15((61-194))-7 were similar in magnitude to those determined for UGT2B15. Phenolphthalein 50-65 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 85-91 17223084-5 2007 Moreover, glucuronidation of the non-selective substrate 4-methylumbelliferone (4MU) by UGT2B7-15((61-194))-7 and UGT2B15 followed Michaelis-Menten and weak substrate inhibition kinetics, respectively, whereas 4MU glucuronidation by UGT2B7 exhibited sigmoidal kinetics characteristic of autoactivation. Hymecromone 57-78 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 88-94 17223084-5 2007 Moreover, glucuronidation of the non-selective substrate 4-methylumbelliferone (4MU) by UGT2B7-15((61-194))-7 and UGT2B15 followed Michaelis-Menten and weak substrate inhibition kinetics, respectively, whereas 4MU glucuronidation by UGT2B7 exhibited sigmoidal kinetics characteristic of autoactivation. Hymecromone 57-78 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 233-239 17223084-5 2007 Moreover, glucuronidation of the non-selective substrate 4-methylumbelliferone (4MU) by UGT2B7-15((61-194))-7 and UGT2B15 followed Michaelis-Menten and weak substrate inhibition kinetics, respectively, whereas 4MU glucuronidation by UGT2B7 exhibited sigmoidal kinetics characteristic of autoactivation. Hymecromone 80-83 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 88-94 17223084-5 2007 Moreover, glucuronidation of the non-selective substrate 4-methylumbelliferone (4MU) by UGT2B7-15((61-194))-7 and UGT2B15 followed Michaelis-Menten and weak substrate inhibition kinetics, respectively, whereas 4MU glucuronidation by UGT2B7 exhibited sigmoidal kinetics characteristic of autoactivation. Hymecromone 80-83 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 233-239 17495417-3 2007 Morphine is metabolized to 3-glucuronide (no analgesic effect) and 6-glucuronide (more potently analgesic than morphine) mainly by UGT2B7. Morphine 0-8 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 131-137 17429314-1 2007 INTRODUCTION: The polymorphic enzyme UGT2B7 metabolizes mycophenolic acid into acyl-mycophenolic acid-glucuronide (AcMPAG), a presumably toxic metabolite. Mycophenolic Acid 56-73 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 37-43 17429314-1 2007 INTRODUCTION: The polymorphic enzyme UGT2B7 metabolizes mycophenolic acid into acyl-mycophenolic acid-glucuronide (AcMPAG), a presumably toxic metabolite. acyl-mycophenolic acid-glucuronide 79-113 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 37-43 17429314-1 2007 INTRODUCTION: The polymorphic enzyme UGT2B7 metabolizes mycophenolic acid into acyl-mycophenolic acid-glucuronide (AcMPAG), a presumably toxic metabolite. mycophenolic acid acyl glucuronide 115-121 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 37-43 17429314-2 2007 This study aimed at investigating in vitro and in vivo the impact on AcMPAG production of: (i) the UGT2B7 gene G-842A single nucleotide polymorphism, in complete linkage disequilibrium with most other known single nucleotide polymorphisms in the promoter region of this gene and with the C802T single nucleotide polymorphism in exon 2 (UGT2B*2); and (ii) of the other immunosuppressants given to renal transplant patients in association with mycophenolate mofetil. Mycophenolic Acid 442-463 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 99-105 17429314-10 2007 Consistently, the UGT2B7 genotype significantly influenced AcMPAG area under the curve (AUC0-9 h)/dose in patients on sirolimus at months 1 and 3 after transplant (P=0.04 for both). Sirolimus 118-127 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 18-24 17429314-13 2007 CONCLUSION: Both UGT2B7 polymorphisms and co-medications significantly influenced AcMPAG production, but cyclosporin and tacrolimus hindered the phenotypic impact of this trait. mycophenolic acid acyl glucuronide 82-88 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 17-23 17495417-3 2007 Morphine is metabolized to 3-glucuronide (no analgesic effect) and 6-glucuronide (more potently analgesic than morphine) mainly by UGT2B7. 6-glucuronide 67-80 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 131-137 17495417-3 2007 Morphine is metabolized to 3-glucuronide (no analgesic effect) and 6-glucuronide (more potently analgesic than morphine) mainly by UGT2B7. Morphine 111-119 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 131-137 17237258-5 2007 Oleic, linoleic, and arachidonic acid inhibited AZT and 4MU glucuronidation by HLM and/or UGT2B7, due to an increase in Km/S50 without a change in Vmax. oleic 0-5 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 90-96 17237258-0 2007 Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. Fatty Acids 22-33 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 72-103 17237258-5 2007 Oleic, linoleic, and arachidonic acid inhibited AZT and 4MU glucuronidation by HLM and/or UGT2B7, due to an increase in Km/S50 without a change in Vmax. Linoleic Acid 7-15 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 90-96 17237258-2 2007 Addition of bovine serum albumin (BSA) and fatty acid-free human serum albumin (HSA-FAF), but not "crude" HSA, resulted in an approximate 90% reduction in the Km values for the glucuronidation of zidovudine (AZT) by human liver microsomes (HLM) and UGT2B7 and a 50 to 75% reduction in the S50 for 4-methylumbelliferone (4MU) glucuronidation by UGT2B7, without affecting Vmax. Fatty Acids 43-53 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 249-255 17237258-2 2007 Addition of bovine serum albumin (BSA) and fatty acid-free human serum albumin (HSA-FAF), but not "crude" HSA, resulted in an approximate 90% reduction in the Km values for the glucuronidation of zidovudine (AZT) by human liver microsomes (HLM) and UGT2B7 and a 50 to 75% reduction in the S50 for 4-methylumbelliferone (4MU) glucuronidation by UGT2B7, without affecting Vmax. Fatty Acids 43-53 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 344-350 17237258-5 2007 Oleic, linoleic, and arachidonic acid inhibited AZT and 4MU glucuronidation by HLM and/or UGT2B7, due to an increase in Km/S50 without a change in Vmax. Arachidonic Acid 21-37 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 90-96 17339869-0 2007 The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Mycophenolic Acid 97-114 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 34-40 17237258-2 2007 Addition of bovine serum albumin (BSA) and fatty acid-free human serum albumin (HSA-FAF), but not "crude" HSA, resulted in an approximate 90% reduction in the Km values for the glucuronidation of zidovudine (AZT) by human liver microsomes (HLM) and UGT2B7 and a 50 to 75% reduction in the S50 for 4-methylumbelliferone (4MU) glucuronidation by UGT2B7, without affecting Vmax. Altretamine 80-83 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 249-255 17237258-2 2007 Addition of bovine serum albumin (BSA) and fatty acid-free human serum albumin (HSA-FAF), but not "crude" HSA, resulted in an approximate 90% reduction in the Km values for the glucuronidation of zidovudine (AZT) by human liver microsomes (HLM) and UGT2B7 and a 50 to 75% reduction in the S50 for 4-methylumbelliferone (4MU) glucuronidation by UGT2B7, without affecting Vmax. Altretamine 80-83 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 344-350 17237258-2 2007 Addition of bovine serum albumin (BSA) and fatty acid-free human serum albumin (HSA-FAF), but not "crude" HSA, resulted in an approximate 90% reduction in the Km values for the glucuronidation of zidovudine (AZT) by human liver microsomes (HLM) and UGT2B7 and a 50 to 75% reduction in the S50 for 4-methylumbelliferone (4MU) glucuronidation by UGT2B7, without affecting Vmax. Zidovudine 196-206 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 249-255 17237258-2 2007 Addition of bovine serum albumin (BSA) and fatty acid-free human serum albumin (HSA-FAF), but not "crude" HSA, resulted in an approximate 90% reduction in the Km values for the glucuronidation of zidovudine (AZT) by human liver microsomes (HLM) and UGT2B7 and a 50 to 75% reduction in the S50 for 4-methylumbelliferone (4MU) glucuronidation by UGT2B7, without affecting Vmax. Zidovudine 196-206 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 344-350 17237258-3 2007 Oleic, linoleic, and arachidonic acids were shown to be the most abundant unsaturated long-chain fatty acids present in crude HSA and in the membranes of HLM and human embryonic kidney (HEK)293 cells, and it was demonstrated that these and other unsaturated long-chain fatty acids were UGT2B7 substrates. oleic 0-5 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 286-292 17237258-3 2007 Oleic, linoleic, and arachidonic acids were shown to be the most abundant unsaturated long-chain fatty acids present in crude HSA and in the membranes of HLM and human embryonic kidney (HEK)293 cells, and it was demonstrated that these and other unsaturated long-chain fatty acids were UGT2B7 substrates. Arachidonic Acids 21-38 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 286-292 17339869-1 2007 We studied whether polymorphisms in the UGT1A8, UGT1A9, and UGT2B7 genes, the enzymes producing the phenolic (MPAG) and acyl (AcMPAG) glucuronides of mycophenolic acid (MPA), could contribute to the interindividual variation observed in mycophenolate mofetil (MMF) pharmacokinetics (PKs). mycophenolic acid glucuronide 110-114 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 60-66 17339869-1 2007 We studied whether polymorphisms in the UGT1A8, UGT1A9, and UGT2B7 genes, the enzymes producing the phenolic (MPAG) and acyl (AcMPAG) glucuronides of mycophenolic acid (MPA), could contribute to the interindividual variation observed in mycophenolate mofetil (MMF) pharmacokinetics (PKs). Glucuronides 134-146 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 60-66 17339869-1 2007 We studied whether polymorphisms in the UGT1A8, UGT1A9, and UGT2B7 genes, the enzymes producing the phenolic (MPAG) and acyl (AcMPAG) glucuronides of mycophenolic acid (MPA), could contribute to the interindividual variation observed in mycophenolate mofetil (MMF) pharmacokinetics (PKs). Mycophenolic Acid 150-167 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 60-66 17339869-1 2007 We studied whether polymorphisms in the UGT1A8, UGT1A9, and UGT2B7 genes, the enzymes producing the phenolic (MPAG) and acyl (AcMPAG) glucuronides of mycophenolic acid (MPA), could contribute to the interindividual variation observed in mycophenolate mofetil (MMF) pharmacokinetics (PKs). Mycophenolic Acid 110-113 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 60-66 17339869-1 2007 We studied whether polymorphisms in the UGT1A8, UGT1A9, and UGT2B7 genes, the enzymes producing the phenolic (MPAG) and acyl (AcMPAG) glucuronides of mycophenolic acid (MPA), could contribute to the interindividual variation observed in mycophenolate mofetil (MMF) pharmacokinetics (PKs). Mycophenolic Acid 237-258 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 60-66 17339869-1 2007 We studied whether polymorphisms in the UGT1A8, UGT1A9, and UGT2B7 genes, the enzymes producing the phenolic (MPAG) and acyl (AcMPAG) glucuronides of mycophenolic acid (MPA), could contribute to the interindividual variation observed in mycophenolate mofetil (MMF) pharmacokinetics (PKs). Mycophenolic Acid 260-263 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 60-66 17151189-4 2007 Of the remaining compounds, comparative kinetic and inhibition studies indicated that 6alpha- and 21-hydroxyprogesterone (OHP) were glucuronidated selectively by human liver microsomal UGT2B7. 6alpha- and 21-hydroxyprogesterone 86-120 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 185-191 17329852-7 2007 The results suggested that the factors of interindividual variation for carvedilol clearance were creatinine clearance and polymorphisms of UGT2B7 and CYP2D6 in the Japanese population with heart disease. Carvedilol 72-82 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 140-146 17151189-4 2007 Of the remaining compounds, comparative kinetic and inhibition studies indicated that 6alpha- and 21-hydroxyprogesterone (OHP) were glucuronidated selectively by human liver microsomal UGT2B7. 2-hydroxyphenylacetic acid 122-125 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 185-191 17329852-8 2007 It was estimated that UGT2B7*3 decreased the clearance of carvedilol by 37%, but UGT2B7*2 did not show any effect. Carvedilol 58-68 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 22-28 17151189-6 2007 UGT2B7 was also identified as the enzyme responsible for the high-affinity component of human liver microsomal 11alpha-OHP glucuronidation. 11alpha-ohp 111-122 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 17151189-10 2007 The results indicate that 6alpha- and 21-OHP may be used as selective "probes" for human liver microsomal UGT2B7 activity and, taken together, provide insights into the regio- and stereoselectivity of hydroxysteroid glucuronidation by human UGTs. 6alpha- 26-33 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 106-112 17151189-10 2007 The results indicate that 6alpha- and 21-OHP may be used as selective "probes" for human liver microsomal UGT2B7 activity and, taken together, provide insights into the regio- and stereoselectivity of hydroxysteroid glucuronidation by human UGTs. 21-ohp 38-44 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 106-112 17151190-7 2007 UGT2B7 was involved in the formation of both mono-BVMG (I) (V(max) = 6.1 pmol/min/mg of protein, K(m) = 6.0 microM) and mono-BVMG (II) (V(max) = 6.5 pmol/min/mg of protein, K(m) = 7.8 microM). mono-bvmg 45-54 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 17151190-7 2007 UGT2B7 was involved in the formation of both mono-BVMG (I) (V(max) = 6.1 pmol/min/mg of protein, K(m) = 6.0 microM) and mono-BVMG (II) (V(max) = 6.5 pmol/min/mg of protein, K(m) = 7.8 microM). mono-bvmg 120-129 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 17241877-2 2007 We hypothesized that susceptibility to hepatotoxicity would be associated with genetic polymorphisms in the genes encoding the enzymes UGT2B7 and CYP2C8, which determine the formation of reactive diclofenac metabolites and in ABCC2 encoding the transporter MRP2 contributing to the biliary excretion of the reactive metabolite. Diclofenac 196-206 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 135-141 17245571-4 2007 RESULTS: Among the UGT isozymes investigated, UGT1A1, 1A3, 1A9, and 2B7 showed glucuronidation activity for indomethacin, with UGT1A9 possessing the highest activity, followed by UGT2B7. Indomethacin 108-120 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 179-185 17245571-6 2007 The glucuronidation of indomethacin was significantly correlated with morphine 3OH-glucuronidation (r = 0.69, p < 0.05) and 3"-azido-3"-deoxythymidine glucuronidation (r = 0.82, p < 0.05), a reaction mainly catalyzed by UGT2B7. Indomethacin 23-35 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 226-232 17245571-7 2007 Propofol inhibited indomethacin glucuronidation in HLM with an IC(50) value of 248 microM, which is between the IC(50) value in recombinant UGT1A9 (106 microM) and UGT2B7 (> 400 microM). Propofol 0-8 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 164-170 17245571-8 2007 CONCLUSIONS: These findings suggest that UGT2B7 plays a predominant role in indomethacin glucuronidation in the human liver and that UGT1A9 is partially involved. Indomethacin 76-88 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 41-47 17200831-7 2007 The IC(50) values for NSAIDs against AZTG in recombinant human UGT2B7 were similar to those obtained in HLM. aztg 37-41 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 63-69 17200831-9 2007 Among the nine NSAIDs investigated, mefenamic acid had the strongest inhibitory effect on UGT2B7-catalyzed AZTG in HLM. Mefenamic Acid 36-50 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 90-96 17200831-9 2007 Among the nine NSAIDs investigated, mefenamic acid had the strongest inhibitory effect on UGT2B7-catalyzed AZTG in HLM. aztg 107-111 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 90-96 17115150-1 2007 OBJECTIVE: UDP-glucuronosyltransferases (UGTs) UGT1A9 and UGT2B7 are involved in the metabolism of antimalarial dihydroartemisinin and antiretroviral zidovudine. artenimol 112-130 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 58-64 17115150-1 2007 OBJECTIVE: UDP-glucuronosyltransferases (UGTs) UGT1A9 and UGT2B7 are involved in the metabolism of antimalarial dihydroartemisinin and antiretroviral zidovudine. Zidovudine 150-160 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 58-64 17211619-0 2007 Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Mycophenolic Acid 56-73 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 24-30 17211619-1 2007 OBJECTIVE: UGT1A8 and UGT2B7 are important uridine diphosphate-glucuronosyltransferase isoforms for the glucuronidation of mycophenolic acid (MPA). Mycophenolic Acid 123-140 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 22-28 17211619-1 2007 OBJECTIVE: UGT1A8 and UGT2B7 are important uridine diphosphate-glucuronosyltransferase isoforms for the glucuronidation of mycophenolic acid (MPA). Mycophenolic Acid 142-145 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 22-28 17263731-2 2007 The human UDP-glucuronosyltransferase (UGT) isoforms UGT2B4 and UGT2B7 play a major role in the detoxification of bile acids, steroids and phenols. Bile Acids and Salts 114-124 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 64-70 17263731-2 2007 The human UDP-glucuronosyltransferase (UGT) isoforms UGT2B4 and UGT2B7 play a major role in the detoxification of bile acids, steroids and phenols. Steroids 126-134 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 64-70 17263731-2 2007 The human UDP-glucuronosyltransferase (UGT) isoforms UGT2B4 and UGT2B7 play a major role in the detoxification of bile acids, steroids and phenols. Phenols 139-146 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 64-70 17263731-5 2007 On the other hand, the substrate specificity of the mutant UGT2B4F33Y, in which phenylalanine was replaced by tyrosine, as found at position 33 of UGT2B7, was similar to wild-type UGT2B4. Phenylalanine 80-93 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 147-153 17263731-5 2007 On the other hand, the substrate specificity of the mutant UGT2B4F33Y, in which phenylalanine was replaced by tyrosine, as found at position 33 of UGT2B7, was similar to wild-type UGT2B4. Tyrosine 110-118 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 147-153 17263731-6 2007 In the case of UGT2B7, replacement of tyrosine 33 by leucine strongly reduced the activity towards all the tested substrates, with the exception of 17-epiestriol. 17-Epiestriol 148-161 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 15-21 17132765-4 2007 A comparison of K(m) values indicated that UGT1A9 has the potential to catalyze the glucuronidation of MK-0524 in the liver, whereas UGT1A3 and UGT2B7 have the potential to catalyze the glucuronidation in the intestine. MK-0524 103-110 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 144-150 17241877-5 2007 RESULTS: The UGT2B7*2 allele was more common in diclofenac hepatotoxicity patients compared with hospital controls (odds ratio [OR], 8.5, P = .03) and healthy controls (OR, 7.7, P = .03). Diclofenac 48-58 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 13-19 17241877-8 2007 CONCLUSIONS: Allelic variants of UGT2B7, CYP2C8, and ABCC2, which may predispose to the formation and accumulation of reactive diclofenac metabolites are associated with diclofenac hepatotoxicity. Diclofenac 127-137 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 33-39 17241877-8 2007 CONCLUSIONS: Allelic variants of UGT2B7, CYP2C8, and ABCC2, which may predispose to the formation and accumulation of reactive diclofenac metabolites are associated with diclofenac hepatotoxicity. Diclofenac 170-180 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 33-39 16985101-2 2006 An important pathway for epirubicin detoxification is UGT2B7-dependent glucuronidation. Epirubicin 25-35 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 54-60 18686368-0 2007 The association between the C802T polymorphism of the UDP-glucuronosyltransferase 2B7 gene and effective topiramate dosage. Topiramate 105-115 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 54-85 16790554-0 2006 Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. phenolic and acyl glucuronides 103-133 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 55-61 16480962-6 2006 Only UGT1A4 catalyzed the N-linked glucuronidation of 4-HO-TAM among recombinant human UGT isoforms (UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B15, and UGT2B17) expressed in insect cells. 4-ho-tam 54-62 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 174-180 16790554-0 2006 Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Mycophenolic Acid 137-154 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 55-61 16790554-8 2006 The variant of the UGT2B7 protein (UGT2B7*2 Y268), the main enzyme involved in the formation of AcMPAG, demonstrated a catalytic efficiency comparable with that of UGT2B7*1 (H268). mycophenolic acid acyl glucuronide 96-102 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 19-25 16790554-8 2006 The variant of the UGT2B7 protein (UGT2B7*2 Y268), the main enzyme involved in the formation of AcMPAG, demonstrated a catalytic efficiency comparable with that of UGT2B7*1 (H268). mycophenolic acid acyl glucuronide 96-102 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 35-41 16790554-8 2006 The variant of the UGT2B7 protein (UGT2B7*2 Y268), the main enzyme involved in the formation of AcMPAG, demonstrated a catalytic efficiency comparable with that of UGT2B7*1 (H268). mycophenolic acid acyl glucuronide 96-102 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 35-41 16679387-0 2006 Inhibition of UDP-glucuronosyltransferase 2b7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode. Morphine 56-64 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 14-45 16679387-0 2006 Inhibition of UDP-glucuronosyltransferase 2b7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode. Ketoconazole 84-96 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 14-45 16679387-1 2006 Glucuronidation of morphine in humans is predominantly catalyzed by UDP-glucuronosyltransferase 2B7 (UGT2B7). Morphine 19-27 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 68-99 16679387-1 2006 Glucuronidation of morphine in humans is predominantly catalyzed by UDP-glucuronosyltransferase 2B7 (UGT2B7). Morphine 19-27 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 101-107 16679387-4 2006 To address this issue, we investigated the effects of P450 inhibitors (cimetidine, sulfaphenazole, erythromycin, nifedipine, and ketoconazole) on the UGT2B7-catalyzed formation of morphine-3-glucuronide (M-3-G) and morphine-6-glucuronide (M-6-G). Cimetidine 71-81 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 150-156 16679387-4 2006 To address this issue, we investigated the effects of P450 inhibitors (cimetidine, sulfaphenazole, erythromycin, nifedipine, and ketoconazole) on the UGT2B7-catalyzed formation of morphine-3-glucuronide (M-3-G) and morphine-6-glucuronide (M-6-G). Sulfaphenazole 83-97 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 150-156 16679387-4 2006 To address this issue, we investigated the effects of P450 inhibitors (cimetidine, sulfaphenazole, erythromycin, nifedipine, and ketoconazole) on the UGT2B7-catalyzed formation of morphine-3-glucuronide (M-3-G) and morphine-6-glucuronide (M-6-G). Erythromycin 99-111 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 150-156 16679387-4 2006 To address this issue, we investigated the effects of P450 inhibitors (cimetidine, sulfaphenazole, erythromycin, nifedipine, and ketoconazole) on the UGT2B7-catalyzed formation of morphine-3-glucuronide (M-3-G) and morphine-6-glucuronide (M-6-G). Nifedipine 113-123 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 150-156 16679387-4 2006 To address this issue, we investigated the effects of P450 inhibitors (cimetidine, sulfaphenazole, erythromycin, nifedipine, and ketoconazole) on the UGT2B7-catalyzed formation of morphine-3-glucuronide (M-3-G) and morphine-6-glucuronide (M-6-G). Ketoconazole 129-141 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 150-156 16679387-4 2006 To address this issue, we investigated the effects of P450 inhibitors (cimetidine, sulfaphenazole, erythromycin, nifedipine, and ketoconazole) on the UGT2B7-catalyzed formation of morphine-3-glucuronide (M-3-G) and morphine-6-glucuronide (M-6-G). morphine-3-glucuronide 180-202 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 150-156 16679387-4 2006 To address this issue, we investigated the effects of P450 inhibitors (cimetidine, sulfaphenazole, erythromycin, nifedipine, and ketoconazole) on the UGT2B7-catalyzed formation of morphine-3-glucuronide (M-3-G) and morphine-6-glucuronide (M-6-G). morphine-6-glucuronide 215-237 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 150-156 16679387-8 2006 In addition, ketoconazole had an ability to inhibit morphine UGT activity of recombinant UGT2B7 freed from P450. Ketoconazole 13-25 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 89-95 16679387-8 2006 In addition, ketoconazole had an ability to inhibit morphine UGT activity of recombinant UGT2B7 freed from P450. Morphine 52-60 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 89-95 16565174-5 2006 Although recombinant UGT2B7 exhibited only low activity toward LTG, inhibition by zidovudine and fluconazole and activation by bovine serum albumin (BSA) (2%) strongly suggested that this enzyme was responsible for the Hill component of microsomal LTG N2-glucuronidation. Zidovudine 82-92 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 21-27 16565174-5 2006 Although recombinant UGT2B7 exhibited only low activity toward LTG, inhibition by zidovudine and fluconazole and activation by bovine serum albumin (BSA) (2%) strongly suggested that this enzyme was responsible for the Hill component of microsomal LTG N2-glucuronidation. Fluconazole 97-108 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 21-27 16565174-8 2006 Consistent with published data for the effect of fluconazole on zidovudine glucuronidation by human liver microsomal UGT2B7, the Ki value generated in the presence of BSA predicted the magnitude of the LTG-VPA interaction reported in vivo. Fluconazole 49-60 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 117-123 16565174-8 2006 Consistent with published data for the effect of fluconazole on zidovudine glucuronidation by human liver microsomal UGT2B7, the Ki value generated in the presence of BSA predicted the magnitude of the LTG-VPA interaction reported in vivo. Zidovudine 64-74 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 117-123 16763014-5 2006 The glucuronidation kinetics of R-propranolol by UGT2B4 exhibited a sigmoid curve, whereas the glucuronidation of the same substrate by UGT2B7 was inhibited by substrate concentrations above 1 mM. Propranolol 32-45 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 136-142 16720684-6 2006 Of the 10 expressed human UGTs (1A1, 1A3, 1A4, 1A6, 1A9, 2B4, 2B7, 2B15, and 2B17) studied, only hUGT2B4 and hUGT2B7 catalyzed the N-glucuronidation of FOSA. Nitrogen 131-132 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 109-116 16720684-8 2006 These data show that rat liver UGT1.1, UGT2B1, and UGT2B12 catalyze the N-glucuronidation of FOSA, albeit at low rates, and that hUGT2B4 and hUGT2B7 catalyze the N-glucuronidation of FOSA. Nitrogen 72-73 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 141-148 16381668-9 2006 Inhibition of UGT2B7 by quinidine was also investigated further, because the effects of this compound on morphine pharmacokinetics (a known UGT2B7 substrate) have been ascribed to inhibition of P-glycoprotein. Quinidine 24-33 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 14-20 16542204-2 2006 METHODS: Kinetic constants for AZT glucuronidation were generated using human liver microsomes (HLM) and recombinant UGT2B7, the principal enzyme responsible for AZT glucuronidation, as the enzyme sources with and without fluconazole. Zidovudine 31-34 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 117-123 16542204-2 2006 METHODS: Kinetic constants for AZT glucuronidation were generated using human liver microsomes (HLM) and recombinant UGT2B7, the principal enzyme responsible for AZT glucuronidation, as the enzyme sources with and without fluconazole. Zidovudine 162-165 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 117-123 16542204-4 2006 RESULTS: Addition of BSA (2%) to incubations decreased the K(m) values for AZT glucuronidation by 85-90% for the HLM (923 +/- 357 to 91 +/- 9 microm) and UGT2B7 (478-70 microm) catalysed reactions, with little effect on V(max). Zidovudine 75-78 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 154-160 16542204-5 2006 Fluconazole, which was shown to be a selective inhibitor of UGT2B7, competitively inhibited AZT glucuronidation by HLM and UGT2B7. Fluconazole 0-11 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 60-66 16542204-5 2006 Fluconazole, which was shown to be a selective inhibitor of UGT2B7, competitively inhibited AZT glucuronidation by HLM and UGT2B7. Fluconazole 0-11 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 123-129 16542204-5 2006 Fluconazole, which was shown to be a selective inhibitor of UGT2B7, competitively inhibited AZT glucuronidation by HLM and UGT2B7. Zidovudine 92-95 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 60-66 16542204-5 2006 Fluconazole, which was shown to be a selective inhibitor of UGT2B7, competitively inhibited AZT glucuronidation by HLM and UGT2B7. Zidovudine 92-95 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 123-129 16542204-6 2006 Like the K(m), BSA caused an 87% reduction in the K(i) for fluconazole inhibition of AZT glucuronidation by HLM (1133 +/- 403 to 145 +/- 36 microm) and UGT2B7 (529 to 73 microm). Fluconazole 59-70 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 152-158 16542204-7 2006 K(i) values determined for fluconazole using HLM and UGT2B7 in the presence (but not absence) of BSA predicted an interaction in vivo. Fluconazole 27-38 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 53-59 16606339-3 2006 The alcohols studied were primarily glucuronidated by UGT2B7 and UGT2B17. Alcohols 4-12 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 54-60 16381668-9 2006 Inhibition of UGT2B7 by quinidine was also investigated further, because the effects of this compound on morphine pharmacokinetics (a known UGT2B7 substrate) have been ascribed to inhibition of P-glycoprotein. Morphine 105-113 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 140-146 16381668-10 2006 Quinidine inhibited human liver microsomal and recombinant UGT2B7, with respective Ki values of 335+/-128 microM and 186 microM. Quinidine 0-9 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 59-65 16849011-1 2006 PURPOSE: It has been reported that carvedilol, which has beta-adrenergic blocking and vasodilating activities, is mainly metabolized by UDP-glucuronosyltransferase (UGT) 1A1, UGT2B4, UGT2B7 and CYP2D6. Carvedilol 35-45 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 183-189 16397224-0 2006 Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Estradiol 143-152 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-53 16397224-0 2006 Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Estrone 157-164 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-53 16397224-2 2006 In this study, we conducted functional analyses of genetic variants in the UDP-glucuronosyltransferase UGT1A8, UGT1A9, and UGT2B7 enzymes primarily involved in the inactivation of 4-OHCEs. 4-ohces 180-187 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 123-129 16397224-3 2006 Compared with UGT2B7*2 (H268Y), UGT2B7*1 exhibited a 2-fold lower efficiency (intrinsic clearance) at conjugating 4-hydroxyestrone and 4-hydroxyestradiol at positions 3 and 4 caused by altered capacities (Vmax) and affinities (Km). 4-hydroxyestrone 114-130 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 14-20 16397224-3 2006 Compared with UGT2B7*2 (H268Y), UGT2B7*1 exhibited a 2-fold lower efficiency (intrinsic clearance) at conjugating 4-hydroxyestrone and 4-hydroxyestradiol at positions 3 and 4 caused by altered capacities (Vmax) and affinities (Km). 4-hydroxyestrone 114-130 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 32-38 16397224-3 2006 Compared with UGT2B7*2 (H268Y), UGT2B7*1 exhibited a 2-fold lower efficiency (intrinsic clearance) at conjugating 4-hydroxyestrone and 4-hydroxyestradiol at positions 3 and 4 caused by altered capacities (Vmax) and affinities (Km). 4-hydroxyestradiol 135-153 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 14-20 16397224-3 2006 Compared with UGT2B7*2 (H268Y), UGT2B7*1 exhibited a 2-fold lower efficiency (intrinsic clearance) at conjugating 4-hydroxyestrone and 4-hydroxyestradiol at positions 3 and 4 caused by altered capacities (Vmax) and affinities (Km). 4-hydroxyestradiol 135-153 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 32-38 16221753-8 2006 N-Carbamoyl glucuronidation was catalyzed by UGT2B7 in human liver microsomes when incubations were conducted under a CO2 atmosphere. N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide 118-121 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 45-51 16849011-8 2006 CONCLUSION: Polymorphisms of UGT1A1, UGT2B7 and CYP2D6 strongly affect the pharmacokinetics and disposition of carvedilol in Japanese. Carvedilol 111-121 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 37-43 16129696-2 2005 It was found that UDP-gal, but not UDP-GlcNAc, also served as a sugar donor primarily through catalysis by UGT2B7, although at a significantly reduced catalytic rate. Uridine Diphosphate Galactose 18-25 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 107-113 16051636-3 2005 It is known that different isoforms of UDP-glucuronosyltransferase (UGT) are involved in E2 glucuronidation: UGT1A1 leads exclusively to the 3-glucuronide and is stimulated by E2 via homotropic kinetics, whereas UGT2B7 gives rise to the 17-glucuronide of E2 following Michaelis-Menten kinetics. 3-glucuronide 141-154 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 212-218 16051636-3 2005 It is known that different isoforms of UDP-glucuronosyltransferase (UGT) are involved in E2 glucuronidation: UGT1A1 leads exclusively to the 3-glucuronide and is stimulated by E2 via homotropic kinetics, whereas UGT2B7 gives rise to the 17-glucuronide of E2 following Michaelis-Menten kinetics. 17-glucuronide 237-251 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 212-218 16129696-2 2005 It was found that UDP-gal, but not UDP-GlcNAc, also served as a sugar donor primarily through catalysis by UGT2B7, although at a significantly reduced catalytic rate. Sugars 64-69 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 107-113 16129696-4 2005 In contrast, only UDP-GlcA served as the sugar donor for the conjugation of diclofenac, a known UGT2B7 substrate, with an apparent K(m) for UDP-GlcA of 96 +/- 17 microM. Uridine Diphosphate Glucuronic Acid 18-26 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 96-102 16129696-4 2005 In contrast, only UDP-GlcA served as the sugar donor for the conjugation of diclofenac, a known UGT2B7 substrate, with an apparent K(m) for UDP-GlcA of 96 +/- 17 microM. Sugars 41-46 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 96-102 16129696-4 2005 In contrast, only UDP-GlcA served as the sugar donor for the conjugation of diclofenac, a known UGT2B7 substrate, with an apparent K(m) for UDP-GlcA of 96 +/- 17 microM. Diclofenac 76-86 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 96-102 16129696-4 2005 In contrast, only UDP-GlcA served as the sugar donor for the conjugation of diclofenac, a known UGT2B7 substrate, with an apparent K(m) for UDP-GlcA of 96 +/- 17 microM. Uridine Diphosphate Glucuronic Acid 140-148 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 96-102 16129696-7 2005 The findings of this study indicate that the selectivity of UGT2B7 toward UDP-sugars is aglycone-dependent. Uridine Diphosphate Sugars 74-84 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 60-66 16129696-7 2005 The findings of this study indicate that the selectivity of UGT2B7 toward UDP-sugars is aglycone-dependent. CHEBI:166892 88-96 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 60-66 16129696-8 2005 With Compound A as the acceptor substrate, human UGT2B7 becomes more accommodative in the transfer of the glycosyl group from UDP-sugars beyond UDP-GlcA. Uridine Diphosphate Sugars 126-136 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 49-55 16129696-8 2005 With Compound A as the acceptor substrate, human UGT2B7 becomes more accommodative in the transfer of the glycosyl group from UDP-sugars beyond UDP-GlcA. Uridine Diphosphate Glucuronic Acid 144-152 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 49-55 16187975-9 2005 UGT2B7 exhibited an apparent K(m) (72 microm) of the same order as the high-affinity human liver microsomal activity, which was inhibited by the UGT2B7 selective "probe" fluconazole. Fluconazole 170-181 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 16049128-5 2005 We sought to characterize the kinetics of glucuronidation of the selective UGT2B7 substrate AZT (3"-azido-3"-deoxythymidine), a selective UGT2B7 substrate, in human liver microsomes (HLMs), recombinant UGT2B7, and human hepatocytes. Zidovudine 92-95 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 75-81 16049128-5 2005 We sought to characterize the kinetics of glucuronidation of the selective UGT2B7 substrate AZT (3"-azido-3"-deoxythymidine), a selective UGT2B7 substrate, in human liver microsomes (HLMs), recombinant UGT2B7, and human hepatocytes. Zidovudine 92-95 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 138-144 16049128-5 2005 We sought to characterize the kinetics of glucuronidation of the selective UGT2B7 substrate AZT (3"-azido-3"-deoxythymidine), a selective UGT2B7 substrate, in human liver microsomes (HLMs), recombinant UGT2B7, and human hepatocytes. Zidovudine 92-95 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 138-144 16049128-5 2005 We sought to characterize the kinetics of glucuronidation of the selective UGT2B7 substrate AZT (3"-azido-3"-deoxythymidine), a selective UGT2B7 substrate, in human liver microsomes (HLMs), recombinant UGT2B7, and human hepatocytes. Zidovudine 97-123 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 75-81 16049128-5 2005 We sought to characterize the kinetics of glucuronidation of the selective UGT2B7 substrate AZT (3"-azido-3"-deoxythymidine), a selective UGT2B7 substrate, in human liver microsomes (HLMs), recombinant UGT2B7, and human hepatocytes. Zidovudine 97-123 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 138-144 16049128-5 2005 We sought to characterize the kinetics of glucuronidation of the selective UGT2B7 substrate AZT (3"-azido-3"-deoxythymidine), a selective UGT2B7 substrate, in human liver microsomes (HLMs), recombinant UGT2B7, and human hepatocytes. Zidovudine 97-123 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 138-144 16187975-9 2005 UGT2B7 exhibited an apparent K(m) (72 microm) of the same order as the high-affinity human liver microsomal activity, which was inhibited by the UGT2B7 selective "probe" fluconazole. Fluconazole 170-181 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 145-151 15980101-7 2005 The IC(50) for S-flurbiprofen inhibition of gemcabene glucuronidation was similar in HLM (60.6 microM) compared with recombinant UGT2B7 (27.4 microM), consistent with a major role for UGT2B7 in gemcabene glucuronidation in HLM. Flurbiprofen 15-29 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 184-190 16215614-3 2005 Data suggest that variability in genes encoding the enzyme metabolising morphine (UGT2B7 gene), mu-opioid receptors (OPRM1 gene) and BBB transport of morphine by multidrug resistance transporters (MDR1 gene) influence the clinical efficacy of morphine. Morphine 72-80 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 82-88 16166450-1 2005 PURPOSE: Ketoconazole has been shown to inhibit the glucuronidation of the UGT2B7 substrates zidovudine and lorazepam. Ketoconazole 9-21 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 75-81 16166450-1 2005 PURPOSE: Ketoconazole has been shown to inhibit the glucuronidation of the UGT2B7 substrates zidovudine and lorazepam. Zidovudine 93-103 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 75-81 16166450-1 2005 PURPOSE: Ketoconazole has been shown to inhibit the glucuronidation of the UGT2B7 substrates zidovudine and lorazepam. Lorazepam 108-117 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 75-81 15980101-0 2005 Udp-glucuronosyltransferase 2b7 is the major enzyme responsible for gemcabene glucuronidation in human liver microsomes. gemcabene 68-77 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-31 15980101-9 2005 Reaction rates for gemcabene glucuronidation from a human liver bank correlated well (r(2)=0.722, P<0.0001; n=24) with rates of glucuronidation of the UGT2B7 probe substrate 3"-azido-3"-deoxythymidine. gemcabene 19-28 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 154-160 15980101-3 2005 Glucuronidation of gemcabene was catalyzed by recombinant UGT1A3, recombinant UGT2B7, and recombinant UGT2B17, as well as by human liver microsomes (HLM). gemcabene 19-28 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 78-84 15980101-6 2005 S-Flurbiprofen was identified as a more selective inhibitor of recombinant UGT2B7-catalyzed gemcabene glucuronidation (>23-fold lower IC(50)) when compared with recombinant UGT1A3- or recombinant UGT2B17-catalyzed gemcabene glucuronidation. Flurbiprofen 0-14 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 75-81 15980101-9 2005 Reaction rates for gemcabene glucuronidation from a human liver bank correlated well (r(2)=0.722, P<0.0001; n=24) with rates of glucuronidation of the UGT2B7 probe substrate 3"-azido-3"-deoxythymidine. Zidovudine 177-203 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 154-160 15980101-6 2005 S-Flurbiprofen was identified as a more selective inhibitor of recombinant UGT2B7-catalyzed gemcabene glucuronidation (>23-fold lower IC(50)) when compared with recombinant UGT1A3- or recombinant UGT2B17-catalyzed gemcabene glucuronidation. gemcabene 92-101 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 75-81 15980101-6 2005 S-Flurbiprofen was identified as a more selective inhibitor of recombinant UGT2B7-catalyzed gemcabene glucuronidation (>23-fold lower IC(50)) when compared with recombinant UGT1A3- or recombinant UGT2B17-catalyzed gemcabene glucuronidation. gemcabene 217-226 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 75-81 15980101-10 2005 In conclusion, using the three independent experimental approaches typically used for cytochrome P450 reaction phenotyping, UGT2B7 is the major enzyme contributing to gemcabene glucuronidation in human liver microsomes. gemcabene 167-176 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 124-130 16141602-6 2005 Trans-3"-hydroxycotinine is glucuronidated to O-glucuronide mainly by UGT2B7 and partly by UGT1A9. hydroxycotinine 0-24 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 70-76 16045647-3 2005 We review data which shows that variability in genes coding the enzyme metabolizing morphine (UGT2B7 gene), mu-opioid receptors (OPRM gene) and blood-brain barrier (BBB) transport of morphine by multidrug resistance transporters (MDR1 gene) influences the clinical efficacy of morphine. Morphine 84-92 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 94-100 16045647-3 2005 We review data which shows that variability in genes coding the enzyme metabolizing morphine (UGT2B7 gene), mu-opioid receptors (OPRM gene) and blood-brain barrier (BBB) transport of morphine by multidrug resistance transporters (MDR1 gene) influences the clinical efficacy of morphine. Morphine 183-191 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 94-100 16045647-3 2005 We review data which shows that variability in genes coding the enzyme metabolizing morphine (UGT2B7 gene), mu-opioid receptors (OPRM gene) and blood-brain barrier (BBB) transport of morphine by multidrug resistance transporters (MDR1 gene) influences the clinical efficacy of morphine. Morphine 183-191 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 94-100 16141602-6 2005 Trans-3"-hydroxycotinine is glucuronidated to O-glucuronide mainly by UGT2B7 and partly by UGT1A9. o-glucuronide 46-59 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 70-76 15615884-2 2005 To evaluate the possible association of UGT2B7 gene polymorphism with bladder cancer risk for benzidine-exposed subjects, diagnosed bladder cancer cases (n = 36) who were members of a cohort of benzidine-exposed workers in the Chinese dyestuff industry were investigated. benzidine 94-103 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 40-46 15821044-0 2005 Lithocholic acid decreases expression of UGT2B7 in Caco-2 cells: a potential role for a negative farnesoid X receptor response element. Lithocholic Acid 0-16 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 41-47 15821044-1 2005 Human UDP-glucuronosyltransferase (UGT) 2B7 is the major isoform catalyzing the glucuronidation of a variety of endogenous compounds including bile acids. Bile Acids and Salts 143-153 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 6-43 15821044-2 2005 To determine the role of bile acids in the regulation of UGT2B7 expression, Caco-2 cells were incubated with the natural human farnesoid X receptor (hFXR) ligand, chenodeoxycholic acid, as well as the secondary bile acid, lithocholic acid, derived from chenodeoxycholic acid. Bile Acids and Salts 25-35 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 57-63 15615884-0 2005 An association of UDP-glucuronosyltransferase 2B7 C802T (His268Tyr) polymorphism with bladder cancer in benzidine-exposed workers in China. benzidine 104-113 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 18-49 15821044-2 2005 To determine the role of bile acids in the regulation of UGT2B7 expression, Caco-2 cells were incubated with the natural human farnesoid X receptor (hFXR) ligand, chenodeoxycholic acid, as well as the secondary bile acid, lithocholic acid, derived from chenodeoxycholic acid. Bile Acids and Salts 25-34 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 57-63 15821044-3 2005 Incubation of Caco-2 cells with lithocholic acid in the absence of exogenous hFXR resulted in a dose-dependent down-regulation of UGT2B7 mRNA levels, with an IC(50) of 13 microM. Lithocholic Acid 32-48 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 130-136 15821044-6 2005 UGT2B7 promoter transfection experiments and deletion/mutation analysis showed that lithocholic acid-activated hFXR decreased UGT2B7 promoter activity via a negative hFXR response element (NFRE) located between nucleotides -148 and -134. Lithocholic Acid 84-100 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 15821044-6 2005 UGT2B7 promoter transfection experiments and deletion/mutation analysis showed that lithocholic acid-activated hFXR decreased UGT2B7 promoter activity via a negative hFXR response element (NFRE) located between nucleotides -148 and -134. Lithocholic Acid 84-100 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 126-132 15821044-8 2005 Electrophoretic mobility shift assays additionally confirmed the role of NFRE in UGT2B7 down-regulation by lithocholic acid. Lithocholic Acid 107-123 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 81-87 15821044-9 2005 These findings suggest that lithocholic acid, an activator of nuclear hFXR, acts as a negative regulator of UGT2B7 expression, indicating that hFXR may play an essential role in lithocholic acid homeostasis through negative regulation of this UGT that is involved in lithocholic acid biotransformation. Lithocholic Acid 28-44 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 108-114 15821044-9 2005 These findings suggest that lithocholic acid, an activator of nuclear hFXR, acts as a negative regulator of UGT2B7 expression, indicating that hFXR may play an essential role in lithocholic acid homeostasis through negative regulation of this UGT that is involved in lithocholic acid biotransformation. Lithocholic Acid 178-194 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 108-114 15821044-9 2005 These findings suggest that lithocholic acid, an activator of nuclear hFXR, acts as a negative regulator of UGT2B7 expression, indicating that hFXR may play an essential role in lithocholic acid homeostasis through negative regulation of this UGT that is involved in lithocholic acid biotransformation. Lithocholic Acid 178-194 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 108-114 15821044-10 2005 Therefore, it is postulated that lithocholic acid toxicity may be due to down-regulation of genes involved in its detoxification, including UGT2B7, leading to limited excretion of lithocholic acid from the body. Lithocholic Acid 33-49 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 140-146 15821044-10 2005 Therefore, it is postulated that lithocholic acid toxicity may be due to down-regulation of genes involved in its detoxification, including UGT2B7, leading to limited excretion of lithocholic acid from the body. Lithocholic Acid 180-196 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 140-146 15988124-4 2005 The TA-1801A glucuronosyltransferase activity in human liver microsomes was inhibited by bilirubin (typical substrate for UGT1A1), propofol (typical substrate for UGT1A9), diclofenac (substrate for UGT1A9 and UGT2B7), and genistein (substrate for UGT1A1, UGT1A3, and UGT1A9). Bilirubin 89-98 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 209-215 15988124-4 2005 The TA-1801A glucuronosyltransferase activity in human liver microsomes was inhibited by bilirubin (typical substrate for UGT1A1), propofol (typical substrate for UGT1A9), diclofenac (substrate for UGT1A9 and UGT2B7), and genistein (substrate for UGT1A1, UGT1A3, and UGT1A9). Propofol 131-139 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 209-215 15988124-5 2005 The inhibition by bilirubin, propofol, and diclofenac of the TA-1801A glucuronidation was less pronounced in jejunum microsomes than liver microsomes, suggesting that the contribution of UGT1A1, UGT1A9, and UGT2B7 to the TA-1801A glucuronidation is smaller in the intestine than the liver. Bilirubin 18-27 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 207-213 15988124-5 2005 The inhibition by bilirubin, propofol, and diclofenac of the TA-1801A glucuronidation was less pronounced in jejunum microsomes than liver microsomes, suggesting that the contribution of UGT1A1, UGT1A9, and UGT2B7 to the TA-1801A glucuronidation is smaller in the intestine than the liver. Propofol 29-37 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 207-213 15988124-5 2005 The inhibition by bilirubin, propofol, and diclofenac of the TA-1801A glucuronidation was less pronounced in jejunum microsomes than liver microsomes, suggesting that the contribution of UGT1A1, UGT1A9, and UGT2B7 to the TA-1801A glucuronidation is smaller in the intestine than the liver. Diclofenac 43-53 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 207-213 15615884-1 2005 UDP-Glucuronyltransferase 2B7 (UGT2B7) is involved in benzidine metabolism, as demonstrated by in vitro experiments with liver slices. benzidine 54-63 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-29 15615884-1 2005 UDP-Glucuronyltransferase 2B7 (UGT2B7) is involved in benzidine metabolism, as demonstrated by in vitro experiments with liver slices. benzidine 54-63 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 31-37 15615884-9 2005 This study points for the first time to an association between a homozygous mutant genotype of human UDP-glucuronosyltransferase 2B7 catalyzing the biotransformation of benzidine and an elevated bladder cancer risk for formerly benzidine-exposed workers of the dyestuff industry. benzidine 169-178 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 101-132 15615884-9 2005 This study points for the first time to an association between a homozygous mutant genotype of human UDP-glucuronosyltransferase 2B7 catalyzing the biotransformation of benzidine and an elevated bladder cancer risk for formerly benzidine-exposed workers of the dyestuff industry. benzidine 228-237 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 101-132 15611481-0 2005 Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. Morphine 138-146 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 102-108 15608137-9 2005 The K(m) value of denopamine glucuronidation in recombinant UGT2B7 microsomes was close to those in human liver and jejunum microsomes. denopamine 18-28 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 60-66 15608137-10 2005 The formation of denopamine glucuronidation by human liver, jejunum, and recombinant UGT2B7 microsomes was effectively inhibited by diclofenac, a known substrate for UGT2B7. denopamine 17-27 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 85-91 15608137-10 2005 The formation of denopamine glucuronidation by human liver, jejunum, and recombinant UGT2B7 microsomes was effectively inhibited by diclofenac, a known substrate for UGT2B7. denopamine 17-27 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 166-172 15608137-10 2005 The formation of denopamine glucuronidation by human liver, jejunum, and recombinant UGT2B7 microsomes was effectively inhibited by diclofenac, a known substrate for UGT2B7. Diclofenac 132-142 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 85-91 15608137-10 2005 The formation of denopamine glucuronidation by human liver, jejunum, and recombinant UGT2B7 microsomes was effectively inhibited by diclofenac, a known substrate for UGT2B7. Diclofenac 132-142 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 166-172 15608137-12 2005 These results demonstrate that the denopamine glucuronidation in human liver and intestine is mainly catalyzed by UGT2B7 and that glucuronidation of the alcoholic hydroxyl group, but not the phenolic hydroxyl group, occurs regioselectively in humans. denopamine 35-45 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 114-120 15611481-1 2005 Modulation of UDP-glucuronosyltransferase 2B7 (UGT2B7)-catalyzed morphine glucuronidation by cytochrome P450 (P450) was studied. Morphine 65-73 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-53 15611481-2 2005 The effects of P450 isozymes on the kinetic parameters of UGT2B7-catalyzed glucuronidation of the morphine 3-hydroxyl group were examined by simultaneous expression of UGT2B7 and either CYP3A4, -1A2, or -2C9 in COS-1 cells. Morphine 98-106 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 58-64 15611481-8 2005 In contrast, the formation of morphine-3-glucuronide by detergent-treated microsomes from COS-1 cells expressing UGT2B7 was reduced by CYP3A4, whereas the formation of the 6-glucuronide was enhanced. morphine-3-glucuronide 30-52 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 113-119 15611481-8 2005 In contrast, the formation of morphine-3-glucuronide by detergent-treated microsomes from COS-1 cells expressing UGT2B7 was reduced by CYP3A4, whereas the formation of the 6-glucuronide was enhanced. carbonyl sulfide 90-93 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 113-119 15611481-8 2005 In contrast, the formation of morphine-3-glucuronide by detergent-treated microsomes from COS-1 cells expressing UGT2B7 was reduced by CYP3A4, whereas the formation of the 6-glucuronide was enhanced. 6-glucuronide 172-185 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 113-119 15611481-9 2005 These results strongly suggest that 1) the glucuronidation activity of UGT2B7 toward morphine is specifically modulated by interaction with CYP3A4 in microsomal membranes and that 2) CYP3A4 alters UGT2B7 regioselectivity so that the ratio of morphine activation/detoxication is increased. Morphine 85-93 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 71-77 15611481-9 2005 These results strongly suggest that 1) the glucuronidation activity of UGT2B7 toward morphine is specifically modulated by interaction with CYP3A4 in microsomal membranes and that 2) CYP3A4 alters UGT2B7 regioselectivity so that the ratio of morphine activation/detoxication is increased. Morphine 242-250 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 71-77 15611481-9 2005 These results strongly suggest that 1) the glucuronidation activity of UGT2B7 toward morphine is specifically modulated by interaction with CYP3A4 in microsomal membranes and that 2) CYP3A4 alters UGT2B7 regioselectivity so that the ratio of morphine activation/detoxication is increased. Morphine 242-250 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 197-203 16103897-2 2005 This study evaluated genetic variation in the mu-opioid receptor, betaarrestin2, stat6 and uridine diphosphate-glucuronysltransferase 2B7 (UGT2B7) genes, in patients who responded to morphine vs those who were switched to alternative opioids. Morphine 183-191 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 91-137 15470160-12 2005 Trans-3"-hydroxycotinine O-glucuronosyltransferase activities in 13 human liver microsomes ranged from 2.4 to 12.6 pmol/min/mg and were significantly correlated with valproic acid glucuronidation (r = 0.716, p < 0.01), which is catalyzed by UGT2B7, UGT1A6, and UGT1A9. Valproic Acid 166-179 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 244-250 15470160-14 2005 Interestingly, imipramine (IC(50) = 45 microM), androstanediol (IC(50) = 21 microM), and propofol (IC(50) = 41 microM) also inhibited trans-3"-hydroxycotinine O-glucuronosyltransferase activity by recombinant UGT2B7. Imipramine 15-25 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 209-215 15470160-14 2005 Interestingly, imipramine (IC(50) = 45 microM), androstanediol (IC(50) = 21 microM), and propofol (IC(50) = 41 microM) also inhibited trans-3"-hydroxycotinine O-glucuronosyltransferase activity by recombinant UGT2B7. Androstane-3,17-diol 48-62 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 209-215 15470160-14 2005 Interestingly, imipramine (IC(50) = 45 microM), androstanediol (IC(50) = 21 microM), and propofol (IC(50) = 41 microM) also inhibited trans-3"-hydroxycotinine O-glucuronosyltransferase activity by recombinant UGT2B7. Propofol 89-97 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 209-215 15470160-14 2005 Interestingly, imipramine (IC(50) = 45 microM), androstanediol (IC(50) = 21 microM), and propofol (IC(50) = 41 microM) also inhibited trans-3"-hydroxycotinine O-glucuronosyltransferase activity by recombinant UGT2B7. hydroxycotinine 134-158 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 209-215 15470160-15 2005 These findings suggested that trans-3"-hydroxycotinine O-glucuronidation in human liver microsomes is catalyzed by mainly UGT2B7 and, to a minor extent, by UGT1A9. hydroxycotinine 30-54 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 122-128 15547048-7 2005 Sertraline N-carbamoyl glucuronidation was measured in human liver microsomes in bicarbonate buffer and under a CO2 atmosphere (K(m) = 50 microM) and was catalyzed at the fastest rate by recombinant human UGT2B7. Sertraline 0-10 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 205-211 15470161-10 2005 Although UGT 2B7 was the only isoform producing AcMPAG in a significant amount, the selective inhibitor azidothymidine only moderately reduced this production (approximately -25%). mycophenolic acid acyl glucuronide 48-54 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 9-16 16103897-2 2005 This study evaluated genetic variation in the mu-opioid receptor, betaarrestin2, stat6 and uridine diphosphate-glucuronysltransferase 2B7 (UGT2B7) genes, in patients who responded to morphine vs those who were switched to alternative opioids. Morphine 183-191 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 139-145 15292462-0 2004 N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7. Nitrogen 0-1 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 67-73 15320866-0 2004 Farnesol is glucuronidated in human liver, kidney and intestine in vitro, and is a novel substrate for UGT2B7 and UGT1A1. Farnesol 0-8 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 103-109 15320866-8 2004 Kinetic analysis and inhibition experiments indicate that, in liver microsomes, UGT1A1 is primarily responsible for farnesol glucuronidation; however, in intestine microsomes, UGT2B7 is probably the major isoform involved, with a very-low-micromolar K(m). Farnesol 116-124 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 176-182 15292462-0 2004 N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7. Carbamazepine 21-34 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 67-73 15292462-4 2004 We have developed a sensitive liquid chromatography/mass spectrometry assay to quantify CBZ glucuronidation, and we report that CBZ is specifically glucuronidated by human UGT2B7. Carbamazepine 88-91 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 172-178 15292462-4 2004 We have developed a sensitive liquid chromatography/mass spectrometry assay to quantify CBZ glucuronidation, and we report that CBZ is specifically glucuronidated by human UGT2B7. Carbamazepine 128-131 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 172-178 15292462-5 2004 Kinetics of CBZ glucuronidation in human liver, kidney, and intestine microsomes were consistent with those of recombinant UGT2B7, which displayed a Km value of 214 microM and Vmax value of 0.79 pmol/mg/min. Carbamazepine 12-15 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 123-129 15292462-6 2004 In addition to revealing the isoform responsible for CBZ glucuronidation, this is the first example of primary amine glucuronidation by UGT2B7. Carbamazepine 53-56 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 136-142 15292462-6 2004 In addition to revealing the isoform responsible for CBZ glucuronidation, this is the first example of primary amine glucuronidation by UGT2B7. Amines 111-116 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 136-142 14977865-8 2004 However, UGT2B7 exclusively formed SCH 488128, a trace metabolite detected in dog and human plasma samples after oral administration of ezetimibe. EZETIMIBE HYDROXY GLUCURONIDE 35-45 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 9-15 15135306-7 2004 Only UGT1A4 catalyzed the N-linked glucuronidation of TAM among recombinant UGTs (UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B4, UGT2B7, UGT2B15, and UGT2B17) expressed in insect cells. Tamoxifen 54-57 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 130-136 15047194-2 2004 Several human UDP-glucuronosyltransferases (UGTs) have been shown to catalyze the formation of acyl-glucuronides, including UGT2B7, UGT1A3, and UGT1A9. acyl-glucuronides 95-112 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 124-130 15047194-3 2004 In this study, recombinant expressed UGT isoforms were investigated with many structurally related carboxylic acid analogues, and the UGT rank order for catalyzing the glucuronidation of carboxylic acids was UGT2B7?UGT1A3 approximately UGT1A9. Carboxylic Acids 187-203 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 208-214 15047194-6 2004 Kinetic analysis showed that UGT2B7 exhibits much higher glucuronidation efficiency (Vmax/Km) with ibuprofen, ketoprofen, and others, compared to UGT1A3. Ibuprofen 99-108 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 29-35 15047194-6 2004 Kinetic analysis showed that UGT2B7 exhibits much higher glucuronidation efficiency (Vmax/Km) with ibuprofen, ketoprofen, and others, compared to UGT1A3. Ketoprofen 110-120 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 29-35 15047194-7 2004 These data indicate that UGT2B7 could be the major isoform involved in the glucuronidation of carboxylic acid compounds in humans. carboxylic acid compounds 94-119 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 25-31 15319348-1 2004 Both UDP-glucuronosyltransferase 2B4 (UGT2B4) and UGT2B7 are expressed mainly in the human liver and have several overlapping substrates; e.g., catechol estrogens, bile acids, codeine, and carvedilol. catechol 144-152 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 50-56 15319348-1 2004 Both UDP-glucuronosyltransferase 2B4 (UGT2B4) and UGT2B7 are expressed mainly in the human liver and have several overlapping substrates; e.g., catechol estrogens, bile acids, codeine, and carvedilol. Bile Acids and Salts 164-174 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 50-56 15319348-1 2004 Both UDP-glucuronosyltransferase 2B4 (UGT2B4) and UGT2B7 are expressed mainly in the human liver and have several overlapping substrates; e.g., catechol estrogens, bile acids, codeine, and carvedilol. Codeine 176-183 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 50-56 15319348-1 2004 Both UDP-glucuronosyltransferase 2B4 (UGT2B4) and UGT2B7 are expressed mainly in the human liver and have several overlapping substrates; e.g., catechol estrogens, bile acids, codeine, and carvedilol. Carvedilol 189-199 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 50-56 15100177-0 2004 Amide N-glucuronidation of MaxiPost catalyzed by UDP-glucuronosyltransferase 2B7 in humans. Amides 0-5 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 49-80 15100177-0 2004 Amide N-glucuronidation of MaxiPost catalyzed by UDP-glucuronosyltransferase 2B7 in humans. Nitrogen 6-7 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 49-80 15100177-7 2004 Of the seven human UDP-glucuronosyltransferases (UGT) isozymes (1A1, 1A3, 1A4, 1A6, 1A7, 1A10, and 2B7) tested, only UGT2B7 produced metabolite M. UGT2B7-catalyzed N-glucuronidation of BMS-204352 exhibited Michaelis-Menten kinetics with a K(m) of 14.2 microM and V(max) of 0.29 nmol/min. Nitrogen 164-165 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 117-123 15100177-9 2004 Collectively, these results suggest that amide N-glucuronidation, a major elimination pathway of MaxiPost, is catalyzed by UGT2B7 in humans. Amides 41-46 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 123-129 15100177-9 2004 Collectively, these results suggest that amide N-glucuronidation, a major elimination pathway of MaxiPost, is catalyzed by UGT2B7 in humans. Nitrogen 47-48 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 123-129 15100177-10 2004 This N-glucuronide represents a fully characterized amide N-glucuronide, and glucuronidation at the nitrogen represents a newly identified conjugation reaction for UGT2B7. n-glucuronide 5-18 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 164-170 15100177-10 2004 This N-glucuronide represents a fully characterized amide N-glucuronide, and glucuronidation at the nitrogen represents a newly identified conjugation reaction for UGT2B7. Nitrogen 100-108 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 164-170 15001974-1 2004 To clarify the molecular determinants of the metabolic variability of morphine, we searched for genetic polymorphisms in the gene for uridine diphosphate-glucuronosyltransferase 2B7 (UGT2B7) and evaluated their functional impact in vitro and in patients with cancer receiving long-term morphine therapy. Morphine 70-78 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 134-181 15001974-1 2004 To clarify the molecular determinants of the metabolic variability of morphine, we searched for genetic polymorphisms in the gene for uridine diphosphate-glucuronosyltransferase 2B7 (UGT2B7) and evaluated their functional impact in vitro and in patients with cancer receiving long-term morphine therapy. Morphine 70-78 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 183-189 15001974-1 2004 To clarify the molecular determinants of the metabolic variability of morphine, we searched for genetic polymorphisms in the gene for uridine diphosphate-glucuronosyltransferase 2B7 (UGT2B7) and evaluated their functional impact in vitro and in patients with cancer receiving long-term morphine therapy. Morphine 286-294 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 134-181 14977865-8 2004 However, UGT2B7 exclusively formed SCH 488128, a trace metabolite detected in dog and human plasma samples after oral administration of ezetimibe. Ezetimibe 136-145 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 9-15 14977865-9 2004 In conclusion, the formation of SCH 60663 is mediated via UGT1A1, UGT1A3, and UGT2B15, and the formation SCH 488128 is mediated via UGT2B7. EZETIMIBE HYDROXY GLUCURONIDE 105-115 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 132-138 12920162-2 2003 It has been proposed that UGT2B7 is the major enzyme involved in these reactions, but there is evidence to suggest that other isoforms also catalyze morphine glucuronidation in man. Morphine 149-157 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 26-32 14746343-2 2003 Recombinant UGT2B7, one of the UDP-glucuronosyltransferase (UGT) isoforms, is able to glucuronidate the 3- and 6-hydroxy groups of morphine at nanomolar concentrations. Morphine 131-139 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 12-18 14575648-4 2003 Among these are metabolic factors (bioactivation by hCYP2C9 or hCYP3A4 to thiol-reactive quinone imines, activation by hUGT2B7 to protein-reactive acyl glucuronides and iso-glucuronides, and 4"-hydroxylation secondary to diclofenac glucuronidation), as well as kinetic factors (Mrp2-mediated concentrative transport of diclofenac metabolites into bile). Glucuronides 152-164 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 119-126 14575648-4 2003 Among these are metabolic factors (bioactivation by hCYP2C9 or hCYP3A4 to thiol-reactive quinone imines, activation by hUGT2B7 to protein-reactive acyl glucuronides and iso-glucuronides, and 4"-hydroxylation secondary to diclofenac glucuronidation), as well as kinetic factors (Mrp2-mediated concentrative transport of diclofenac metabolites into bile). diclofenac glucuronidation 221-247 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 119-126 14575648-4 2003 Among these are metabolic factors (bioactivation by hCYP2C9 or hCYP3A4 to thiol-reactive quinone imines, activation by hUGT2B7 to protein-reactive acyl glucuronides and iso-glucuronides, and 4"-hydroxylation secondary to diclofenac glucuronidation), as well as kinetic factors (Mrp2-mediated concentrative transport of diclofenac metabolites into bile). Diclofenac 221-231 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 119-126 12920168-0 2003 Evaluation of 3"-azido-3"-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Zidovudine 14-40 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 88-119 12920168-0 2003 Evaluation of 3"-azido-3"-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Zidovudine 14-40 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 121-127 14744946-0 2004 Involvement of human hepatic UGT1A1, UGT2B4, and UGT2B7 in the glucuronidation of carvedilol. Carvedilol 82-92 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 49-55 14744946-4 2004 The glucuronidation of carvedilol was catalyzed by at least three recombinant UGT isoforms: UGT1A1, UGT2B4, and UGT2B7. Carvedilol 23-33 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 112-118 14744946-5 2004 UGT2B4 formed both G1 and G2, whereas UGT1A1 and UGT2B7 were responsible for the formation of glucuronide G2 and G1, respectively. Glucuronides 94-105 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 49-55 14744946-6 2004 The enzyme kinetics for carvedilol glucuronidation by UGT1A1, UGT2B4, and UGT2B7 in addition to human liver microsomes were examined by Lineweaver-Burk analysis. Carvedilol 24-34 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 74-80 14667942-0 2004 Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Fatty Acids, Unsaturated 14-37 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 187-193 14508389-12 2003 High concentrations of heroin and 6-MAM may inhibit UGT 2B7, the enzyme responsible for glucuronidation of morphine. Heroin 23-29 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 52-59 14508389-12 2003 High concentrations of heroin and 6-MAM may inhibit UGT 2B7, the enzyme responsible for glucuronidation of morphine. Morphine 107-115 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 52-59 12920168-0 2003 Evaluation of 3"-azido-3"-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Codeine 56-63 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 88-119 12920168-0 2003 Evaluation of 3"-azido-3"-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Codeine 56-63 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 121-127 12920162-10 2003 These data suggest that M6G formation may be used as a selective probe for UGT2B7 activity, and morphine glucuronidation by UGT2B7 appears to involve the simultaneous binding of two substrate molecules, highlighting the need for careful analysis of morphine glucuronidation kinetics in vitro. Morphine 96-104 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 124-130 12920168-4 2003 Of 11 different UGTs screened, UGT2B7 was the principal isoform mediating AZT glucuronidation, morphine-3-glucuronidation, and morphine-6-glucuronidation. Zidovudine 74-77 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 31-37 12920168-4 2003 Of 11 different UGTs screened, UGT2B7 was the principal isoform mediating AZT glucuronidation, morphine-3-glucuronidation, and morphine-6-glucuronidation. Morphine 95-103 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 31-37 12746330-4 2003 Kinetic analyses reveal that UGT2B7 polymorphisms glucuronidate mineralocorticoids with a 5.5- to 20-fold higher affinity than glucocorticoids. glucuronidate 50-63 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 29-35 12920168-4 2003 Of 11 different UGTs screened, UGT2B7 was the principal isoform mediating AZT glucuronidation, morphine-3-glucuronidation, and morphine-6-glucuronidation. Morphine 127-135 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 31-37 12920168-5 2003 Codeine was glucuronidated equally well by UGT2B4 and UGT2B7. Codeine 0-7 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 54-60 12920168-8 2003 Microsomal UGT2B7 protein content correlated well with AZT glucuronidation (rs = 0.77), to a lesser extent with morphine-3-glucuronidation (rs = 0.50) and morphine-6-glucuronidation (rs = 0.51), but very weakly with codeine glucuronidation (rs = 0.33). Morphine 155-163 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 11-17 12920168-8 2003 Microsomal UGT2B7 protein content correlated well with AZT glucuronidation (rs = 0.77), to a lesser extent with morphine-3-glucuronidation (rs = 0.50) and morphine-6-glucuronidation (rs = 0.51), but very weakly with codeine glucuronidation (rs = 0.33). Codeine 216-223 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 11-17 12920168-11 2003 In conclusion, although both AZT and morphine can serve as in vitro probe substrates for UGT2B7, AZT appears to be more selective than morphine. Zidovudine 29-32 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 89-95 12920168-11 2003 In conclusion, although both AZT and morphine can serve as in vitro probe substrates for UGT2B7, AZT appears to be more selective than morphine. Morphine 37-45 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 89-95 12811366-0 2003 A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Morphine 97-105 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 27-74 12811366-1 2003 We investigated the variation in the uridine diphosphate-glucuronosyltransferase 2B7 (UGT2B7) gene in patients receiving patient-controlled analgesia with morphine. Morphine 155-163 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 37-84 12811366-1 2003 We investigated the variation in the uridine diphosphate-glucuronosyltransferase 2B7 (UGT2B7) gene in patients receiving patient-controlled analgesia with morphine. Morphine 155-163 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 86-92 12811366-2 2003 UGT2B7 was sequenced in phenotypic extremes (n = 12) of the distribution of morphine-6-glucuronide/morphine plasma ratios. morphine-6-glucuronide 76-98 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 12811366-2 2003 UGT2B7 was sequenced in phenotypic extremes (n = 12) of the distribution of morphine-6-glucuronide/morphine plasma ratios. Morphine 76-84 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 12811366-8 2003 Interindividual differences in morphine glucuronidation may be the result of genetic variation in UGT2B7, and further studies are indicated. Morphine 31-39 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 98-104 12756209-9 2003 Naphthol, propofol, morphine, and androstanediol were used as probe UGT substrates selective for UGT1A6, UGT1A9, UGT2B7, and UGT2B15, respectively. Naphthols 0-8 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 113-119 12756209-9 2003 Naphthol, propofol, morphine, and androstanediol were used as probe UGT substrates selective for UGT1A6, UGT1A9, UGT2B7, and UGT2B15, respectively. Propofol 10-18 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 113-119 12756209-9 2003 Naphthol, propofol, morphine, and androstanediol were used as probe UGT substrates selective for UGT1A6, UGT1A9, UGT2B7, and UGT2B15, respectively. Morphine 20-28 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 113-119 12756209-9 2003 Naphthol, propofol, morphine, and androstanediol were used as probe UGT substrates selective for UGT1A6, UGT1A9, UGT2B7, and UGT2B15, respectively. Androstane-3,17-diol 34-48 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 113-119 12746330-5 2003 For the first time, a significant difference between the two allelic variants of UGT2B7 is described, because UGT2B7H((268)) possesses an 11-fold higher aldosterone glucuronidation efficiency (ratio Vmax((app.))/Km((app.))) Aldosterone 153-164 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 81-87 12695347-8 2003 The inhibitory effects of 4-nitrophenol (IC(50) = 121.0 microM) as a typical substrate for UGT1A6 and UGT1A9, imipramine (IC(50) = 393.8 microM) as a typical substrate for UGT1A3 and UGT1A4, and morphine (IC(50) = 109.3 microM) as a typical substrate for UGT2B7 were relatively weak. 4-nitrophenol 26-39 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 255-261 12695355-0 2003 Involvement of human UGT2B7 and 2B15 in rofecoxib metabolism. rofecoxib 40-49 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 21-27 12695355-10 2003 Because polymorphisms have been identified in human UGT2B7, 2B15 genes and O-glucuronidation of 5-hydroxyrofecoxib plays a major role in biotransformation of rofecoxib, it is possible that human UGT2B7 and 2B15 polymorphisms for O-glucuronidation of 5-hydroxyrofecoxib are responsible for the high variability in bimodal patterns in human plasma concentration-time curves. rofecoxib 105-114 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 52-58 12695355-10 2003 Because polymorphisms have been identified in human UGT2B7, 2B15 genes and O-glucuronidation of 5-hydroxyrofecoxib plays a major role in biotransformation of rofecoxib, it is possible that human UGT2B7 and 2B15 polymorphisms for O-glucuronidation of 5-hydroxyrofecoxib are responsible for the high variability in bimodal patterns in human plasma concentration-time curves. 5-hydroxyrofecoxib 96-114 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 195-201 12695355-10 2003 Because polymorphisms have been identified in human UGT2B7, 2B15 genes and O-glucuronidation of 5-hydroxyrofecoxib plays a major role in biotransformation of rofecoxib, it is possible that human UGT2B7 and 2B15 polymorphisms for O-glucuronidation of 5-hydroxyrofecoxib are responsible for the high variability in bimodal patterns in human plasma concentration-time curves. rofecoxib 105-114 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 195-201 12695355-10 2003 Because polymorphisms have been identified in human UGT2B7, 2B15 genes and O-glucuronidation of 5-hydroxyrofecoxib plays a major role in biotransformation of rofecoxib, it is possible that human UGT2B7 and 2B15 polymorphisms for O-glucuronidation of 5-hydroxyrofecoxib are responsible for the high variability in bimodal patterns in human plasma concentration-time curves. 5-hydroxyrofecoxib 250-268 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 52-58 12695358-1 2003 In this case report, we present genetic differences in two morphine-related gene sequences, UDP-glucuronosyltransferase 2B7 (UGT2B7) and mu opioid receptors (MOR1), in two cancer patients whose clinical responses to morphine were very different [i.e., sensitive (patient 1) and low responder (patient 2)]. Morphine 59-67 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 125-131 12695358-1 2003 In this case report, we present genetic differences in two morphine-related gene sequences, UDP-glucuronosyltransferase 2B7 (UGT2B7) and mu opioid receptors (MOR1), in two cancer patients whose clinical responses to morphine were very different [i.e., sensitive (patient 1) and low responder (patient 2)]. Morphine 216-224 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 125-131 12623074-0 2003 Glucuronidation of catechols by human hepatic, gastric, and intestinal microsomal UDP-glucuronosyltransferases (UGT) and recombinant UGT1A6, UGT1A9, and UGT2B7. Catechols 19-28 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 153-159 12657745-0 2003 Glucuronidation of 1"-hydroxyestragole (1"-HE) by human UDP-glucuronosyltransferases UGT2B7 and UGT1A9. 1'-hydroxyestragole 19-38 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 85-91 12657745-0 2003 Glucuronidation of 1"-hydroxyestragole (1"-HE) by human UDP-glucuronosyltransferases UGT2B7 and UGT1A9. 1'-hydroxyestragole 40-45 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 85-91 12657745-9 2003 1"-HE glucuronidation in 27 individual human liver samples significantly (p < 0.05) correlated with the glucuronidation of other UGT2B7 substrates (morphine and ibuprofen). Morphine 151-159 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 132-138 12657745-9 2003 1"-HE glucuronidation in 27 individual human liver samples significantly (p < 0.05) correlated with the glucuronidation of other UGT2B7 substrates (morphine and ibuprofen). Ibuprofen 164-173 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 132-138 12657745-10 2003 These results imply that concomitant chronic intake of therapeutic drugs and dietary components that are UGT2B7 and/or UGT1A9 substrates may interfere with estragole metabolism. estragole 156-165 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 105-111 12657745-11 2003 Our results also have toxicogenetic significance, as UGT2B7 is polymorphic and could potentially result in genetic differences in glucuronidation of 1"-HE and, hence, toxicity of estragole. estragole 179-188 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 53-59 12732356-1 2003 Valproic acid glucuronidation kinetics were carried our with three human UGT isoforms: UGT1A6, UGT1A9, and UGT2B7 as well as human liver and kidney microsomes. Valproic Acid 0-13 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 107-113 12732356-5 2003 Valproic acid inhibited UGT1A9 catalyzed propofol glucuronidation in an uncompetitive manner and UGT2B7 catalyzed AZT glucuronidation competitively (K(i)=1.6+/-0.06mM). Zidovudine 114-117 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 97-103 12435745-3 2003 The activity of recombinant UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT2B4, UGT2B7, and UGT2B15 was almost fully inhibited by 0.2% Triton X-100. Octoxynol 123-135 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 68-74 12527334-3 2003 The glucosidation by UGT2B7 was specific for HDCA and was not observed with the other bile acids examined, lithocholic acid, chenodeoxycholic acid, and ursodeoxycholic acid. Chenodeoxycholic Acid 125-146 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 21-27 12527334-8 2003 UGT2B7 catalyzed the addition of the glucose and glucuronic acid moieties to an hydroxyl group on HDCA and also possessed some capacity to use UDP-xylose as sugar donor. Glucose 37-44 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 12527334-10 2003 This is the first report that identifies UGT2B7 as the enzyme responsible for the glucosidation of the bile acid, HDCA. Bile Acids and Salts 103-112 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 41-47 12527334-8 2003 UGT2B7 catalyzed the addition of the glucose and glucuronic acid moieties to an hydroxyl group on HDCA and also possessed some capacity to use UDP-xylose as sugar donor. Glucuronic Acid 49-64 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 12527334-8 2003 UGT2B7 catalyzed the addition of the glucose and glucuronic acid moieties to an hydroxyl group on HDCA and also possessed some capacity to use UDP-xylose as sugar donor. Uridine Diphosphate Xylose 143-153 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 12527334-8 2003 UGT2B7 catalyzed the addition of the glucose and glucuronic acid moieties to an hydroxyl group on HDCA and also possessed some capacity to use UDP-xylose as sugar donor. Sugars 157-162 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 12527799-1 2003 The UDP-glucuronosyltransferase UGT2B7 is an important human UGT isoform that catalyzes the conjugation of many endogenous and exogenous compounds, among them opioids, resulting in the formation of D-glucuronides. d-glucuronides 198-212 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 32-38 12527799-4 2003 Three maltose binding protein-UGT2B7 fusion proteins, 2B7F3 and 2B7F4 incorporating the amino acids 24 to 118 and 24 to 96 of UGT2B7, respectively, and 2B7F5 incorporating amino acids 84 to 118 of UGT2B7 were expressed in Escherichia coli and purified by affinity chromatography. Maltose 6-13 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 30-36 12485951-9 2003 We herein report a drug acyl glucoside formed in human liver microsomes at a considerable turnover rate and provide the evidence for a UGT isoform (UGT2B7) capable of transferring both glucuronic acid and glucose from UDPGA and UDPG to an aglycone. acyl glucoside 24-38 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 148-154 12485951-9 2003 We herein report a drug acyl glucoside formed in human liver microsomes at a considerable turnover rate and provide the evidence for a UGT isoform (UGT2B7) capable of transferring both glucuronic acid and glucose from UDPGA and UDPG to an aglycone. Glucuronic Acid 185-200 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 148-154 12485951-9 2003 We herein report a drug acyl glucoside formed in human liver microsomes at a considerable turnover rate and provide the evidence for a UGT isoform (UGT2B7) capable of transferring both glucuronic acid and glucose from UDPGA and UDPG to an aglycone. Glucose 205-212 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 148-154 12485951-9 2003 We herein report a drug acyl glucoside formed in human liver microsomes at a considerable turnover rate and provide the evidence for a UGT isoform (UGT2B7) capable of transferring both glucuronic acid and glucose from UDPGA and UDPG to an aglycone. CHEBI:166892 239-247 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 148-154 12519692-8 2003 Using several human UGT-expressing microsomes, UGT1A3 and UGT2B7 were principally responsible for glucuronidation of pitavastatin leading to lactonization. pitavastatin 117-129 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 58-64 15018021-6 2003 These results suggest that the activity of UDP glucuronosyltransferase 2B7 in the intestinal metabolism of morphine may play an active part in a large interindividual variation in the ratio of metabolites to morphine. Morphine 107-115 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 43-74 15018021-6 2003 These results suggest that the activity of UDP glucuronosyltransferase 2B7 in the intestinal metabolism of morphine may play an active part in a large interindividual variation in the ratio of metabolites to morphine. Morphine 208-216 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 43-74 12629580-0 2003 Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Morphine 175-183 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 27-58 12629580-0 2003 Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Morphine 175-183 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 60-66 12433804-2 2002 Although UGT1A1 uniquely catalyzes the glucuronidation of the endobiotic, bilirubin, and UGT2B7 uniquely catalyzes the glucuronidation of morphine to both the 3-0 glucuronide and the 6-0 glucuronide, both catalyze the glucuronidation of the mixed opioid agonist/antagonist buprenorphine with high efficiency. Morphine 138-146 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 89-95 12433804-2 2002 Although UGT1A1 uniquely catalyzes the glucuronidation of the endobiotic, bilirubin, and UGT2B7 uniquely catalyzes the glucuronidation of morphine to both the 3-0 glucuronide and the 6-0 glucuronide, both catalyze the glucuronidation of the mixed opioid agonist/antagonist buprenorphine with high efficiency. 3-0 glucuronide 159-174 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 89-95 12433804-2 2002 Although UGT1A1 uniquely catalyzes the glucuronidation of the endobiotic, bilirubin, and UGT2B7 uniquely catalyzes the glucuronidation of morphine to both the 3-0 glucuronide and the 6-0 glucuronide, both catalyze the glucuronidation of the mixed opioid agonist/antagonist buprenorphine with high efficiency. 6-0 glucuronide 183-198 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 89-95 12433804-2 2002 Although UGT1A1 uniquely catalyzes the glucuronidation of the endobiotic, bilirubin, and UGT2B7 uniquely catalyzes the glucuronidation of morphine to both the 3-0 glucuronide and the 6-0 glucuronide, both catalyze the glucuronidation of the mixed opioid agonist/antagonist buprenorphine with high efficiency. Buprenorphine 273-286 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 89-95 12433804-3 2002 Etonitazenyl, a mu opioid receptor antagonist, was found to inhibit competitively opioid, steroid, and other substrate glucuronidation reactions catalyzed by UGT2B7. etonitazenyl 0-12 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 158-164 12433804-3 2002 Etonitazenyl, a mu opioid receptor antagonist, was found to inhibit competitively opioid, steroid, and other substrate glucuronidation reactions catalyzed by UGT2B7. Steroids 90-97 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 158-164 12433804-4 2002 Data showing several benzodiazepines and alternative substrates interacting competitively support previous work, which indicates a single binding domain within UGT2B7. Benzodiazepines 21-36 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 160-166 11950783-1 2002 Linoleic acid has recently been shown to be glucuronidated in vitro by human liver and intestinal microsomes and recombinant UGT2B7. Linoleic Acid 0-13 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 125-131 12487149-3 2002 The metabolism of DMXAA has been extensively studied mainly using hepatic microsomes, which indicated that UGT1A9 and UGT2B7-catalyzed glucuronidation on its acetic acid side chain and to a lesser extent CYP1A2-catalyzed hydroxylation of the 6-methyl group are the major metabolic pathways, resulting in DMXAA acyl glucuronide (DMXAA-G) and 6-hydroxymethyl-5-methylxanthenone-4-acetic acid. vadimezan 18-23 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 118-124 12487149-3 2002 The metabolism of DMXAA has been extensively studied mainly using hepatic microsomes, which indicated that UGT1A9 and UGT2B7-catalyzed glucuronidation on its acetic acid side chain and to a lesser extent CYP1A2-catalyzed hydroxylation of the 6-methyl group are the major metabolic pathways, resulting in DMXAA acyl glucuronide (DMXAA-G) and 6-hydroxymethyl-5-methylxanthenone-4-acetic acid. Acetic Acid 158-169 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 118-124 12487149-3 2002 The metabolism of DMXAA has been extensively studied mainly using hepatic microsomes, which indicated that UGT1A9 and UGT2B7-catalyzed glucuronidation on its acetic acid side chain and to a lesser extent CYP1A2-catalyzed hydroxylation of the 6-methyl group are the major metabolic pathways, resulting in DMXAA acyl glucuronide (DMXAA-G) and 6-hydroxymethyl-5-methylxanthenone-4-acetic acid. dmxaa acyl glucuronide 304-326 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 118-124 12487149-3 2002 The metabolism of DMXAA has been extensively studied mainly using hepatic microsomes, which indicated that UGT1A9 and UGT2B7-catalyzed glucuronidation on its acetic acid side chain and to a lesser extent CYP1A2-catalyzed hydroxylation of the 6-methyl group are the major metabolic pathways, resulting in DMXAA acyl glucuronide (DMXAA-G) and 6-hydroxymethyl-5-methylxanthenone-4-acetic acid. vadimezan 304-309 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 118-124 12487149-3 2002 The metabolism of DMXAA has been extensively studied mainly using hepatic microsomes, which indicated that UGT1A9 and UGT2B7-catalyzed glucuronidation on its acetic acid side chain and to a lesser extent CYP1A2-catalyzed hydroxylation of the 6-methyl group are the major metabolic pathways, resulting in DMXAA acyl glucuronide (DMXAA-G) and 6-hydroxymethyl-5-methylxanthenone-4-acetic acid. -hydroxymethyl-5-methylxanthenone-4-acetic acid 342-389 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 118-124 12487149-10 2002 Based on in vitro metabolic inhibition studies, it appears possible to predict the effects on the plasma kinetic profile of DMXAA of drugs such as diclofenac, which are mainly metabolized by UGT2B7. vadimezan 124-129 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 191-197 12487149-10 2002 Based on in vitro metabolic inhibition studies, it appears possible to predict the effects on the plasma kinetic profile of DMXAA of drugs such as diclofenac, which are mainly metabolized by UGT2B7. Diclofenac 147-157 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 191-197 12351142-7 2002 Glucuronidation of BZ and its analogues exhibited the following relative ranking of UDP-glucuronosyltransferase (UGT) metabolism: UGT1A9>UGT1A4>>UGT2B7>UGT1A6 approximately UGT1A1. benzidine 19-21 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 154-160 12167566-13 2002 Alpha-DHA-G was formed in incubations of DHA with expressed UGT1A9 (K(m) 32 microM, V(max) 8.9 pmol min(-1) mg(-1)) or UGT2B7 (K(m) 438 microM, V(max) 10.9 pmol mg(-1) min(-1)) but not with UGT1A1 or UGT1A6. artenimol 6-9 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 119-125 12167566-15 2002 We conclude that alpha-DHA-G is an important metabolite of DHA in humans and that its formation is catalyzed by UGT1A9 and UGT2B7. alpha-dha-g 17-28 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 123-129 12167566-15 2002 We conclude that alpha-DHA-G is an important metabolite of DHA in humans and that its formation is catalyzed by UGT1A9 and UGT2B7. artenimol 23-26 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 123-129 12018987-7 2002 Human UGT1A1, UGT1A8, and UGT1A9 were shown to be especially active in conjugation of both flavonoids, whereas UGT1A4 and UGT1A10 and the isoenzymes from the UGTB family, UGT2B7 and UGT2B15, were less efficient. Flavonoids 91-101 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 171-177 12386133-0 2002 Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Oxazepam 31-39 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 165-171 12386133-0 2002 Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Oxazepam 86-96 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 165-171 12386133-8 2002 In contrast, R-oxazepam was glucuronidated by UGT1A9 and UGT2B7. Oxazepam 13-23 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 57-63 12386134-9 2002 The UGT2B7 substrates morphine and ibuprofen had no effect on estradiol 3-glucuronidation, whereas retinoic acid was slightly inhibitory. Morphine 22-30 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 4-10 12236850-0 2002 Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential. pyranoprofen 54-65 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 26-32 12236850-5 2002 RESULTS: Zaltoprofen was extensively metabolized by CYP2C9 and UGT2B7. pyranoprofen 9-20 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 63-69 12236850-13 2002 CONCLUSIONS: Zaltoprofen is predominantly metabolized by CYP2C9 and UGT2B7, and is considered unlikely to cause significant drug interactions in vivo when coadministered with CYP substrates at clinically effective doses. pyranoprofen 13-24 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 68-74 12167566-13 2002 Alpha-DHA-G was formed in incubations of DHA with expressed UGT1A9 (K(m) 32 microM, V(max) 8.9 pmol min(-1) mg(-1)) or UGT2B7 (K(m) 438 microM, V(max) 10.9 pmol mg(-1) min(-1)) but not with UGT1A1 or UGT1A6. alpha-dha-g 0-11 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 119-125 12185559-1 2002 OBJECTIVE: UDP-glucuronosyltransferase (UGT) 2B7 is the major UGT isoform responsible for the 3- and 6-glucuronidation of morphine in humans. Morphine 122-130 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 11-48 12185559-3 2002 Our objective was to investigate whether the UGT2B7 H268Y and UGT1A1*28 polymorphisms contribute to the variability in morphine glucuronide-to-morphine plasma ratios among cancer patients undergoing analgesic therapy with morphine. Morphine 119-127 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 45-51 12185559-3 2002 Our objective was to investigate whether the UGT2B7 H268Y and UGT1A1*28 polymorphisms contribute to the variability in morphine glucuronide-to-morphine plasma ratios among cancer patients undergoing analgesic therapy with morphine. Glucuronides 128-139 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 45-51 12185559-3 2002 Our objective was to investigate whether the UGT2B7 H268Y and UGT1A1*28 polymorphisms contribute to the variability in morphine glucuronide-to-morphine plasma ratios among cancer patients undergoing analgesic therapy with morphine. Morphine 143-151 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 45-51 12185559-3 2002 Our objective was to investigate whether the UGT2B7 H268Y and UGT1A1*28 polymorphisms contribute to the variability in morphine glucuronide-to-morphine plasma ratios among cancer patients undergoing analgesic therapy with morphine. Morphine 143-151 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 45-51 12201491-13 2002 Studies have indicated that DMXAA glucuronidation is catalysed by uridine diphosphate glucuronosyltransferases (UGT1A9 and UGT2B7), and 6-methylhydroxylation by cytochrome P450 (CYP1A2). vadimezan 28-33 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 123-129 11950783-4 2002 Kinetic analysis produced relatively low K(m) values for PA with both HLM and UGT2B7 (149 and 108 microM, respectively). Phytanic Acid 57-59 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 78-84 11950783-5 2002 The K(m) for DHA glucuronidation by HLM (460 microM) was considerably higher than that for UGT2B7 (168 microM), suggesting the involvement in microsomes of other UGT isoforms in addition to UGT2B7. Docosahexaenoic Acids 13-16 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 190-196 11777184-4 2002 Morphine has a unique metabolism via glucuronidation (UGT2B7), which results in an active metabolite (morphine-6-glucuronide). Morphine 0-8 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 54-60 11943730-0 2002 Expression of UGT2B7, a UDP-glucuronosyltransferase implicated in the metabolism of 4-hydroxyestrone and all-trans retinoic acid, in normal human breast parenchyma and in invasive and in situ breast cancers. 4-hydroxyestrone 84-100 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 14-20 11943730-0 2002 Expression of UGT2B7, a UDP-glucuronosyltransferase implicated in the metabolism of 4-hydroxyestrone and all-trans retinoic acid, in normal human breast parenchyma and in invasive and in situ breast cancers. 2-octenal 40-45 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 14-20 11943730-0 2002 Expression of UGT2B7, a UDP-glucuronosyltransferase implicated in the metabolism of 4-hydroxyestrone and all-trans retinoic acid, in normal human breast parenchyma and in invasive and in situ breast cancers. Tretinoin 115-128 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 14-20 11943730-3 2002 The goal of this study was to determine whether UGT2B7, the isoenzyme with a high affinity for 4-hydroxyestrone, is expressed in human breast parenchyma. 4-hydroxyestrone 95-111 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 48-54 11943730-5 2002 Using reverse transcriptase-polymerase chain reaction, immunocytochemistry, immunoblot analyses, and assays of glucuronidation of 4-hydroxyestrone, we show that UGT2B7 is expressed in human mammary epithelium, and that its expression is dramatically reduced in invasive breast cancers. 4-hydroxyestrone 130-146 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 161-167 11943730-7 2002 The finding of reduced UGT2B7 protein and glucuronidation of 4-hydroxyestrone in invasive cancers suggests a tumor-suppressor function for the enzyme. 4-hydroxyestrone 61-77 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 23-29 11943730-8 2002 Recent identification of all-trans retinoic acid as a substrate of UGT2B7 suggests that this function includes the generation of retinoyl-beta-glucuronide, a potent mediator of actions of retinoids important for maintaining epithelia in a differentiated state. Tretinoin 25-48 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 67-73 11943730-8 2002 Recent identification of all-trans retinoic acid as a substrate of UGT2B7 suggests that this function includes the generation of retinoyl-beta-glucuronide, a potent mediator of actions of retinoids important for maintaining epithelia in a differentiated state. retinoyl glucuronide 129-154 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 67-73 11943730-8 2002 Recent identification of all-trans retinoic acid as a substrate of UGT2B7 suggests that this function includes the generation of retinoyl-beta-glucuronide, a potent mediator of actions of retinoids important for maintaining epithelia in a differentiated state. Retinoids 188-197 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 67-73 11777184-4 2002 Morphine has a unique metabolism via glucuronidation (UGT2B7), which results in an active metabolite (morphine-6-glucuronide). morphine-6-glucuronide 102-124 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 54-60 11353807-1 2001 The UDP-glucuronosyltransferase UGT2B7 is an important human UGT isoform that catalyzes the conjugation of many endogenous and exogenous compounds, among them opioids, resulting in the formation of D-glucuronides. d-glucuronides 198-212 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 32-38 11556815-11 2001 The activity supported by UGT2B7 and UGT2B15 was very low and restricted to cis-resveratrol. Resveratrol 76-91 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 26-32 11353807-4 2001 Two maltose binding protein fusion proteins, 2B7F1 and 2B7F2, incorporating the first 157 or 119 amino acids, respectively, of UGT2B7 were expressed in Escherichia coli and purified by affinity chromatography. Maltose 4-11 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 127-133 11294973-3 2001 Conversely, human UGT2B7 displayed a high rate of diclofenac glucuronide formation (>500 pmol/min/mg protein). 1-O-(2-((2',6'-dichlorophenyl)amino)phenylacetyl)glucopyranuronic acid 50-72 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 18-24 11302935-11 2001 Only UGT2B7 converted epirubicin to its glucuronide. Epirubicin 22-32 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 5-11 11302935-11 2001 Only UGT2B7 converted epirubicin to its glucuronide. Glucuronides 40-51 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 5-11 11302935-13 2001 Catalytic efficiency (V(max)/K(m)) of epirubicin glucuronidation was 1.4 microl/min/mg, a value higher than that observed for morphine, a substrate of UGT2B7. Epirubicin 38-48 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 151-157 11302935-13 2001 Catalytic efficiency (V(max)/K(m)) of epirubicin glucuronidation was 1.4 microl/min/mg, a value higher than that observed for morphine, a substrate of UGT2B7. Morphine 126-134 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 151-157 11302935-16 2001 UGT2B7 is the major human UGT catalyzing epirubicin glucuronidation, and UGT2B7 is the candidate gene for this phenotype. Epirubicin 41-51 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 11302935-16 2001 UGT2B7 is the major human UGT catalyzing epirubicin glucuronidation, and UGT2B7 is the candidate gene for this phenotype. Epirubicin 41-51 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 73-79 11302935-17 2001 The reported tyrosine to histidine polymorphism in UGT2B7 does not alter the formation rate of epirubicin glucuronide, and undiscovered genetic polymorphisms in UGT2B7 might change the metabolic fate of this important anticancer agent. Tyrosine 13-21 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 51-57 11302935-17 2001 The reported tyrosine to histidine polymorphism in UGT2B7 does not alter the formation rate of epirubicin glucuronide, and undiscovered genetic polymorphisms in UGT2B7 might change the metabolic fate of this important anticancer agent. Histidine 25-34 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 51-57 11451170-0 2001 Identification of cyclosporine A and tacrolimus glucuronidation in human liver and the gastrointestinal tract by a differentially expressed UDP-glucuronosyltransferase: UGT2B7. Cyclosporine 18-32 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 169-175 11451170-0 2001 Identification of cyclosporine A and tacrolimus glucuronidation in human liver and the gastrointestinal tract by a differentially expressed UDP-glucuronosyltransferase: UGT2B7. Tacrolimus 37-47 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 169-175 11451170-7 2001 Analyses using recombinant UDPglucuronosyltransferases identified UGT2B7 as a human UDP-glucuronosyltransferase with specific activity toward cyclosporine A and tacrolimus. Cyclosporine 142-156 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 66-72 11451170-7 2001 Analyses using recombinant UDPglucuronosyltransferases identified UGT2B7 as a human UDP-glucuronosyltransferase with specific activity toward cyclosporine A and tacrolimus. Tacrolimus 161-171 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 66-72 11339806-0 2001 Glucuronidation of linoleic acid diols by human microsomal and recombinant UDP-glucuronosyltransferases: identification of UGT2B7 as the major isoform involved. linoleic acid diols 19-38 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 123-129 11339806-5 2001 Studies with human recombinant UGTs demonstrated that only UGT2B7 glucuronidated LA and LA-diols. la-diols 88-96 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 59-65 11339806-7 2001 These studies indicate that LA and LA-diols are excellent substrates for intestinal UGTs and provide the first evidence for UGT2B7 being the major isoform involved. la and 28-34 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 124-130 11302930-2 2001 In the present studies, both linoleic acid (LA) and its biologically active oxidized derivatives, 13-hydroxyoctadecadienoic acid (13-HODE) and 13-oxooctadecadienoic acid (13-OXO), have been shown to be effective substrates for human liver UDP-glucuronosyltransferases (UGT) and recombinant UGT2B7. 13-hydroxy-9,11-octadecadienoic acid 98-128 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 290-296 11302930-2 2001 In the present studies, both linoleic acid (LA) and its biologically active oxidized derivatives, 13-hydroxyoctadecadienoic acid (13-HODE) and 13-oxooctadecadienoic acid (13-OXO), have been shown to be effective substrates for human liver UDP-glucuronosyltransferases (UGT) and recombinant UGT2B7. 13-oxo-9,11-octadecadienoic acid 143-169 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 290-296 11302930-3 2001 LA (carboxyl glucuronide) and 13-OXO (carboxyl glucuronide, unproven) were actively glucuronidated by human liver microsomes (HLM) and human recombinant UGT2B7 with similar activities, in the range of 2 nmol/mg. 13-oxo-9,11-octadecadienoic acid 30-36 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 153-159 11302930-7 2001 This is the first demonstration of glucuronidation of LA and its oxidized derivatives, 13-HODE and 13-OXO, by HLM and recombinant UGT2B7. 13-hydroxy-9,11-octadecadienoic acid 87-94 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 130-136 11302930-7 2001 This is the first demonstration of glucuronidation of LA and its oxidized derivatives, 13-HODE and 13-OXO, by HLM and recombinant UGT2B7. 13-oxo-9,11-octadecadienoic acid 99-105 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 130-136 11302935-0 2001 Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Epirubicin 0-10 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 49-80 11294973-7 2001 Morphine is a known substrate for rat UGT2B1 and human UGT2B7 and both total morphine glucuronidation (3-O- and 6-O-glucuronides) and diclofenac glucuronidation reactions showed a strong correlation with one another in human liver microsome samples. Morphine 0-8 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 55-61 11294973-9 2001 These data suggested that rat UGT2B1 and human UGT2B7 were the major UGT isoforms involved in the glucuronidation of diclofenac. Diclofenac 117-127 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-53 11159850-10 2001 UGT2B7 was demonstrated to glucuronidate estrogens, catechol estrogens, and androstane-3alpha,17beta-diol more efficiently than any other human UGTB isoform. glucuronidate 27-40 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 11159800-4 2001 Intrinsic clearance values for human UGT1A1 and UGT2B7 substrates were an order of magnitude higher in DLM than in HLM (e.g., gemfibrozil: 31 microl/min/mg versus 3.0 microl/min/mg; ketoprofen: 2.4 microl/min/mg versus 0.2 microl/min/mg). Gemfibrozil 126-137 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 48-54 11159850-10 2001 UGT2B7 was demonstrated to glucuronidate estrogens, catechol estrogens, and androstane-3alpha,17beta-diol more efficiently than any other human UGTB isoform. catechol 52-60 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 11159800-4 2001 Intrinsic clearance values for human UGT1A1 and UGT2B7 substrates were an order of magnitude higher in DLM than in HLM (e.g., gemfibrozil: 31 microl/min/mg versus 3.0 microl/min/mg; ketoprofen: 2.4 microl/min/mg versus 0.2 microl/min/mg). Ketoprofen 182-192 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 48-54 11159850-10 2001 UGT2B7 was demonstrated to glucuronidate estrogens, catechol estrogens, and androstane-3alpha,17beta-diol more efficiently than any other human UGTB isoform. androstane-3alpha 76-93 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 11159850-10 2001 UGT2B7 was demonstrated to glucuronidate estrogens, catechol estrogens, and androstane-3alpha,17beta-diol more efficiently than any other human UGTB isoform. 17beta-diol 94-105 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 10748067-8 2000 Hyodeoxycholic acid glucuronidation, catalyzed primarily by UGT2B4 and UGT2B7, showed a 7-fold interindividual variation in small intestinal duodenal samples, in contrast to limited variation in the presence of 4-methylumbelliferone, a substrate glucuronidated by most UGT1A and UGT2B gene products. hyodeoxycholic acid 0-19 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 71-77 10748067-8 2000 Hyodeoxycholic acid glucuronidation, catalyzed primarily by UGT2B4 and UGT2B7, showed a 7-fold interindividual variation in small intestinal duodenal samples, in contrast to limited variation in the presence of 4-methylumbelliferone, a substrate glucuronidated by most UGT1A and UGT2B gene products. Hymecromone 211-232 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 71-77 11186130-3 2000 Two variant UGT2B7 cDNAs encoding enzymes with either His or Tyr at residue 268 have been isolated. Histidine 54-57 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 12-18 11038164-0 2000 O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9. 4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol 41-87 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 104-144 11038164-0 2000 O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9. 4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol 89-93 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 104-144 11186130-3 2000 Two variant UGT2B7 cDNAs encoding enzymes with either His or Tyr at residue 268 have been isolated. Tyrosine 61-64 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 12-18 10702251-0 2000 4-hydroxyretinoic acid, a novel substrate for human liver microsomal UDP-glucuronosyltransferase(s) and recombinant UGT2B7. 4-hydroxyretinoic acid 0-22 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 116-122 10820138-2 2000 In humans, morphine is known to undergo extensive metabolism by glucuronidation, and the UDP-glucuronosyltransferase isoform, which catalyzes the formation of morphine-3-O-glucuronide and morphine-6-O-glucuronide is UGT2B7. Morphine 11-19 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 216-222 10820138-2 2000 In humans, morphine is known to undergo extensive metabolism by glucuronidation, and the UDP-glucuronosyltransferase isoform, which catalyzes the formation of morphine-3-O-glucuronide and morphine-6-O-glucuronide is UGT2B7. morphine-3-o-glucuronide 159-183 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 216-222 10820138-2 2000 In humans, morphine is known to undergo extensive metabolism by glucuronidation, and the UDP-glucuronosyltransferase isoform, which catalyzes the formation of morphine-3-O-glucuronide and morphine-6-O-glucuronide is UGT2B7. morphine-6-o-glucuronide 188-212 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 216-222 10820138-5 2000 The K(m) of morphine using beagle dog liver microsomes was approximately 270 microM, which is similar to that found for expressed human UGT2B7. Morphine 12-20 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 136-142 10820138-7 2000 Flunitrazepam inhibited the glucuronidation of morphine in dog liver microsomes, and the K(i) was 40 microM, which is similar to human UGT2B7 for other substrates. Flunitrazepam 0-13 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 135-141 10820138-7 2000 Flunitrazepam inhibited the glucuronidation of morphine in dog liver microsomes, and the K(i) was 40 microM, which is similar to human UGT2B7 for other substrates. Morphine 47-55 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 135-141 10772627-0 2000 3"-azido-3"-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). 3"-azido-3"-deoxythimidine 0-26 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 60-91 10772627-0 2000 3"-azido-3"-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). 3"-azido-3"-deoxythimidine 0-26 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 93-99 10772627-0 2000 3"-azido-3"-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Zidovudine 28-31 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 60-91 10772627-0 2000 3"-azido-3"-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Zidovudine 28-31 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 93-99 10772627-3 2000 Using labeled [(14)C]UDP-glucuronic acid and microsomal preparations from human kidney 293 cells stably expressing the different human UGT2B isoenzymes, it was demonstrated that AZT glucuronidation is catalyzed specifically by human UGT2B7. [(14)c]udp-glucuronic acid 14-40 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 233-239 10772627-3 2000 Using labeled [(14)C]UDP-glucuronic acid and microsomal preparations from human kidney 293 cells stably expressing the different human UGT2B isoenzymes, it was demonstrated that AZT glucuronidation is catalyzed specifically by human UGT2B7. Zidovudine 178-181 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 233-239 10772627-9 2000 It remains possible that other UGT enzymes are also involved in AZT conjugation; however, the glucuronidation of AZT by UGT2B7, which is a UGT2B protein expressed in the liver, is consistent with previous findings and supports the physiological relevance of this enzyme in AZT conjugation. Zidovudine 64-67 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 120-126 10772627-9 2000 It remains possible that other UGT enzymes are also involved in AZT conjugation; however, the glucuronidation of AZT by UGT2B7, which is a UGT2B protein expressed in the liver, is consistent with previous findings and supports the physiological relevance of this enzyme in AZT conjugation. Zidovudine 113-116 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 120-126 10772627-9 2000 It remains possible that other UGT enzymes are also involved in AZT conjugation; however, the glucuronidation of AZT by UGT2B7, which is a UGT2B protein expressed in the liver, is consistent with previous findings and supports the physiological relevance of this enzyme in AZT conjugation. Zidovudine 113-116 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 120-126 10779377-1 2000 The human UDP glucuronosyltransferase, UGT2B7, is expressed in the liver and gastrointestinal tract, where it catalyzes the glucuronidation of steroids and bile acids. Steroids 143-151 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 39-45 10779377-1 2000 The human UDP glucuronosyltransferase, UGT2B7, is expressed in the liver and gastrointestinal tract, where it catalyzes the glucuronidation of steroids and bile acids. Bile Acids and Salts 156-166 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 39-45 11465081-2 2000 Three human UDP-glucuronosyltransferases (UGTs) catalyzing the hepatic glucuronidation of carboxylic acid drugs have been identified, UGT1A3, UGT1A9 and a UGT2B7 variant. Carboxylic Acids 90-105 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 155-161 10833461-3 2000 Among the UGT2B subfamily, UGT2B7, a UGT enzyme present in the liver and several steroid target tissues, is an important member since it conjugates a large variety of compounds including estrogens, androgens, morphine, AZT, and retinoic acid. Steroids 81-88 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 27-33 10833461-3 2000 Among the UGT2B subfamily, UGT2B7, a UGT enzyme present in the liver and several steroid target tissues, is an important member since it conjugates a large variety of compounds including estrogens, androgens, morphine, AZT, and retinoic acid. Morphine 209-217 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 27-33 10833461-3 2000 Among the UGT2B subfamily, UGT2B7, a UGT enzyme present in the liver and several steroid target tissues, is an important member since it conjugates a large variety of compounds including estrogens, androgens, morphine, AZT, and retinoic acid. Zidovudine 219-222 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 27-33 10833461-3 2000 Among the UGT2B subfamily, UGT2B7, a UGT enzyme present in the liver and several steroid target tissues, is an important member since it conjugates a large variety of compounds including estrogens, androgens, morphine, AZT, and retinoic acid. Tretinoin 228-241 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 27-33 10702251-7 2000 We have also determined that human recombinant UGT2B7 can glucuronidate atRA, 4-OH-RA, and 4-OH-RAc with activities similar to those found in human liver microsomes. Tretinoin 72-76 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-53 10702251-7 2000 We have also determined that human recombinant UGT2B7 can glucuronidate atRA, 4-OH-RA, and 4-OH-RAc with activities similar to those found in human liver microsomes. 4-oh-ra 78-85 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-53 10702251-7 2000 We have also determined that human recombinant UGT2B7 can glucuronidate atRA, 4-OH-RA, and 4-OH-RAc with activities similar to those found in human liver microsomes. 4-oh-rac 91-99 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-53 10506112-10 1999 UGT2B7 was the only product of the UGT2 gene family examined and it metabolized all the aromatic amines at similar low relative levels compared with a preferred substrate, 4-OH-estrone. aromatic amines 88-103 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 10901286-4 2000 RT-PCR experiments indicated that the PD-7 and TC-7 clones expressed the UDP-glucuronosyltransferase (UGT) isoforms UGT1A6, UGT1A3 and UGT2B7, which could account for the glucuronidation of phenols and carboxylic acids observed. Phenols 190-197 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 135-141 10901286-4 2000 RT-PCR experiments indicated that the PD-7 and TC-7 clones expressed the UDP-glucuronosyltransferase (UGT) isoforms UGT1A6, UGT1A3 and UGT2B7, which could account for the glucuronidation of phenols and carboxylic acids observed. Carboxylic Acids 202-218 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 135-141 10579317-9 1999 Primary structure analysis shows that UGT2B23 is in the same family of enzymes as the previously characterized monkey isoforms UGT2B9 and UGT2B18, which are active on hydroxyandrogens. hydroxyandrogens 167-183 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 127-133 10506112-10 1999 UGT2B7 was the only product of the UGT2 gene family examined and it metabolized all the aromatic amines at similar low relative levels compared with a preferred substrate, 4-OH-estrone. 4-oh-estrone 172-184 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 10506112-14 1999 Likewise, the O-glucuronide of 3-OH-benzidine was stable at pH 7.4, with 52% remaining at pH 5.5 after 24 h. These results suggest the following relative ranking of transferase metabolism: UGT1A9 > UGT1A4 > > UGT2B7 > UGT1A6 approximately UGT1A1. o-glucuronide 14-27 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 218-224 10506112-14 1999 Likewise, the O-glucuronide of 3-OH-benzidine was stable at pH 7.4, with 52% remaining at pH 5.5 after 24 h. These results suggest the following relative ranking of transferase metabolism: UGT1A9 > UGT1A4 > > UGT2B7 > UGT1A6 approximately UGT1A1. 3-oh-benzidine 31-45 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 218-224 10222050-6 1999 These studies suggest that UGT2B7 may play an important role in the overall contribution of morphine analgesia by serving to generate the potent morphine-6-O-glucuronide in situ. Morphine 92-100 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 27-33 10529008-5 1999 Both UGT2B7 allelic variants glucuronidated the bile acid substrates at both carboxyl and hydroxyl moieties, however, the 3alpha-hydroxyl position was preferentially conjugated compared to the carboxyl function. Bile Acids and Salts 48-57 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 5-11 10529008-6 1999 Similarly, androsterone, a 3alpha-hydroxylated androgenic steroid, was glucuronidated at very high rates by expressed UGT2B7. Androsterone 11-23 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 118-124 10529008-6 1999 Similarly, androsterone, a 3alpha-hydroxylated androgenic steroid, was glucuronidated at very high rates by expressed UGT2B7. Steroids 58-65 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 118-124 10529008-7 1999 Of the estrogenic compounds tested, UGT2B7 catalyzed the glucuronidation of estriol at rates comparable to those determined for androsterone. Estriol 76-83 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 36-42 10529008-8 1999 Other structural discrimination was found with UGT2B7 which had activity toward estriol and estradiol exclusively at the 17beta-OH position, yielding the cholestatic steroid D-ring glucuronides. Estradiol 92-101 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-53 10529008-8 1999 Other structural discrimination was found with UGT2B7 which had activity toward estriol and estradiol exclusively at the 17beta-OH position, yielding the cholestatic steroid D-ring glucuronides. 17beta-oh 121-130 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-53 10529008-8 1999 Other structural discrimination was found with UGT2B7 which had activity toward estriol and estradiol exclusively at the 17beta-OH position, yielding the cholestatic steroid D-ring glucuronides. Steroids 166-173 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-53 10529008-8 1999 Other structural discrimination was found with UGT2B7 which had activity toward estriol and estradiol exclusively at the 17beta-OH position, yielding the cholestatic steroid D-ring glucuronides. Glucuronides 181-193 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 47-53 10222050-6 1999 These studies suggest that UGT2B7 may play an important role in the overall contribution of morphine analgesia by serving to generate the potent morphine-6-O-glucuronide in situ. morphine-6-o-glucuronide 145-169 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 27-33 10220484-1 1999 Human colon carcinoma Caco-2 cells were used to study the induction of UDP glucuronosyltransferase (UGT) isoforms UGT1A6, UGT1A9, and UGT2B7 by aryl hydrocarbon receptor agonists and by antioxidant-type inducers with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and t-butylhydroquinone (TBHQ), respectively. 2-tert-butylhydroquinone 264-283 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 134-140 10220484-1 1999 Human colon carcinoma Caco-2 cells were used to study the induction of UDP glucuronosyltransferase (UGT) isoforms UGT1A6, UGT1A9, and UGT2B7 by aryl hydrocarbon receptor agonists and by antioxidant-type inducers with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and t-butylhydroquinone (TBHQ), respectively. 2-tert-butylhydroquinone 285-289 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 134-140 10220484-0 1999 Induction of human UDP glucuronosyltransferases (UGT1A6, UGT1A9, and UGT2B7) by t-butylhydroquinone and 2,3,7,8-tetrachlorodibenzo-p-dioxin in Caco-2 cells. 2-tert-butylhydroquinone 80-99 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 69-75 9795217-8 1998 Screening for RNA expression by RT-PCR confirmed the absence of UGT2B4 and UGT1A6 and showed expression of UGT2B7, a hepatic isoform shown to glucuronidate androsterone, in all intestinal segments. glucuronidate androsterone 142-168 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 107-113 10220484-0 1999 Induction of human UDP glucuronosyltransferases (UGT1A6, UGT1A9, and UGT2B7) by t-butylhydroquinone and 2,3,7,8-tetrachlorodibenzo-p-dioxin in Caco-2 cells. Polychlorinated Dibenzodioxins 104-139 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 69-75 10220484-1 1999 Human colon carcinoma Caco-2 cells were used to study the induction of UDP glucuronosyltransferase (UGT) isoforms UGT1A6, UGT1A9, and UGT2B7 by aryl hydrocarbon receptor agonists and by antioxidant-type inducers with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and t-butylhydroquinone (TBHQ), respectively. Polychlorinated Dibenzodioxins 217-252 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 134-140 10220484-1 1999 Human colon carcinoma Caco-2 cells were used to study the induction of UDP glucuronosyltransferase (UGT) isoforms UGT1A6, UGT1A9, and UGT2B7 by aryl hydrocarbon receptor agonists and by antioxidant-type inducers with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and t-butylhydroquinone (TBHQ), respectively. Polychlorinated Dibenzodioxins 254-258 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 134-140 9848110-10 1998 FNZ competitively inhibited buprenorphine glucuronidation with UGT1A1 and UGT2B7 but had no inhibitory activity toward UGT1A3. Buprenorphine 28-41 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 74-80 9848110-3 1998 Three human liver UDP-glucuronosyltransferases, UGT2B7, UGT1A1, and UGT1A3, have been shown to catalyze the glucuronidation of catechol estrogens and lead to their enhanced elimination via urine or bile. catechol 127-135 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 48-54 9590580-13 1998 Comparison of the results from the inhibition studies with those reported previously for codeine and morphine suggest that the UDP-glucuronosyltransferase isoform UGT2B7 is involved in the glucuronidation of DHC. Codeine 89-96 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 163-169 9848110-6 1998 UGT2B7(Y) reacted with higher efficiency toward 4-hydroxyestrogenic catechols, whereas UGT1A1 and UGT1A3 showed higher activities toward 2-hydroxyestrogens. Catechols 68-77 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 9848110-7 1998 UGT2B7(H) catalyzed estrogen catechol glucuronidation with efficiencies similar to UGT2B7(Y). catechol 29-37 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 9848110-8 1998 Flunitrazepam (FNZ), a competitive inhibitor of morphine glucuronidation in hepatic microsomes, competitively inhibited catechol estrogen glucuronidation catalyzed by UGT2B7(Y), UGT1A1, and UGT1A3. Flunitrazepam 0-13 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 167-173 9848110-8 1998 Flunitrazepam (FNZ), a competitive inhibitor of morphine glucuronidation in hepatic microsomes, competitively inhibited catechol estrogen glucuronidation catalyzed by UGT2B7(Y), UGT1A1, and UGT1A3. Morphine 48-56 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 167-173 9848110-8 1998 Flunitrazepam (FNZ), a competitive inhibitor of morphine glucuronidation in hepatic microsomes, competitively inhibited catechol estrogen glucuronidation catalyzed by UGT2B7(Y), UGT1A1, and UGT1A3. catechol 120-128 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 167-173 9760450-1 1998 Following expression of UDPGTh1 and UDPGTh2 in Cos-1 cells, each isoform metabolized three types of dihydroxy- or trihydroxy-substituted ring structures, including the 3,4-catechol estrogen (4-hydroxyestrone), estriol and 17-epiestriol, and hyodeoxycholic acid (HDCA), but the UDPGTh2 isozyme was 100-fold more efficient than UDPGTh1. 3,4-catechol 168-180 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 36-43 9760450-1 1998 Following expression of UDPGTh1 and UDPGTh2 in Cos-1 cells, each isoform metabolized three types of dihydroxy- or trihydroxy-substituted ring structures, including the 3,4-catechol estrogen (4-hydroxyestrone), estriol and 17-epiestriol, and hyodeoxycholic acid (HDCA), but the UDPGTh2 isozyme was 100-fold more efficient than UDPGTh1. 4-hydroxyestrone 191-207 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 36-43 9760450-1 1998 Following expression of UDPGTh1 and UDPGTh2 in Cos-1 cells, each isoform metabolized three types of dihydroxy- or trihydroxy-substituted ring structures, including the 3,4-catechol estrogen (4-hydroxyestrone), estriol and 17-epiestriol, and hyodeoxycholic acid (HDCA), but the UDPGTh2 isozyme was 100-fold more efficient than UDPGTh1. Estriol 210-217 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 36-43 9760450-1 1998 Following expression of UDPGTh1 and UDPGTh2 in Cos-1 cells, each isoform metabolized three types of dihydroxy- or trihydroxy-substituted ring structures, including the 3,4-catechol estrogen (4-hydroxyestrone), estriol and 17-epiestriol, and hyodeoxycholic acid (HDCA), but the UDPGTh2 isozyme was 100-fold more efficient than UDPGTh1. 17-Epiestriol 222-235 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 36-43 9760450-1 1998 Following expression of UDPGTh1 and UDPGTh2 in Cos-1 cells, each isoform metabolized three types of dihydroxy- or trihydroxy-substituted ring structures, including the 3,4-catechol estrogen (4-hydroxyestrone), estriol and 17-epiestriol, and hyodeoxycholic acid (HDCA), but the UDPGTh2 isozyme was 100-fold more efficient than UDPGTh1. hyodeoxycholic acid 241-260 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 36-43 9590580-13 1998 Comparison of the results from the inhibition studies with those reported previously for codeine and morphine suggest that the UDP-glucuronosyltransferase isoform UGT2B7 is involved in the glucuronidation of DHC. Morphine 101-109 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 163-169 9590580-13 1998 Comparison of the results from the inhibition studies with those reported previously for codeine and morphine suggest that the UDP-glucuronosyltransferase isoform UGT2B7 is involved in the glucuronidation of DHC. dihydrocodeine 208-211 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 163-169 18982489-1 1997 Two human liver UDP-glucuronosyltransferase cDNA clones, HLUG25 and UDPGTh2 were previously shown to encode isozymes active in the glucuronidation of hyodeoxycholic acid (HDCA) and certain estrogen derivatives (e.g., estriol and 3,4-catechol estrogens), respectively. hyodeoxycholic acid 150-169 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 68-75 9394029-0 1997 Glucuronidation of opioids, carboxylic acid-containing drugs, and hydroxylated xenobiotics catalyzed by expressed monkey UDP-glucuronosyltransferase 2B9 protein. Carboxylic Acids 28-43 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 121-152 9394029-3 1997 UGT2B9, stably expressed in human embryonic kidney 293 cells, catalyzes the 3-O- and 6-O-glucuronidation of morphine and the 6-O-glucuronidation of codeine. 3-o 76-79 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 9394029-3 1997 UGT2B9, stably expressed in human embryonic kidney 293 cells, catalyzes the 3-O- and 6-O-glucuronidation of morphine and the 6-O-glucuronidation of codeine. 6-o 85-88 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 9394029-3 1997 UGT2B9, stably expressed in human embryonic kidney 293 cells, catalyzes the 3-O- and 6-O-glucuronidation of morphine and the 6-O-glucuronidation of codeine. Morphine 108-116 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 9394029-3 1997 UGT2B9, stably expressed in human embryonic kidney 293 cells, catalyzes the 3-O- and 6-O-glucuronidation of morphine and the 6-O-glucuronidation of codeine. 6-o 125-128 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 9394029-3 1997 UGT2B9, stably expressed in human embryonic kidney 293 cells, catalyzes the 3-O- and 6-O-glucuronidation of morphine and the 6-O-glucuronidation of codeine. Codeine 148-155 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 9394029-6 1997 Stably expressed UGT2B9 also catalyzes the glucuronidation of profen nonsteroidal anti-inflammatory drugs, fibrate hypolipidemic agents, and straight-chain fatty acids at the carboxylic acid moiety. straight-chain fatty acids 141-167 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 17-23 9394029-6 1997 Stably expressed UGT2B9 also catalyzes the glucuronidation of profen nonsteroidal anti-inflammatory drugs, fibrate hypolipidemic agents, and straight-chain fatty acids at the carboxylic acid moiety. Carboxylic Acids 175-190 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 17-23 9394029-8 1997 Expressed UGT2B9 exhibits enantioselective glucuronidation for (R/S)-ibuprofen, (R/S)-propanolol, and (+)/(-)-menthol. (r/s)-ibuprofen 63-78 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 10-16 9394029-8 1997 Expressed UGT2B9 exhibits enantioselective glucuronidation for (R/S)-ibuprofen, (R/S)-propanolol, and (+)/(-)-menthol. (r/s)-propanolol 80-96 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 10-16 9394029-8 1997 Expressed UGT2B9 exhibits enantioselective glucuronidation for (R/S)-ibuprofen, (R/S)-propanolol, and (+)/(-)-menthol. Menthol 102-117 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 10-16 9443856-3 1998 UGT2B7 has been shown to catalyze NSAIDs, catechol estrogens, and morphine-3- and -6-glucuronidation. catechol 42-50 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 9443856-3 1998 UGT2B7 has been shown to catalyze NSAIDs, catechol estrogens, and morphine-3- and -6-glucuronidation. Morphine 66-74 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 9443856-3 1998 UGT2B7 has been shown to catalyze NSAIDs, catechol estrogens, and morphine-3- and -6-glucuronidation. and -6 78-84 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 9443856-9 1998 Our data suggest that UGT2B7 is a major isoform responsible for the glucuronidation of androsterone. Androsterone 87-99 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 22-28 9443856-11 1998 UGT2B7 seems to be a major human isoform responsible for the glucuronidation of opioids of the morphinan and oripavine class and is capable of catalyzing the glucuronidation of both the 3- and 6-hydroxyl moieties on these molecules. Morphinans 95-104 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 9443856-11 1998 UGT2B7 seems to be a major human isoform responsible for the glucuronidation of opioids of the morphinan and oripavine class and is capable of catalyzing the glucuronidation of both the 3- and 6-hydroxyl moieties on these molecules. oripavine 109-118 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 9443856-12 1998 Thus, UGT2B7 plays a major role in the conversion of morphine to morphine-6-glucuronide, the potent analgesic metabolite of morphine. Morphine 53-61 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 6-12 9443856-12 1998 Thus, UGT2B7 plays a major role in the conversion of morphine to morphine-6-glucuronide, the potent analgesic metabolite of morphine. morphine-6-glucuronide 65-87 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 6-12 9443856-12 1998 Thus, UGT2B7 plays a major role in the conversion of morphine to morphine-6-glucuronide, the potent analgesic metabolite of morphine. Morphine 65-73 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 6-12 18982489-1 1997 Two human liver UDP-glucuronosyltransferase cDNA clones, HLUG25 and UDPGTh2 were previously shown to encode isozymes active in the glucuronidation of hyodeoxycholic acid (HDCA) and certain estrogen derivatives (e.g., estriol and 3,4-catechol estrogens), respectively. Estriol 217-224 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 68-75 18982489-1 1997 Two human liver UDP-glucuronosyltransferase cDNA clones, HLUG25 and UDPGTh2 were previously shown to encode isozymes active in the glucuronidation of hyodeoxycholic acid (HDCA) and certain estrogen derivatives (e.g., estriol and 3,4-catechol estrogens), respectively. 3,4-catechol 229-241 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 68-75 18982489-7 1997 These data indicate, that UDPGTh2 is a primary isoform responsible for the detoxification of the bile salt intermediate as well as the active estrogen intermediates. Bile Acids and Salts 97-106 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 26-33 9010622-7 1997 Since humans excrete morphine-3-glucuronide and morphine-6-glucuronide after morphine administration, it is likely that UGT2B7 is a major isoform in humans responsible for the metabolism of this important drug and its surrogates. morphine-3-glucuronide 21-43 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 120-126 9169006-2 1997 All mono- and dihydroxylated androgens with a hydroxyl function in the 3 alpha, 6 alpha, and 17 beta positions were glucuronidated by UGT2B7, but highest activity was generally observed for steroids containing a 3 alpha-hydroxy substituent. Steroids 190-198 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 134-140 9169006-4 1997 3 alpha-Hydroxypregnanes were also glucuronidated by UGT2B7. 3 alpha-hydroxypregnanes 0-24 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 53-59 9169006-6 1997 Although 11 alpha-hydroxylated androgens were not glucuronidated by UGT2B7, this enzyme exhibited high activity toward the 11 alpha-hydroxylated derivatives of 5 beta-prenanedione and progesterone. beta-prenanedione 162-179 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 68-74 9169006-6 1997 Although 11 alpha-hydroxylated androgens were not glucuronidated by UGT2B7, this enzyme exhibited high activity toward the 11 alpha-hydroxylated derivatives of 5 beta-prenanedione and progesterone. Progesterone 184-196 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 68-74 9169006-9 1997 Overall, the data indicate a high degree of stereo- and regioselectivity in the glucuronidation of hydroxyandrogens and -pregnanes by UGT2B7 and UGT2B11 and further suggest that UGT2B7 may contribute to the glucuronidation of 3 alpha-hydroxysteroids in humans. hydroxyandrogens 99-115 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 134-140 9169006-9 1997 Overall, the data indicate a high degree of stereo- and regioselectivity in the glucuronidation of hydroxyandrogens and -pregnanes by UGT2B7 and UGT2B11 and further suggest that UGT2B7 may contribute to the glucuronidation of 3 alpha-hydroxysteroids in humans. hydroxyandrogens 99-115 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 178-184 9169006-9 1997 Overall, the data indicate a high degree of stereo- and regioselectivity in the glucuronidation of hydroxyandrogens and -pregnanes by UGT2B7 and UGT2B11 and further suggest that UGT2B7 may contribute to the glucuronidation of 3 alpha-hydroxysteroids in humans. Pregnanes 121-130 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 134-140 9169006-9 1997 Overall, the data indicate a high degree of stereo- and regioselectivity in the glucuronidation of hydroxyandrogens and -pregnanes by UGT2B7 and UGT2B11 and further suggest that UGT2B7 may contribute to the glucuronidation of 3 alpha-hydroxysteroids in humans. Pregnanes 121-130 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 178-184 9169006-9 1997 Overall, the data indicate a high degree of stereo- and regioselectivity in the glucuronidation of hydroxyandrogens and -pregnanes by UGT2B7 and UGT2B11 and further suggest that UGT2B7 may contribute to the glucuronidation of 3 alpha-hydroxysteroids in humans. 3 alpha-hydroxysteroids 226-249 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 134-140 9169006-9 1997 Overall, the data indicate a high degree of stereo- and regioselectivity in the glucuronidation of hydroxyandrogens and -pregnanes by UGT2B7 and UGT2B11 and further suggest that UGT2B7 may contribute to the glucuronidation of 3 alpha-hydroxysteroids in humans. 3 alpha-hydroxysteroids 226-249 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 178-184 9000569-3 1997 Two cDNA-expressed UGT isoforms, UGT1*02 and UGT2B7, had the capacity to glucuronidate DMXAA, although comparative kinetic and inhibitor studies were more consistent with a greater contribution of UGT2B7 to the human hepatic reaction. vadimezan 87-92 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 45-51 9000569-3 1997 Two cDNA-expressed UGT isoforms, UGT1*02 and UGT2B7, had the capacity to glucuronidate DMXAA, although comparative kinetic and inhibitor studies were more consistent with a greater contribution of UGT2B7 to the human hepatic reaction. vadimezan 87-92 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 197-203 9010622-0 1997 Human UGT2B7 catalyzes morphine glucuronidation. Morphine 23-31 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 6-12 9010622-2 1997 A full length cDNA was isolated from a human liver cDNA library and found to be identical to the UGT2B7 form having a tyrosine at position 288. Tyrosine 118-126 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 97-103 9010622-4 1997 Cell homogenates and membrane preparations from HK 293 cells expressing UGT2B7 catalyzed the glucuronidation of morphine and other clinically significant opioid agonists, antagonists, and partial agonists. Morphine 112-120 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 72-78 9010622-5 1997 UGT2B7 catalyzed morphine glucuronidation at the 3- and 6-hydroxy positions and also mediated the formation of codeine-6-glucuronide from codeine. Morphine 17-25 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 9010622-7 1997 Since humans excrete morphine-3-glucuronide and morphine-6-glucuronide after morphine administration, it is likely that UGT2B7 is a major isoform in humans responsible for the metabolism of this important drug and its surrogates. morphine-6-glucuronide 48-70 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 120-126 9010622-5 1997 UGT2B7 catalyzed morphine glucuronidation at the 3- and 6-hydroxy positions and also mediated the formation of codeine-6-glucuronide from codeine. codeine-6-glucuronide 111-132 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 9010622-5 1997 UGT2B7 catalyzed morphine glucuronidation at the 3- and 6-hydroxy positions and also mediated the formation of codeine-6-glucuronide from codeine. Codeine 111-118 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 9010622-7 1997 Since humans excrete morphine-3-glucuronide and morphine-6-glucuronide after morphine administration, it is likely that UGT2B7 is a major isoform in humans responsible for the metabolism of this important drug and its surrogates. Morphine 21-29 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 120-126 8674824-4 1995 Among these UGTs, UGT2B7 is specific for estriol and 3,4-catechol estrogens, UGT2B15 glucuronidates 17beta-hydroxy-C19 steroids while UGT2B10 has as yet an undescribed activity. Estriol 41-48 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 18-24 8674824-4 1995 Among these UGTs, UGT2B7 is specific for estriol and 3,4-catechol estrogens, UGT2B15 glucuronidates 17beta-hydroxy-C19 steroids while UGT2B10 has as yet an undescribed activity. 3,4-catechol 53-65 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 18-24 8674824-4 1995 Among these UGTs, UGT2B7 is specific for estriol and 3,4-catechol estrogens, UGT2B15 glucuronidates 17beta-hydroxy-C19 steroids while UGT2B10 has as yet an undescribed activity. 17beta-hydroxy-c19 steroids 100-127 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 18-24 8423545-8 1993 It is, therefore, apparent that UGT2B7 variant has the capacity to glucuronidate with a degree of specificity both endogenous compounds and xenobiotics. glucuronidate 67-80 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 32-38 7773302-0 1995 (S)oxazepam glucuronidation is inhibited by ketoprofen and other substrates of UGT2B7. Oxazepam 3-11 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 79-85 7773302-10 1995 The inhibition profile of (S)oxazepam glucuronidation suggests that UGT2B7 is the catalysing enzyme. Oxazepam 26-37 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 68-74 8399210-16 1993 udpgth-2 and udpgth-1 metabolized parallel substrates (stereospecific estriols, 3,4-catechol estrogens, and the bile salt hyodeoxycholate), except that udpgth-2 was 100-fold more effective than udpgth-1. 3,4-catechol 80-92 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-8 8399210-16 1993 udpgth-2 and udpgth-1 metabolized parallel substrates (stereospecific estriols, 3,4-catechol estrogens, and the bile salt hyodeoxycholate), except that udpgth-2 was 100-fold more effective than udpgth-1. Bile Acids and Salts 112-121 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-8 8399210-16 1993 udpgth-2 and udpgth-1 metabolized parallel substrates (stereospecific estriols, 3,4-catechol estrogens, and the bile salt hyodeoxycholate), except that udpgth-2 was 100-fold more effective than udpgth-1. Hyodeoxycholate 122-137 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-8 8399210-18 1993 Each of the liver mRNA species encoding udpgth-3, udpgth-2, or udpgth-1 was induced 2.5-3-fold by phenobarbital treatment of the Erythrocebus patas monkey. Phenobarbital 98-111 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 50-58 8269638-1 1993 The capacity of four cDNA-expressed human liver UDP-glucuronosyltransferases (UGT), UGT1*6, UGT2B7, UGT2B10 and UGT2B11, to glucuronidate hydroxylated metabolites of benzo[a]pyrene (B[a]P) and 2-acetylaminofluorene (AAF) has been investigated. glucuronidate 124-137 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 92-98 8269638-3 1993 UGT2B7 glucuronidated the B[a]P trans 4,5- and 7,8-dihydrodiols and the 1-,2-,4-,5-,6-,8-,9- and 10-monophenols. 4,5- and 7,8-dihydrodiols 38-63 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 8269638-3 1993 UGT2B7 glucuronidated the B[a]P trans 4,5- and 7,8-dihydrodiols and the 1-,2-,4-,5-,6-,8-,9- and 10-monophenols. 1-,2-,4-,5-,6-,8-,9- and 10-monophenols 72-111 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 0-6 8423545-4 1993 Additionally, the stereoselectivity of ketoprofen, naproxen (S/R ratio approximately unity) and ibuprofen (S/R ratio 1.62) glucuronidation by the UGT2B7 variant was shown to differ. Ketoprofen 39-49 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 146-152 8423545-4 1993 Additionally, the stereoselectivity of ketoprofen, naproxen (S/R ratio approximately unity) and ibuprofen (S/R ratio 1.62) glucuronidation by the UGT2B7 variant was shown to differ. Naproxen 51-59 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 146-152 8423545-9 1993 Preferred substrates for UGT2B7 variant include xenobiotic carboxylic acids, polyhydroxylated estrogens and hyodeoxycholic acid. xenobiotic carboxylic acids 48-75 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 25-31 8423545-4 1993 Additionally, the stereoselectivity of ketoprofen, naproxen (S/R ratio approximately unity) and ibuprofen (S/R ratio 1.62) glucuronidation by the UGT2B7 variant was shown to differ. Ibuprofen 96-105 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 146-152 8423545-5 1993 Two other carboxylic acid-containing drugs (clofibric acid and valproic acid) and a limited range of drugs containing an alcohol or phenolic functional group were also glucoronidated by expressed UGT2B7 variant. Carboxylic Acids 10-25 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 196-202 8423545-5 1993 Two other carboxylic acid-containing drugs (clofibric acid and valproic acid) and a limited range of drugs containing an alcohol or phenolic functional group were also glucoronidated by expressed UGT2B7 variant. Clofibric Acid 44-58 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 196-202 8423545-9 1993 Preferred substrates for UGT2B7 variant include xenobiotic carboxylic acids, polyhydroxylated estrogens and hyodeoxycholic acid. hyodeoxycholic acid 108-127 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 25-31 8423545-5 1993 Two other carboxylic acid-containing drugs (clofibric acid and valproic acid) and a limited range of drugs containing an alcohol or phenolic functional group were also glucoronidated by expressed UGT2B7 variant. Valproic Acid 63-76 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 196-202 8423545-5 1993 Two other carboxylic acid-containing drugs (clofibric acid and valproic acid) and a limited range of drugs containing an alcohol or phenolic functional group were also glucoronidated by expressed UGT2B7 variant. Alcohols 121-128 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 196-202 34910929-8 2022 For UGT, negligible to moderate inhibition by vicagrel was observed with IC50 values of >50.0, >50.0, 28.2, 8.7, >50.0 and 28.2 muM for UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9 and UGT2B7, respectively. methyl 2-(2-acetoxy-6,7-dihydrothieno(3,2-c)pyridin-5(4H)-yl)-2-(2-chlorophenyl)acetate 46-54 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 179-185 34862252-10 2021 The major metabolic pathway was carboxylic acid glucuronidation, which was catalyzed predominantly by UGT2B7. Carboxylic Acids 32-47 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 102-108 34493601-7 2021 Strong inhibition of UGT2B7 was also observed for THC and CBN; no or weak inhibition was observed with cannabinoid metabolites. Dronabinol 50-53 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 21-27 34493601-7 2021 Strong inhibition of UGT2B7 was also observed for THC and CBN; no or weak inhibition was observed with cannabinoid metabolites. Cannabinol 58-61 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 21-27 34493601-9 2021 Significance Statement Major cannabinoids found in the plasma of cannabis users inhibit several UGT enzymes, including UGT1A6, UGT1A9, UGT2B4, and UGT2B7. Cannabinoids 29-41 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 147-153 34390491-9 2021 Significant correlation between abundance and activity (measured by mycophenolic acid clearance) was observed for UGT1A9 (Rs=0.65, p=0.004) and UGT2B7 (Rs=0.70, p=0.023). Mycophenolic Acid 68-85 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 144-150 35303539-6 2022 Patients with UGT2B7*2 polymorphism TT genotype had 1.2-fold higher LTG ratios (p = 0.0078) and 0.78-fold lower GLU/LTG ratio (p = 0.0275) than patients homozygous for the C allele. Lamotrigine 68-71 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 14-20 35303539-6 2022 Patients with UGT2B7*2 polymorphism TT genotype had 1.2-fold higher LTG ratios (p = 0.0078) and 0.78-fold lower GLU/LTG ratio (p = 0.0275) than patients homozygous for the C allele. Glutamic Acid 112-115 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 14-20 35303539-6 2022 Patients with UGT2B7*2 polymorphism TT genotype had 1.2-fold higher LTG ratios (p = 0.0078) and 0.78-fold lower GLU/LTG ratio (p = 0.0275) than patients homozygous for the C allele. Lamotrigine 116-119 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 14-20 35303539-11 2022 Sex specific differences in enzyme activity (most prominent effect in women) on LTG metabolism were found for UGT2B15, UGT2B17, UGT1A4 and UGT2B7 polymorphisms. Lamotrigine 80-83 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 139-145 35303539-12 2022 Multiple regression analysis confirmed the significant effect of OC, VPA and UGT1A4 * 2 and UGT2B7 * 2 on LTG metabolism. Lamotrigine 106-109 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 92-98 35303539-13 2022 CONCLUSION: Our study confirms the previous findings that genetic variations in UGT2B7 and UGT1A4 genes are associated with serum LTG concentrations. Lamotrigine 130-133 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 80-86 35563116-8 2022 The capacity of diclofenac-AG to form covalent adducts with UGT1A9 or UGT2B7 was approximately 10 times higher than that of mefenamic acid-AG. Diclofenac 16-26 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 70-76 35563116-11 2022 A significant negative correlation between the half-lives of NSAIDs-AG in phosphate buffers and the amount of covalent adduct with UGT2B7 was observed, suggesting the more labile NSAID-AG forms higher irreversible bindings to UGT. phosphate buffers 74-91 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 131-137 34255042-10 2021 For example, SRD5A2, which encodes a steroid 5-alpha reductase that is involved in processing androgens, and UGT3A1 and UGT2B7 which encode enzymes likely to be involved in estradiol elimination. Estradiol 173-182 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 120-126 34721047-7 2021 Study with recombinant human UGTs suggested that multiple UGT isoforms including UGT1A9, UGT1A7, UGT1A3, UGT1A4, UGT1A1, UGT2B7 and UGT1A8 are involved in the conversion of ticagrelor to ticagrelor-O-glucuronide with UGT1A9 showing highest catalytic activity. Ticagrelor 173-183 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 121-127 34721047-7 2021 Study with recombinant human UGTs suggested that multiple UGT isoforms including UGT1A9, UGT1A7, UGT1A3, UGT1A4, UGT1A1, UGT2B7 and UGT1A8 are involved in the conversion of ticagrelor to ticagrelor-O-glucuronide with UGT1A9 showing highest catalytic activity. ticagrelor-o-glucuronide 187-211 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 121-127 34721047-9 2021 Little or no inhibition of UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9 and UGT2B7 by ticagrelor and ticagrelor-O-glucuronide was noted. Ticagrelor 80-90 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 70-76 35370140-6 2022 11-OH-THC (50 nM) was metabolized by CYP3A (CLint: 0.26 {plus minus} 0.058 mL/min/mg; fm: 0.51 {plus minus} 0.11) and UGT2B7 (CLint: 0.13 {plus minus} 0.027 mL/min/mg; fm: 0.25 {plus minus} 0.053). 11-Hydroxytetrahydrocannabinol 0-9 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 118-124 35129779-8 2022 Not only does CYP3A4, flavin-containing monooxygenase 3 (FMO3), and uridine 5"-diphospho-glucuronosyltransferase (UGT) also metabolize dasatinib, and similarly, by glucuronidation process, asciminib gets metabolized by UGT enzymes (UGT1A3, UGT1A4, UGT2B7, and UGT2B17). Dasatinib 135-144 UDP glucuronosyltransferase family 2 member B7 Homo sapiens 248-254